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~ Summary ~
Tamoxifen has long been the drug of choice in endocrine therapy of oestrogen receptor a 
(ERa)-positive breast cancer and still remains widely used due to its well-documented 
beneficial effect. However, its efficacy is often limited by the onset of acquired 
resistance and several clinical studies have suggested that a proportion of tumours, 
which are initially ERa-positive, lack the receptor at the time of tamoxifen relapse in the 
adjuvant or metastatic setting. The mechanisms underlying acquired ERa-negativity 
remain largely unknown and their elucidation is of therapeutic importance since breast 
cancer lacking ERa is associated with endocrine resistance, aggressive tumour biology 
and poor prognosis. This study addressed the issue of acquired ERa-negativity during 
tamoxifen therapy by assessing ERa expression in tamoxifen-resistant MCF-7-derived 
cells, which were cultured in the presence of the anti-hormone over a 30-month period. 
Results showed a progressive and significant reduction of total ERa mRNA and protein 
expression in response to tamoxifen therapy and this was accompanied with greatly 
increased aggressive tumour cell behaviour. The tamoxifen-treatment regimen also 
resulted in reduced expression of all ERa mRNA variants, which are generated through 
alternative promoter usage of the ERa gene. Such reduction was most apparent for 
ERa-mRNA variants C. Importantly, pharmacological modulation of cell signalling 
pathways identified the epidermal growth factor receptor (EGFR) signalling maintaining 
ERa levels, whilst c-Src kinase activity appeared to be the key underlying cause of ERa 
loss during tamoxifen therapy. Encouragingly, even after a 30-month treatment regime 
with tamoxifen, ERa loss was reversible with a c-Src inhibitor. The data presented in 
this thesis suggest that combinations of anti-hormones with c-Src inhibitors could retain 
ERa functions during tamoxifen therapy and prevent a drift towards more aggressive 
cancer cell behaviour.
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Chapter 1
~ Introduction ~
( l u i p k r  1. I n t r o d u c t i o n
1.1 Cancer: facts and figures
Cancer can be viewed as a set of chronic diseases characterised by an 
uncontrolled tissue growth, in which cells divide in defiance of normal restraints and 
are capable of invading and colonizing other tissues, ultimately forming fatal 
metastasis. There are over 200 types of cancer but the most commonly diagnosed are 
lung, colorectal, prostate and breast cancers, which accounted for over half of all new 
cases diagnosed in 2005 (Office for National Statistics, 2005; Cancer Research UK, 
2007). Cancer development is complex and is now well acknowledged to be an 
evolutionary process at the cell level in which genomic instability plays a significant 
role (Schneider & Kulesz-Martin, 2004). A good example of genomic instability is 
that normal cells do not display is the mutation of the p53 tumour suppressor protein, 
famously known as the “guardian o f the genome” for its protective role against DNA 
damage. Over 50% of human cancers lack the pro-apoptotic function o f p53 due to 
mutations occurring in the TP53 gene (Vogelstein et al., 2000). As reviewed by 
Hanahan & Weinberg (2000), most if not all human cancers share six common 
physiological properties which define the pathological characteristic of cell 
malignancy, known as the “hallmark of cancer”. These are (i) self-sufficiency in 
growth signals (activation of many dominant oncogenes), (ii) insensitivity to growth- 
inhibitory signals (loss o f key tumour suppressor genes), which lead to (iii) evasion 
from the programmed cell-death (apoptosis), (iv) un-limited replicative potential 
(telomere maintenance), (v) sustained angiogenesis, and (vi) metastasis.
It is estimated that 1 in 3 people will develop some form of cancer over the course of 
a lifetime with more than half of all cancer cases diagnosed in persons aged 65 and 
older. In the UK there were just over 250,000 diagnosed cases of cancer each year in 
2002-2004 with an average of 154,000 cancer-related deaths each year during the 
same period (Office for National Statistics, 2005). In 2007, cancer killed 7.9 million 
people worldwide and this figure could rise to over 10 million by 2030 with poor 
countries shouldering the heaviest burden from the disease (World Health 
Organization, 2007). Yet about 50% of malignant diseases could be prevented if 
significant widespread changes are made on population’s behaviour towards tobacco,
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alcohol consumption, physical activity, and sun exposure to mention just a few (Stein 
& Colditz, 2004).
1.2 Breast cancer
1.2.1 Incidence and risk factors
With an estimated 1 million new cases each year in the world, breast cancer 
represents by far the most common form of cancer in women (Ferlay et al., 2004). 
The incidence and mortality rates can vary up to five fold across the globe but are the 
highest in developed countries due to lifestyle-related causes. In the UK, breast 
cancer accounts for just over 30% of all new female cancers with more than 44,000 
new cases diagnosed in 2004. The overall lifetime risk (all ages) of developing breast 
cancer is 1 in 9 but this increases considerably with age particularly after 50 (Office 
for National Statistics, 2005; Cancer Research UK, 2007). Although it is rare, breast 
cancer in men can also be diagnosed with around 300 new cases each year in the UK 
(Cancer Research UK, 2007). The introduction o f national mammographic screening 
across the UK in 1988, together with improved treatments has led to a considerable 
decrease in mortality from breast cancer while the incidence has increased (Figure 
1 .1).
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Figure 1.1 Age standardised (European) incidence and mortality rates 
of female breast cancer between 1975 and 2005 in the UK (adapted from the 
Office for National Statistics, 2007).
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One of the strongest epidemiological risk factors for breast cancer is age but many 
other non-genetic predisposing factors have been identified, most of which are 
related to the Western lifestyle (McPherson et al., 2000). They include early 
menarche (start of the menstrual periods), late menopause, delayed age at first 
pregnancy, lack of breast feeding, prolonged hormone replacement therapy, and post­
menopausal obesity. While the vast majority of breast cancer cases are thought to be 
sporadic with no apparent hereditary traits, a smaller proportion (5-10%) is known to 
be linked to the inheritance of one or several mutated genes. The most established 
ones are the tumour suppressor genes BRCA1/BRCA2, whose mutations account for 
almost half of familial breast cancers and increase the overall lifetime risk o f getting 
the disease by up to 80% by the age o f 70 (Ford et al., 1998). Other mutated genes 
like TP53 and PTEN can also contribute to hereditary breast cancer although to a 
much lesser extent. It is believed that additional genes could be involved 
(McPherson et al., 2000). Clearly, breast cancer is a complex disease involving 
numerous genetic and non-genetic predisposing factors. However, the etiology of 
the disease can be assigned to two main categories: failure to maintain genomic 
stability and excessive exposure to oestrogens, which is the focus of this thesis 
(Imyanitov & Hanson, 2004).
1.2.2 Breast cancer development and subtypes
The human breast is a complex organ that begins development early in gestation and 
subsequently undergoes dramatic changes in size, shape and function during the 
transition from puberty to menopause. Breast tissue comprises of lobules, a 
collection of milk-producing glands, and ducts, which carry the milk from the 
lobules to the nipple surrounded by the breast stroma consisting of fatty connective 
tissue and numerous vessels of the blood and lymphatic system. The ducts are 
formed by a basal layer of contractile, myo-epithelial cells and a luminal layer of 
specialized epithelial cells (Russo & Russo, 2004). Breast cancers can arise from the 
epithelial cells that line the ducts (ductal carcinoma in situ, DCIS), or from the 
lobules (lobular carcinoma in situ, LCIS). DCIS is more common and accounts for 
20-30% of all newly diagnosed cases of breast cancers while LCIS accounts for
4
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approximately 10% (Olivotto et al., 2006). Both DCIS and LCIS represent pre- 
invasive malignant lesions in which the abnormal breast epithelial cells are contained 
within the mammary epithelial structures, and where no invasion of the basement 
membrane and no infiltration of the breast stroma is apparent (Howard & Gusterson, 
2000). Whilst nearly all premalignant epithelial cells (from the DCIS and LCIS 
lesions) express high levels of the oestrogen receptor (ER, section 1.3), normal breast 
epithelial cells are for the most part ER-negative (Allred et al., 2004). The origins of 
ER-positive breast cancer cells still remain controversial but it is believed that they 
may arise from either ER-positive or adjacent ER-negative progenitor cells, which 
are located at the growing, terminal end of the duct (Dontu et al., 2004).
It is now well acknowledged that breast cancer is a complex heterogeneous disease 
with diverse histo-pathologies, genetic variations, and clinical outcomes. The 
pioneering works from Perou et al. (2000) and Sorlie et al. (2001), using global gene 
expression profiling in invasive breast carcinoma, have demonstrated that breast 
cancer could be classified into 5 categories: luminal A, luminal B, HER-2 
overexpressing, basal-like and normal breast-like. The luminal subtypes (or non- 
basal subtypes) largely corresponded to phenotypically ER-positive tumours, with 
the luminal subgroup A characterized by a higher ER expression and superior 
clinical outcome than the luminal subgroup B. In contrast, the remaining subtypes 
(or basal subtypes) corresponded to ER-negative breast tumours, which are 
associated with poor clinical outcomes. Basal-like breast cancers show considerable 
cross-over with the clinically aggressive “triple-negative” (i.e.: ER/PR/HER-2 
negative) breast tumours, a group of cancers with a particularly poor prognosis and 
for which no effective tailored therapies currently exist. Due to the complexity and 
heterogeneity o f human breast cancer, no single breast cancer cell model is truly 
representative of the disease. However, studies by Neve et al. (2006) using a panel 
o f 51 widely-used breast cancer cell lines demonstrated that these cell models share 
many of the genetic and genomic aberrations found in human breast cancer and 
closely represent a number o f clinical breast cancer subtypes. For example, the 
widely used MCF-7 cell line (originally derived from human pleural effusion of 
breast carcinoma metastasis) corresponds to the most prevalent luminal A breast 
cancer subtype, thus making this cell line clinically relevant (Neve et al., 2006).
5
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1.3 Oestrogen and Breast cancer
The first evidence implicating oestrogen and breast cancer growth was 
provided in 1896 by the British physician Beatson who discovered that ovariectomy 
resulted in tumour regression in premenopausal women with metastatic breast cancer 
(MacGregor & Jordan, 1998). Based on the specific binding of radioactive oestrogen 
in the uterus of rats, Jensen & Jacobsen first came to the conclusion that the 
biological effects of oestrogen were most likely to be mediated by oestrogen 
receptors, ERs (Jensen & Jacobson, 1962). This led to the development of the first 
ER assays in the 1960s to predict whether breast cancer patients would respond to 
oestrogen depletion by ovariectomy (premenopausal women) or adrenalectomy 
(postmenopausal women).
1.3.1 Oestrogen synthesis
The physiological effects o f oestrogen are numerous and include the 
development and maintenance of the female reproductive organs, the reproductive 
cycle, the cardiovascular and central nervous system and bone metabolism (Nilsson 
& Gustafsson, 2000). Importantly, growth and development of breast tumours are 
dependent on oestradiol-17/? (E2), which is the most potent and main circulating 
oestrogen. In premenopausal women, E2 is mainly produced in the ovaries through 
aromatization o f androgens by the cytochrome P450 aromatase enzyme complex, all 
under the stimulatory effects of the pituitary hormones LH (Luteinizing hormone) 
and FSH (follicle-stimulating hormone). In postmenopausal women, aromatization 
from androgens occurs in peripheral tissues such as brain, liver or fat tissues and 
provides the main source o f circulating oestrogen (Dowsett et al., 2005). 
Importantly, postmenopausal breast tissues are able to locally produce E2 at levels 
which can be much higher than the corresponding plasma levels. Such local 
oestrogen production is now known to be mainly due to high aromatase activity 
exhibited by both the stromal and epithelial cell component of breast tissues 
(Blankenstein et al., 1999).
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1.3.2 Oestrogen Receptors: gene structure
More than two decades after the first discovery of the ER by Jensen & 
Jacobson (1962), the gene encoding the receptor was cloned from the breast cancer 
cell line MCF-7 and was named ERa or ESR1 (Green et al., 1986; Greene et al., 
1986). A second and functionally distinct receptor, named ER(3, was later found 
(Kuiper et al., 1996). While the specific functions of ER|3 in normal and neoplastic 
tissues remain largely unknown, the role of ERa in breast carcinogenesis is relatively 
well understood. The complex genomic organization of the human ERa gene has 
been extensively analyzed and a widely acknowledged nomenclature that describes 
the promoter region of the gene has been published (Kos et al., 2001). With the 
exception of the promoter region, the sequence of the human ERa cDNA shows a 
high degree of conservation with that of other species including rat, mouse, and 
chicken (Kos et al., 2001). The ERa gene is a large genetic unit spanning over 300 
kb on the long arm of chromosome 6 (Gosden et al., 1986). This includes a large 
promoter region stretching over 150kb and a protein coding region of -140 kb 
containing 8 exons and 7 introns. As illustrated in Figure 1.2, transcription from the 
ERa gene is complex and can occur from at least 7 promoters (or upstream exons: 
A—>F, and T), which can be located more than 150 kb upstream of the originally 
described transcription start site “+1” (Green et al., 1986). All upstream exons can 
be spliced into a common acceptor splice site that is highly conserved amongst 
species and located at position “+163” in exon 1 of the protein coding region. 
Alternative usage and splicing of these promoters during transcription generate 
multiple mRNA variants, which differ in their 5’-UTRs (untranslated regions) but 
encode a common ERa protein that is 66 kDa in size (ERa-66; Gannon et al., 2002).
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Figure 1.2 Genomic organization of the promoter region of the 
ERa gene. Grey boxes represent upstream exons with broken arrows 
depicting start of transcription. Numbers below upstream exons 
correspond to the distance from the originally described transcription start 
site (+1) in base pairs. Numbers between exons show the size of major 
introns in kilobase pairs. Broke lines below exons symbolize observed 
alternative splicing of the different promoters to the common acceptor 
splice site located at (+163) and represented by an open triangle (adapted 
from Kos et al., 2001).
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1.3.2.1 Alternative promoter usage
It is now well recognised that one o f the implications of multiple promoters in 
the ERa gene is the sensitive tuning of ERa expression according to cell requirement 
in a tissue- and developmental stage-specific manner (Kos et al., 2001). ERa 
transcripts originating from the proximal promoters A and B as well as the distal 
promoter C have been shown to be the predominant ones in tissues expressing 
relatively high levels of ERa including the mammary gland, the ovary and 
endometrium (Flouriot et al., 1998). In contrast, the more distal promoters E and F 
contribute most to the pool of ERa mRNA in liver and osteoblasts, respectively, 
where ERa expression is less abundant (Flouriot et al., 1998; Lambertini et al., 
2003). In addition, the role of E2 in the development of the male reproductive tract 
has been further demonstrated by the identification of the promoter T (T1+T2), 
which has been shown to be used almost exclusively in testis and in the epididymis 
(Brand et al, 2002).
The considerable increase o f ERa levels, characteristically observed in breast 
tumours in comparison with normal breast tissues, has been associated with the 
increased expression of the ERa transcripts A, B, and C. The latter have been shown 
to be up-regulated by up to 30-fold in cancerous breast tissues compared with normal 
breast tissues (Donaghue et al., 1999; Flouriot et al., 1998; Grandien et al., 1995). 
The individual contribution of each transcript to the total pool of ERa mRNA can be 
variable. While some studies have shown that transcript A is the most predominantly 
expressed and account for -50%  of all ERa transcripts in the breast cancer cell line 
MCF-7 (Flouriot et al., 1998), others have reported that transcripts originating from 
promoter C are the most abundant and may largely be responsible for the increased 
expression of ERa (Tanimoto et al., 1999;). In contrast, transcripts originating from 
the promoters E and F are less abundant but are still contributing towards the total 
level of ERa mRNA in ERa-positive cells (Donaghue et al., 1999). Overall, it has 
been suggested that the high levels o f ERa expression is determined by the number 
of the contributing promoters rather than their selective use, as illustrated by the 
observations that non-breast cancer cells use fewer promoters than their cancerous 
counterparts (Donaghue et al., 1999).
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1.3.2.2 Alternative splicing (exon skipping)
In addition to alternative promoter usage, single or multiple exons from the 
protein coding region of the ERa gene can be depleted during the processing of the 
primary transcript (exon skipping). This ultimately results in the production of ERa 
protein variants that are structurally and functionally different (Ferro et al., 2003). 
The so-called alternative splicing occurs in 60% of all human genes and its 
mechanisms can be greatly affected by promoters (i.e.: promoter identity and 
occupancy) through recruitment of factors that have dual functions in transcription 
and splicing (Komblihtt, 2005). In MCF-7 cells for example, Flouriot & colleagues 
(2000) have reported the existence of an ERa mRNA isoform depleted of the entire 
exon 1 containing the A/B domain of the ERa gene, and therefore resulting in an 
AF1-truncated ERa protein that is 46 kDa in size (ERa-46). The same authors have 
shown that ERa-46 is encoded by distinct mRNA variants originating from the 
alternative splicing of promoters E and F directly into exon 2 of the ERa gene. It 
was shown that ERa-46 can heterodimerize with wild-type ERa-66 and greatly 
inhibits the overall transcriptional activity of the receptor in cells where ERa 
signalling is mainly mediated through the AF1 activation domain. Importantly, it has 
been reported that the overall prevalence of the exon-skipped-ERa mRNA variants is 
increased in breast tumours. This is illustrated, for example, by the exon 7 deletion 
form of ERa which has been shown to contribute -20%  of the total ERa mRNA pool 
in MCF-7 cells (Fasco, 1998). The increased expression of alternatively spliced ERa 
mRNAs can ultimately result in the synthesis of ERa protein isoforms that may 
exhibit variations in oestrogen/anti-oestrogen binding properties (Poola & Speirs, 
2001).
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1.3.3 Oestrogen Receptors: protein structure and function
ERs belong to the nuclear receptor superfamily (NR), which consists of 
approximately 150 different members spanning across a wide array of animal species 
including vertebrate and invertebrates (Mangelsdorf et al., 1995). Other members 
include progesterone, thyroid hormone, retinoid and vitamin-D receptors as well as 
the so-called orphan receptors for which no ligands have been identified. Like most 
nuclear receptors, ERa and ERp function as ligand-dependent transcription factors 
that regulate the expression of a large array of specific target genes (McDonnell & 
Norris, 2002). ERa protein is thought to be the predominant receptor for the 
regulation of oestrogen responsive genes in breast cancer (Fuqua et al., 2003). The 
two receptors are functionally distinct, have different tissue distribution, different 
ligand activation and so play different roles in gene activation (Nilsson & 
Gustafsson, 2000). However, ERa and ERp share a common modular structure, 
which includes 6 functional domains (A-F) that characterises all members of the NR 
family (Figure 1.3).
The N-terminal region contains the poorly conserved activation function domain 
AF1 (A/B domain). The poor conservation within the A/B domain of ERa and ERp 
is believed to explain, at least in part, the functional differences between the two 
receptors by interacting with different transcription factors (Nilsson & Gustafsson, 
2000). Probably the best example is the fact that ERa and ERp have opposite 
transcriptional effects on API promoter sites when bound to oestrogen (Paech et al., 
1997). Oestrogen-bound ERa activates while ERp inhibits gene transcription from 
an API site. The DNA binding domain (DBD, C domain) represents the most highly 
conserved region consisting of two zinc-fingers that are crucial for the binding of the 
receptor to target gene. The hinge region (D domain) contains nuclear localisation 
sequences and also several motifs for post-translational modifications of the 
receptors such as acetylation and sumoylation, which can regulate the transcriptional 
activity of ERa (Sentis et al., 2005; Wang et al., 2001).
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Figure 1.3 Structural organization of ERa and ERp 
proteins. Both receptors consists of six functional domains 
(A-F) including the transactivation domains AF-1 and AF-2, 
the DNA binding domain (DBD) and the ligand binding 
domain (LBD). The percentage represents the degree of 
homology between the two receptors (adapted from Shao & 
Brown, 2004).
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Most of the C-terminal region (E/F domain) encompasses the ligand-binding 
domain (LBD) harbouring a dimerisation surface and most importantly the activation 
function domain AF2. The latter is involved in the ligand-dependant interactions of 
the receptors with numerous cofactors (McDonnell & Norris, 2002). 
Crystallographic analysis of the ERa LBD in the presence of either an agonist or an 
antagonist has revealed the presence of a highly mobile hydrophobic segment, a- 
helix 12 (H I2), whose position is altered by the binding of ligands (Figure 1.4, 
Brzozowski et al., 1997). Upon binding of oestrogen, H I2 is positioned over the 
ligand-binding pocket and, together with segments H3-H5, results in the formation of 
a hydrophobic groove that exposes “docking sites” for the binding of co-activator 
proteins. In contrast, the bulky side chain of anti-oestrogens displaces H12 thus 
preventing interaction of the AF2 domain with co-activators. Overall, one major 
function for ligands is to alter the conformation of the LBD, which ultimately 
dictates the type of cofactors interacting with ERs (White & Parker, 1998).
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Figure 1.4 Structural model of the ligand binding 
domain of ERa and the alteration in the positioning of 
helix H12 in the presence of oestrogen or anti-oestrogen.
The yellow spheres schematically represents the area of ligand 
binding (adapted from White & Parker, 1998).
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1.3.4 Oestrogen Receptor: cofactors
In order to regulate the expression of their target genes, ligand-activated ERs 
recruit a multitude of co-regulatory proteins, which can essentially be viewed as 
proteins that complement the cellular effects of ERs by either enhancing 
(coactivators, CoAs) or attenuating (corepressors, CoRs) ER mediated-gene 
transcription (Table 1.1). The degree of complexity to which nuclear receptors can 
interact with cofactors is illustrated by the ever-growing number of identified NR 
coactivators (-200, Lonard & O’Malley, 2006). The overall multiprotein complex 
formed by ERs and coactivators at the promoter regions of target genes ultimately 
results in the remodeling of the local chromatin structure and recruitment of the basal 
transcriptional machinery. Coactivators have been shown to contain a conserved 
“LXXLL” motif (also known as “NR box”), which binds specific sites within the 
AF2 domain of ERs (McKenna & O’Malley, 2002). A common functional property 
of most (but not all) coactivators is histone acetyltransferase (HAT) activity. HAT 
enzymes catalyze the acetylation of lysine residues of the N-terminal tails o f histones 
which, together with other DNA modifications, results in local decondensation of the 
chromatin necessary for gene activation (Umov & Wolffe, 2001). Probably the most 
established AF2-interacting coactivators are the p i60 family, which contain intrinsic 
HAT activity but whose primary functions are thought to be the recmitment of other 
coactivators and HATs like CBP (CREB binding protein)/p300, and pCAF (CBP- 
associated factor). For example, members of the p i60 family include SRC-3 (better 
known as amplified in breast cancer, AIB1), which is amplified and/or overexpressed 
in over half of breast cancers (Massarweh & Schiff, 2006).
Corepressors are equally important in the regulation of ER-mediated gene expression 
and repress transcription when interacting with apo-ERs (unliganded) or antagonist- 
bound receptors. As reviewed by Dobrzycka et al. (2003), corepressors can exert 
their transcriptional repression through a wide variety of mechanisms including 
chromatin remodeling, binding competition with coactivators, sequestration of ERs 
in the cytoplasm, and interference with DNA binding. For example, some 
corepressors negatively regulate transcription due to their ability to recruit histone 
deacetylases (HDACs), which participate in the condensation of chromatin therefore 
preventing the transcriptional apparatus from accessing DNA. The most established
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corepressors for ERs include NCoRs (nuclear corepressors) and SMRT (silencing 
mediator of retinoid and thyroid hormone receptor). It is now increasingly believed 
that, although having opposite functions, both coactivators and corepressors may 
coexist in the same multiprotein complex. Ligand binding on the receptors would 
result in a dynamic and rapid reorientation of the coactivators/corepressors, whose 
balance and activity sensitively tune the expression of the nuclear receptor target 
genes (Kumar et al., 2005).
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Table 1.1 Oestrogen receptor cofactors
Name
ER
binding
site
Function References
NCoR LBD HDACs Lavinsky et al., 1998
SMRT LBD HDACs Smith et al., 1997
RIP140 LBD HDACs, competition with 
coactivators
Cavailles et al., 
1995
CoRs DAX-1 AF-2 Competition with coactivators, Inhibition of ERa dimerization
Zhang et al., 2000
REA LBD Competition with coactivators Klinge et al., 1997
NEDD8 LBD Ubiquitin-like protein involved in 
ERa proteolysis
Fan et al., 2003
SRC1 AF-2 HATs Onate et al., 1995
SRC2/TIF2 AF-2 HATs Voegel et al., 1996
SRC3/AIB1 AF-2 HATs Suen et al., 1998
CoAs p68 AF-1 RNA helicase Endoh et al., 1999
CARM1 none Indirect interaction with ERa through 
binding to p i60,
Methylation o f histones
Stallcup et al., 2003
Cyclin D1 AF-2 Recruitment of SRC-family 
coactivators to ERa
Zwijsen et al., 1998
CoRs, corepressors; CoAs, coactivators.
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1.3.5 ER signalling
In the absence of ligands, ERs exist in a monomeric form, predominantly 
found in the nucleus and sequestered within a large and stabilizing heterocomplex of 
chaperone proteins including the heat-shock proteins Hsp90, Hsp70, and the Hsp- 
interacting protein p23 (Pratt & Toft, 1997). ERs can regulate the expression o f their 
target genes through three distinct but “cross-talking” mechanisms that can be 
referred as (i) the classical genomic, (ii) the non-classical genomic, and (iii) the non- 
genomic/cell membrane mechanisms (Ring & Dowsett, 2004).
1.3.5.1 Classical genomic action of ERs
The lipophilic nature of oestrogen allows the steroid hormone to diffuse 
freely through the cell plasma membrane and reach the nucleus where it binds to the 
ER. Oestrogen binding induces a conformational change of the receptor, which also 
become hyperphosphorylated at several serine and tyrosine residues (Nicholson et 
al., 1999), ultimately resulting in a rapid dissociation of the receptors from the 
Hsp90-based chaperone complex. This is rapidly followed by receptor homo- or 
hetero-dimerisation which, in the case of the classical genomic action of oestrogen, is 
followed by the binding of ERs to oestrogen response elements (EREs). The latter 
are present on the promoter region of oestrogen-responsive genes (Griekspoor et al., 
2007; White & Parker 1998). ER binding to EREs is quickly followed by the 
recruitment of coactivators and components of the RNA polymerase II transcription 
initiation complex for gene activation (Figure 1.5A). A perfect ERE consensus 
consists of two inverted repeats of the sequence “5’-GGTCA-3’” separated by any 3 
nucleotides, and onto which ERs bind with the highest affinity. However, perfect 
EREs are very rare (present in only three E2-regulated genes of the human genome) 
and it has been shown that many E2-responsive genes contain imperfect or half- 
EREs, which still bind ERs with high affinity (Sanchez et al., 2002). A genome- 
wide screen for high affinity EREs has suggested that the occurrence of EREs is high 
with an estimated number of -70,000 motifs in the human genome (Bourdeau et al.,
2004). In the same study, some functional EREs have been located as far as -10 kb 
upstream of transcriptional start sites although most ERE motifs were found to be
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mostly enriched in the vicinity of transcriptional start sites (- 1 to + 2kb region). 
Additionally, large scale chromatin immunoprecipitation analysis (ChIP) on the E2- 
responsive gene pS2 in MCF-7 cells has shown that the recruitment o f cofactors by 
ERs occurs as an ordered and cyclical event (Metivier et al., 2003). However, as 
suggested by the same authors this orderly and sequential recruitment of coactivators 
is likely to be different across E2-responsive genes.
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Figure 1.5 Classical (A) and non-classical (B) genomic action 
of ERs. In the classical mode, E2-activated ERs bind to ERE sites 
and recruit a coactivator multiprotein complex that includes p i60 
and CBP/p300 and which is linked to the transcription apparatus for 
activation of gene transcription. In the non-classical mode, ER- 
mediated gene transcription occurs via binding of the receptors to 
transcription factors like fos/jun heterodimers, which are bound to 
AP-1 sites. GTFs, general transcription factors; TBP, TATA-binding 
protein.
TATA GENE
CBP/p300
GTFs
20
C h a p k * r  1, I n t r o d u c t i o n
1.3.5.2 Non-Classical genomic action of ERs
In addition to signal directly through EREs, ERs can also regulate 
transcription by binding to other DNA-bound transcription factors (tethering), which 
characterize the non-classical nuclear action of ERs (Figure 1.5B). For instance, E2- 
bound-ERa can bind to the API (activating protein 1) transcription factor consisting 
of the heterodimer c-Fos/c-Jun, and activate the AP-1 mediated transcription of 
genes such as cyclin D l, ovalbumin, collagenase, and the growth factor ligand IGF-1 
(Cheung et al., 2005; Bjomstorm & Sjoberg, 2005). Similarly, ERa can also interact 
with the transcription factor Spl (Specificity protein 1) to regulate transcription of 
genes controlled by GC-rich promoters such as c-fos (Kim et al., 2005). Overall, this 
“tethering” mechanism allows oestrogen to regulate the expression of a larger 
number of oestrogen-responsive genes including those that do not contain EREs. 
Interestingly, some Spl binding sites are located in proximity to ERE half-sites, both 
of which need to be occupied for maximal transcription of genes such as PR 
(progesterone receptor) and TGFa (tumour growth factor a) (Bjomstorm & Sjoberg, 
2005). A large scale microarray analysis in MCF-7 cells has revealed that oestrogen- 
mediated cell proliferation is associated with the down-regulation o f -70%  of all E2- 
responsive genes. Those down-regulated genes were identified as transcriptional 
repressors, genes involved in cell cycle inhibition or of pro-apoptotic functions. In 
contrast, the up-regulated genes were involved in cell cycle progression, DNA 
synthesis and growth factor signalling (Frasor et al., 2003).
1.3.5.3 Non-genomic action of ERs
Non-genomic effects o f oestrogen relate to cellular events that occur within 
seconds or minutes of oestrogen administration, which cannot be attributed to 
transcriptional activation o f genes via nuclear ERs because the latter event usually 
occurs in a matter of hours or even days. Some of the well-known rapid
physiological effects of E2 include pituitary prolactin secretion, vasodilatation of
• • • • • • 2+coronary arteries in association with nitric oxide release, and activation of the Ca
channels. E2 is also known to rapidly activate membrane growth factor receptors
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such as IGF-IR (insulin growth factor 1 receptor) and EGFR (epidermal growth 
factor receptor), which lead to the activation of their downstream MAPK (mitogen- 
activated protein kinase) and Akt signalling pathways (Levin, 2005; Nicholson et al.,
2005).
In oestrogen-dependent breast cancer cells, it is thought that the non-nuclear actions 
of E2 are mediated by membrane and/or cytoplasmic ERs which, upon E2 binding, 
physically interact with a large signalling protein complex that rapidly initiate the 
growth factor-induced activation of MAPK and Akt signalling (Song et al. 2005; 
Song & Santen 2006). As proposed by Song & Santen (2006), E2-activated ERa at 
or near the membrane is thought to trans-activate EGFR and IGF-IR through 
interaction with the non-tyrosine kinase c-Src, which rapidly associates with many 
signalling molecules. The latter include G proteins, the scaffold protein MNAR 
(modulator of non-genomic activity of oestrogen), the p85a regulatory domain of 
PI3K (phosphoinositol-3 kinase) and the She protein. As discussed by Warner & 
Gustafsson (2006), there are still controversies as to whether those rapid E2 effects 
are mediated at the plasma membrane by the classical/nuclear ERs, primarily 
because the latter have no transmembrane domains. As mentioned by Bjomstorm & 
Sjoberg (2005), the receptors could undergo palmitoylation for plasma membrane 
targeting. ERa has also been found to interact with the scaffold protein caveolin-1, 
which is found enriched in specialized membrane invaginations, called caveolae. In 
addition to membrane ERs, the issue that a pool of the classical receptors might be 
present in the cytoplasm has also been raised (Levin, 2005). Indeed, a small fraction 
of unliganded nuclear ERa has been identified in the cytosol and shown to constantly 
shuttle between the nucleus and the cytoplasm (Maruvada et al., 2003). 
Additionally, it has been suggested that oestrogen may act through a structurally 
distinct estrogen receptor, named GPR30 (Filardo & Thomas., 2005). Overall and as 
recommended by Warner & Gustafsson (2007), definitive identification of nuclear 
ERs in the membrane or/and the cytoplasm still remains to be fully established.
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1.3.5.4 Convergence of genomic and non-genomic actions of ERs
It is now widely acknowledged that signalling initiated from 
membrane/cytoplasmic ERs (non-genomic) can cross-talk with nuclear ERs 
(genomic) through growth factor receptor tyrosine kinases such as EGFR and IGF- 
IR (Bjomstorm & Sjoberg, 2005; Levin, 2005). As described previously, the E2- 
induced interaction between membrane/cytoplasmic ERs and components o f the 
growth factor signalling pathways leads to downstream activation of MAPK and Akt. 
Importantly, both MAPK and Akt further up-regulate the transcriptional activity o f 
E2-bound nuclear ERs by mediating, respectively, the phosphorylation of Seri 18 and 
Seri 67 residues present within the AF1 domain of the receptors. In the absence of 
oestrogen, these and other residues can still be phosphorylated in response to EGF or 
IGF-1 (Kato et al., 1995). Additionally, the membrane-induced activation of MAPK 
and Akt also leads to phosphorylation of their target transcription factors, such as 
AP-1 and Spl, which are tethered to nuclear ERs at target gene promoters. Overall, 
signalling from the membrane/cytoplasmic ER through kinase cascades provide a 
rapid cellular response which is relayed to and maintained by nuclear ERs which 
provide a fine degree of control on gene transcription and breast epithelial cell 
proliferation and survival (Levin, 2005).
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1.4 Regulation of ERa expression in breast cancer
As described previously, ERa levels are a crucial determinant of cellular 
growth potential for the majority o f breast cancers. Therefore, regulation of ERa 
concentration is a key component in limiting oestrogen responsiveness in target cells 
(Pinzone et al., 2004). Studies attempting to shed light on the molecular mechanisms 
that modulate ERa levels have revealed that its regulation is complex and multi­
dimensional. ERa expression is controlled at (i) the transcriptional level through 
interaction between cX-elements of the promoters and trans-acting factors; (ii) at the 
post-transcriptional level through modulation of mRNA stability and translation 
efficiency; and finally (iii) at the post-translational level via ERa protein 
degradation/turnover.
1.4.1 Transcriptional regulation
Historically, the proximal promoters A and B have been one of the first 
regulatory regions of the ERa gene to be identified and described as key players for 
ERa overexpression in breast cancer (Kos et al., 2001). Therefore, most of what is 
known about the molecular mechanisms regulating ERa gene transcription comes 
from studies identifying the cX-acting elements within these two promoters and their 
interaction with cell-specific transcription factors which are under the control of 
growth-factor signalling pathways. Castles et al. (1997) were amongst the first to 
suggest that ERa protein is able to modulate the activity o f its own gene expression 
in a ligand-dependent manner, and therefore may contribute to its overexpression in 
some breast tumours. The same authors have shown that a -200 bp fragment, 
located just upstream of the transcription start site (+1), contained important e x ­
acting elements whereby ERa is able to auto-regulate itself without directly binding 
to the DNA but through protein-protein interaction with other transcription factors.
It is now known that in breast cancer the majority of ERa promoter activity resides 
within the proximal promoters A and B, precisely between -245 bp and +212 bp 
relative to the originally described transcription start site (Green et al., 1986). This 
region, also known as the minimal promoter, contain several transcriptional motifs
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including a TATA-box for the binding of the TFIID protein via its TATA-box 
binding protein subunit (TBP); and importantly a GC box to which binding o f the 
transcription factors Spl and Sp3 has been shown to be crucial for the activation of 
ERa gene transcription in breast cancer (deGraffenried et al., 2002). A model for 
transcription from the ERa minimal promoter has been proposed for the first time 
(deGraffenried et al., 2004; Figure 1.6). In this model, ERa protein auto-regulates 
its expression through interaction, at the minimal promoter, with a multi-protein 
complex engaged by the binding of Spl and the USF-1 transcription factor (upstream 
stimulatory factor 1) to a GC box and an imperfect E box, respectively. This 
complex is thought to subsequently recruit the RNA polymerase II holoenzyme for 
initiation of ERa transcription.
A transcriptional enhancer element (named ER-EHO) containing binding sites for the 
AP-1 transcription factor has been located within the more distant promoter D, and 
has been described as a dominant ds-acting element for activation of ERa 
transcription in breast cancer cells (Tang et al., 1997). As suggested by 
deGraffenried & co-workers (2004), ER-EHO may enhance ERa transcription 
through binding of AP-1 and as yet unidentified other proteins to the 
ERa/Spl/USFl-based multi-protein complex present in the minimal promoter. 
Adding to the complexity of the regulation of ERa transcription is the identification 
that p53 can also activate the ERa minimal promoter through a protein-protein 
interaction with factors that bind the -70 to -40 bp region of promoter A, such as the 
TATA binding protein (Angeloni et al., 2004). Another potentially important 
transcription factor that can selectively contribute to promoter-specific ERa 
expression in breast cancer cells is ERBF-1. Enhancer elements for this transcription 
factor were located within the distal promoter C, precisely at -1.9 kbp (Tanimoto et 
al., 1999). The authors showed that only breast cancer cells expressing ERBF-1, 
such as MCF-7, can generate high levels of the ERa mRNA variant C.
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Figure 1.6 Model of regulation of ERa gene transcription at the 
minimal promoter. The minimal promoter (-245 to +212 bp) contains 
important c/s-acting regulatory elements including a TATA box for the 
recruitment of the RNA polymerase II holoenzyme components, a GC box 
and a flanking imperfect E box for the binding of Spl and USF-1, 
respectively. A multi-protein complex containing at least USF-1, Spl and 
ERa interacts with the transcription machinery and is able to strongly 
activate transcription of the ERa gene. A 35 bp-long enhancer element 
located within the D promoter region may increase ERa transcription 
through binding of transcription factors (TFs) such as AP-1. GTFs: 
general transcription factors (adapted from deGraffenried et al., 2004).
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The transcription factor Foxo3a has also been implicated in the regulation of 
ERa gene transcription. Foxo3a is a member of the mammalian Forkhead Box (Fox) 
family of transcription factors, which act as transcriptional regulators o f the cell 
cycle progression (Costa, 2005). Using a panel of 5 breast cancer cell lines, Guo & 
Sonenshein (2004) have identified for the first time that the nuclear localization of 
Foxo3a, which is regulated by Akt, correlates with ERa expression. Using ChIP 
analysis and reporter gene assays, the same authors have demonstrated that Foxo3a 
can bind directly to two functional Forkhead Responsive Elements (FHREs) located 
within the promoter C, and induce ERE-meditated reporter activity as well as 
expression of ERa target genes in breast cancer cell lines.
Another potential transcription factor involved in the regulation of ERa gene 
transcription is AP2y, formally known as ERF-1 (McPherson & Weigel, 1999; 
McPherson et al., 1997). The AP2 family of transcription factors consist of five 
members, AP2a-e, o f which the highly homologous AP2a, AP2p and AP2y are 
expressed in several solid tumours including breast cancer (Pellikainen & Kosma, 
2007). AP2y expression has been shown to /rarcs-activate ERa gene transcription in 
human mammary epithelial cells and induce DNase I-hypersensitive sites localized 
to AP2 binding sites just upstream of the start codon within the ERa promoter A. 
(Schuur et al., 2001). In the same study, other binding sites for AP2y have been 
found in the vicinity of the promoters C and E, and have also been shown to coincide 
with DNase I-hypersensitive sites occurring specifically in ERa-positive cells.
The molecular mechanisms, by which ERa transcription is regulated through 
chromatin remodelling in breast cancer, have been demonstrated for the first time in 
vivo with the tumour suppressor pRb2/pl30 (Macaluso et al., 2003; Macaluso et al., 
2005; Macaluso et al., 2007). The latter has been shown to bind directly to a region 
within the promoter A and engage a multi-protein complex with the transcription 
factor E2F4/5 and most importantly with specific chromatin modifying enzymes 
including the histone methyltransferase SUV39H1, DNMT1 (DNA 
methyltransferase 1), HDAC1 and the HAT p300 (Macaluso et al., 2003). Both 
DNMT1 and HDAC1 are important factors involved in the epigenetic silencing of 
many genes including ERs (Yan et al., 2001). Macaluso et al. (2003) have proposed 
that in MCF-7 cells, the presence and high activity of p300 within the pRb2/pl30-
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based macromolecular complex induces the activation of ERa transcription by 
maintaining the chromatin in an “open” state, and therefore allows access o f the 
basal transcription factors to the ERa promoter. In contrast, the same authors have 
shown that in the ER-negative cells MDA-MB-231, the pRb2/pl30-based 
multiprotein complex represses ERa gene transcription through epigenetic 
mechanisms that include the recruitment of DNMT1, and concomitant dislocation of 
p300, which results in chromatin condensation and therefore repress gene expression.
1.4.2 Post-transcriptional regulation
ERa expression is also regulated at the post-transcriptional levels through 
modulation of the receptor mRNA stability, which represents a major mechanism for 
regulation of gene expression. Rates of mRNA degradation in the cytoplasm 
determine protein levels. Like many other steroid hormones, oestradiol autoregulates 
its receptor gene expression by either stabilizing or destabilizing the mRNA in a 
tissue- and developmental-stage specific manner (Ing, 2005; Pinzone et al., 2004). 
In breast cancer, it has long been established that treatment of the MCF-7 cell line 
with oestradiol destabilizes the receptor mRNA and results in a decrease of ERa 
mRNA half-life from approximately 5h in control cells to less than an hour in the 
presence of the hormone (Berthois et al., 1990; Saceda et al., 1998).
The exact molecular mechanisms by which oestradiol regulates ERa mRNA stability 
are still unclear. However, it has been shown that the long 3’-untranslated region 
(3’UTR) of the ERa mRNA has a destabilizing function by mediating cleavage of 
the ERa mRNA by various endoribonucleases (RNases) and therefore reduce the 
ERa mRNA half-life (Kenealy et al., 2000). It is believed that in the context of 
hormonal-mediated regulation o f mRNA stability, oestradiol may regulate the 
expression of RNA-binding proteins that can either protect or expose sites o f the 
ERa mRNA against RNase activities (Ing, 2005). A study by Keen et al. (2005) has 
suggested that the protein phosphatase 2A (PP2A) may be important in the regulation 
of ERa mRNA stability by mediating the binding of a yet-to-be identified factor to 
the 3’UTR of the ERa transcript in MCF-7 cells. The same authors have proposed
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that in the absence of PP2A activity, degradation of ERa mRNA occur as a result of 
the proteasomal degradation of this stabilizing factor. PP2A is a ubiquitously 
expressed holoenzyme and a member of a large protein phosphatase family, which is 
involved in the regulation o f cell proliferation, differentiation and apoptosis 
(Schonthal, 2001).
In addition to modulation of mRNA stability, ERa expression is also determined by 
the translation efficiency of ERa transcripts (Ing, 2005). As mentioned earlier, the 
multiple promoters present within the ERa gene promoters generate mRNA variants 
that differ in their 5’-UTRs (see section 1.5.1). It is known that the structure of 5’- 
UTRs can strongly influence initiation of translation through the presence of 
important regulatory motifs such as upstream open reading frames (uORFs). The 
latter can significantly reduce translation efficiency of the downstream main ORF by 
restricting the access of ribosomes to the authentic start codon (Hughes, 2006; Pesole 
et a/., 2001; Wang & Rothnagel, 2004). The 5’-UTRs of the various ERa mRNA 
variants contain between 1 and 6 uORFs and have been shown to differentially 
regulate ERa expression in breast cancer. Whereas UTRs from the ERa mRNA 
variants T strongly inhibit translation of the downstream main ORF, UTRs from the 
A and C transcripts have been shown to confer the highest translation efficiency, 
which is in agreement with their predominant expression in breast cancer (Kos et al., 
2002).
1.4.3 Post-translational regulation
The rate at which ERa protein is synthesized and degraded (turnover) is also 
a major factor controlling ERa steady state levels and maintaining receptor 
homeostasis. In oestrogen-dependent cell lines, such as MCF-7, unliganded ERa is 
rapidly turned over with a half-life of approximately 5h. As well as activating ERa- 
mediated transcription of target genes, oestrogen binding to the receptor also results 
in a rapid ubiquitination and degradation of ERa via the ubiquitin-proteasome 
pathway, reducing ERa half-life to less than 3h (Lai'os et al., 2005). Different 
ligands can exert opposite effects on steady-state levels of ERa. While the pure anti­
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oestrogen ICI 182,780 (Falsodex®, fulvestrant) causes rapid degradation of the 
receptor with a resulting half-life o f less than lh  (Long & Nephew, 2006), tamoxifen 
stabilizes ERa causing receptor accumulation in the nucleus (Lai’os et al., 2003).
The proteasome-mediated ERa degradation is now known to be necessary for the 
transcriptional activity of ERa as shown by the loss of oestrogen-mediated activation 
of gene transcription concomitant with the use of the proteasome inhibitor MG 132 
(Lonard et al., 2000). Using FRAP analysis (fluorescence recovery after 
photobleaching) and ChIP, Reid et al. (2003) have shown that a proportion of newly 
synthesized and unliganded ERa have high nuclear mobility and continuously cycles 
on E2-responsive genes, with the nuclear matrix-associated proteasome playing a 
central role in clearing the receptor. This cycle is thought to allow continuous 
sensing of E2 levels. Following E2 binding and ERa-mediated transcription, ERa is 
no longer needed and is therefore rapidly degraded by the proteasome in order to 
limit oestrogen responsiveness (Reid et al., 2003). In this cycle, co-factors of ERa 
that are involved in the recruitment of the transcriptional machinery are also 
components of the proteasome degradation pathway and include the ubiquitin ligase 
and coactivators E6-AP and BRCA1 (Chu et al., 2007). Post-translational 
modifications of ERa, such as phosphorylation, also play an important part in 
regulating the cellular levels of the receptor. For example, it has been shown that 
phosphorylation of the serine residue Seri 18 of ERa, which can serve as a 
phosphoacceptor site for MAPKs (Kato et al., 1995), is an essential determinant of 
E2-induced degradation of the receptor (Valley et al., 2005).
J
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1.5 Anti-hormone therapy: response and resistance
1.5.1 Selective Oestrogen Receptor Modulators (SERMs)
Approximately 70% of all breast cancers are dependent for their growth and 
development on oestrogen and a functional ERa (ERa-positive tumours; Ali & 
Coombes, 2002). Therefore, most ERa-positive breast tumours can be effectively 
treated with agents that reduce the growth stimulatory effect of oestrogen. For more 
than 30 years, the anti-oestrogen tamoxifen has been used as the gold standard agent 
for the first line treatment of early and advanced ERa-positive breast cancers in both 
pre- and post-menopausal women (Jordan, 2007). However, a proportion of ERa- 
positive tumours (-30%) do not respond to tamoxifen (de novo resistance). The use 
of tamoxifen as a chemopreventive drug became a clinical reality after the NASBP 
P-l (National Surgical Adjuvant Breast and Bowel Project) study showed that 
administration of tamoxifen at a daily dose of 20 mg for 5 years reduced the 
incidence of invasive and non-invasive breast cancer by approximately 50% in high 
risk pre- and post-menopausal women (Fisher et al., 1998). Thus in 1999, tamoxifen 
became the first drug to be approved by the US food and drug administration (FDA) 
for the prevention of breast cancer in women at increased risk for the disease (Lewis 
& Jordan, 2007).
\ Once in the body, tamoxifen is activated to its active metabolites (including 4-
j hydroxytamoxifen and endoxifene), which binds to ERs with much higher affinityj and competes with oestrogen for binding to the LBD (Ring & Dowset, 2004). This
I results in the blocking of the AF2 region of the receptor and inhibition of ERa-
.mediated transcription through recruitment of co-repressors such as NCoR and 
SMRT (Webb et al., 2003). By failing to inhibit the AF1 region, tamoxifen exhibits 
beneficial oestrogen-like effects in tissues like bones, thus preventing osteoporosis in 
post-menopausal women (Jordan, 2007). However, the partial-agonist activity of 
tamoxifen in the uterus has been shown to increase the risk of endometrial cancer in 
women 50 years o f age and older (Fisher et al., 1998). Other undesirable side effects 
of tamoxifen also include hot flushes and thromboembolic events. The observed 
! oestrogenic and antioestrogenic actions of tamoxifen in different tissues have led to
the reclassification of the drug from a non-steroidal anti-oestrogen to a selective
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oestrogen receptor modulator (SERM, Figure 1.7). Another SERM that has also 
been shown to maintain bone density in postmenopausal women is raloxifene, which 
has been used for the treatment and prevention of osteoporosis for the last 10 years 
(Jordan, 2007). Interestingly, in the multiple outcomes of raloxifene evaluation 
(MORE) study for the prevention of osteoporosis in postmenopausal women, 
raloxifene therapy for 3 years has also been shown to reduce the risk of invasive 
breast cancer by 75% without an increased risk of endometrial cancer (Cumming et 
al., 1999). This study has paved the way for the NSABP-STAR trial (study o f 
tamoxifen and raloxifene), which essentially aimed at testing raloxifene as a 
chemopreventive agent for breast cancer and compared its benefits and side effects 
with tamoxifen in high-risk postmenopausal women (Vogel et al., 2006). Results in 
this study were very promising showing that raloxifene is as effective as tamoxifen in 
k reducing the risk of invasive breast cancer but with reduced risks of endometrial
? cancer and thromboembolic events.
I
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Figure 1.7 Chemical structures of 17/?-oestradiol, fulvestrant, 
tamoxifen and raloxifene.
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1.5.2 Selective Oestrogen Receptor Downregulators (SERDs) and Aromatase
inhibitors
As a result o f the partial oestrogenic effects of SERMs, other anti-hormone 
agents have been developed. Using an alternative endocrine therapy when resistance 
develops can delay the need for cytotoxic chemotherapy, which leads to a 
significantly reduced quality of life and is generally considered to be a last option for 
patients with advanced breast cancer. Therefore, the sequential use of endocrine 
agents is a well acknowledged treatment strategy for advanced breast cancer 
(Gradishar, 2004). Many of the ER-positive breast tumours resistant to tamoxifen 
still respond to second line therapies that can include the pure anti-oestrogen 
fulvestrant or aromatase inhibitors (AIs), indicating that oestrogen still remain an 
important factor in the growth of tamoxifen resistant tumours (Riggins et al., 2007).
Fulvestrant (also known as Faslodex® or ICI 182,780) is the first o f a new type of 
drugs known as selective oestrogen receptor downregulators (SERDs) or pure anti­
oestrogen agents (Figure 1.7). They bind to ER with much higher affinity than 
tamoxifen, and downregulate the cellular levels of the receptor by increasing its 
degradation rate via the 26S proteasome complex. When complexed to ERs, 
fulvestrant prevents receptor dimerisation and disrupt nucleo-cytoplasmic shuttling, 
thereby blocking nuclear localization of the receptor. Most importantly, fulvestrant 
has no oestrogen agonist activity since it is able to block both the AF1 and AF2 sites 
of the receptor, therefore resulting in complete abrogation of ER-mediated 
transcription (Lynn, 2004; Osborne et al., 2004). Phase III clinical trials have shown 
that fulvestrant can be used effectively for the treatment of advanced breast cancers 
that have progressed on tamoxifen but still retain the ER (Howell et al., 2002; 
Osbourne et al., 2002). As a result, fulvestrant is now an FDA-granted alternative 
endocrine agent for the treatment of ER-positive metastatic breast cancer in post­
menopausal women who have relapsed on prior anti-oestrogen therapy including 
tamoxifen (Howell, 2006).
In contrast to SERMs and fulvestrant whose mode of action relies on binding to ERs, 
aromatase inhibitors (AIs) act by preventing the formation of oestrogen from 
androgens in postmenopausal women through inhibition of the aromatase enzymes
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(see section 1.3.1). In postmenopausal women, breast tumours are able to locally 
produce high levels of oestrogen, which can be 10-20 times higher than the 
corresponding plasma oestrogen levels (Geilser, 2003). Anastrozole (arimidex®), 
letrozole (femara®) and exemestane (aromasin®) are the 3 FDA-approved AIs for 
the treatment of ER-positive breast cancer in postmenopausal women (Choueiri et 
al., 2004). AIs are now gradually replacing tamoxifen as a first-line therapy because 
of their superior efficacy for the treatment of metastatic breast cancer in 
postmenopausal women (Dixon & Bundred, 2006). The superior efficacy of AIs 
over tamoxifen has also been shown for the treatment of early breast cancer in 
postmenopausal women by several important phase III clinical trials. For example, 
the Arimidex and Tamoxifen Alone or in Combination (ATAC) trial has shown that 
upfront use of anastrozole for 5 years instead of tamoxifen is a better therapeutic 
option for postmenopausal women with early (localised) ER-positive breast cancer, 
improving disease-free survival by approximately 20% (Howell et al., 2005). 
Although the newer more effective AIs are now gradually being introduced in the 
clinic, tamoxifen still remains the most commonly used anti-hormonal therapy for 
breast cancer for reasons that include its low cost and long-span clinical history (As 
discussed later in this thesis, Chapter 4).
1.5.3 Anti-hormone resistance
Although anti-hormone agents, as represented by SERMs, SERDs and AIs, 
have significantly improved patient care over almost four decades, the major 
consequence of prolonged treatment with endocrine therapy is the development of 
drug resistance. Because tamoxifen is the most commonly used antihormonal agent, 
understanding resistance to tamoxifen is o f obvious clinical importance. Tamoxifen 
treatments result in tumour remission and improve the overall survival in 
approximately 70% of ER-positive breast cancers. However nearly all patients with 
metastatic disease and as many as 40% of patients receiving adjuvant tamoxifen 
therapy (early breast cancer) eventually relapse and acquire resistance to the drug 
despite continued expression of ERa (Ali & Coombes, 2002; Ring & Dowsett,
2004). Resistance to tamoxifen can also be de novo, which is mostly represented by
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patients whose breast cancers lack expression of ERs at the time o f diagnosis 
(approximately 30% of all breast cancer). However, de novo resistance also occurs 
in 30% of ERa-positive breast cancers (Riggins et al., 2007). The efficacy of 
tamoxifen is also greatly limited in ER-positive patients that do not express 
progesterone receptors (Clarke et al., 2003). As reviewed in several publications, 
different mechanisms that could contribute to tamoxifen resistance have been 
proposed including ERa mutation (Graham et al., 1990), increased prevalence of 
ERa protein variants (Poola & Speirs, 2001), alteration of the expression and activity 
of ERa co-factors (Smith et a l,  1997) and of cell cycle regulators (Butt et al., 2005), 
as well as reduced intra-tumoral levels of metabolically activated tamoxifen 
(Osbome et al., 1991). Two other mechanisms that have been identified for 
tamoxifen resistance are utilisation of alternative growth regulatory pathways and 
loss of ERa expression, as described below.
1.5.3.1 Growth factor signalling
One of the most important and well documented mechanisms for tamoxifen 
resistance is aberrant activation of growth factor signalling pathways, which “cross­
talk” with ERs in order to circumvent the anti-proliferative and pro-apoptotic effects 
normally induced by anti-hormonal drugs like tamoxifen (Knowiden et al., 2003; 
Kumar et al., 1996; Kurokawa et al., 2000, Benz et al., 1993). One important and 
well documented signalling pathway involved in mediating tamoxifen resistance is 
EGFR/HER-2/MAPK, whose expression levels and/or activity have been found 
elevated in several in vitro models of tamoxifen-resistant cell lines (Fan et al., 2007; 
Knowlden et al., 2003; Long et al., 1992). The contributing role of EGFR signalling 
in tamoxifen resistance has been demonstrated in vitro with the use of Gefitinib 
(Iressa®), which selectively inhibits EGFR activity resulting in the significant 
inhibition of cell proliferation in TamR cells (Nicholson et al., 2005). An increase in 
EGFR/HER-2 signalling is also evident in clinical materials (Gee et al., 2005).
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EGFR is a member of the ErbB receptor tyrosine kinase family involved in 
regulation of cell proliferation, and which also comprises 3 other members, namely 
erbB2/HER-2, erbB3/HER3 and erbB4. ErbB2 has no known ligand while ErbB3 
harbours a defective tyrosine kinase domain (Harari & Yarden, 2000). It has been 
shown that an EGFR/HER-2-driven autocrine regulatory loop occurs in TamR cells 
in which EGFR/MAPK-induced phosphorylation of tamoxifen-bound ERa at Seri 18 
results in the increased expression of EGFR ligands such as TGFa, and most 
predominantly amphiregulin (AR; Hutcheson et al., 2003; Britton et al., 2006). 
Precisely, Britton et al. have shown that the EGFR/Erkl/2-increased phosphorylation 
of ERa at Seri 18 results in recruitments of the coactivator p68 RNA helicase and 
SRC1 at the AR gene, whose promoter region contain ERE sites (Britton et al.,
2006). As a result, transcription of AR is increased and this provide a constant 
positive feedback loop by further enhancing the activity of EGFR and inducing 
preferential heterodimerization with HER-2. Interestingly, HER-2 is amplified 
and/or overexpressed in 20-30% of breast cancers and is thought to be associated 
with a more aggressive phenotype and a poor clinical outcome to tamoxifen therapy 
(Harari & Yarden, 2000). Encouragingly, recent in vivo studies using xenograft 
models of ERa-positive/HER-2-overexpressing MCF-7 cells, have shown that the 
combinatory inhibition of EGFR (with gefitinib/iressa®) and HER-2 (with 
trastuzumab/herecptin®) result in a significant delay of the development of 
tamoxifen resistance (Arpino et al., 2007).
The role of growth factor receptors and the autocrine actions of their ligands in 
mediating the growth of tamoxifen resistant cells has also been observed with IGF- 
IR and its activating ligand IGF-II. IGF-IR is known to be a key factor in promoting 
the growth of hormone-sensitive breast cancer cells by cross-talking with ERs 
(Nicholson et al., 2005, Cesarone et al., 2006). In vitro studies have demonstrated 
that a “cross-talk” mechanism exists between IGF-IR and EGFR in models o f anti­
hormone resistance including TamR cells (Knowlden et al., 2005; Santen et al.,
2005). One primary consequence of this cross-talk is the further enhancement of 
EGFR signalling in TamR cells. In this cross-talk, the autocrine release of IGF-II 
ligands in TamR cells further activate EGFR signalling through the IGF-IR and the 
non tyrosine kinase c-Src. More precisely, IGF-II-induced activation of c-Src
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through IGF-IR results in phosphorylation of EGFR at tyrosine 845 (Y845) and 
enhancement of EGFR signalling. Interestingly, clinical breast cancer samples 
originating from ER/EGFR-positive tamoxifen-resistant patients have shown 
expression of the activated forms of IGF-IR (Gee et al., 2005). Overall, aberrant 
activation of EGFR signalling (and to a lesser extent IGF-IR signalling) results in 
hyper-activation of downstream effectors such as the MAPKs Erkl/2 and Akt 
(Figure 1.8). The latter components increase the phosphorylation/activity of ERa at 
Seri 18 and Seri67, respectively, thus reducing tamoxifen sensitivity. This so-called 
“cross-talk” mechanism between ERa and growth factor signal pathways is a well 
acknowledged contributory factor of tamoxifen resistance (Osborne et al., 2005; 
Massarweh & Schiff, 2006; Jordan et al., 2004). Furthermore, it was also shown that 
the specific conformation of tamoxifen-bound ERa can result in phosphorylation of 
the receptor at Ser305 by the protein kinase A (PKA), converting tamoxifen from an 
inhibitor to a stimulator of cell proliferation (Michalides et al., 2004).
As mentioned previously, coregulator proteins interacting with ERs at target genes 
can significantly influence ER-mediated transcription. It is now widely recognised 
that alteration of the corepressors to coactivator ratio, which determine the direction 
of transcription (activation or inhibition), can contribute to tamoxifen resistance 
(Kumar et al., 2005; Takimoto et al., 1999). A clinically relevant example is the 
coactivator SRC3/AIB1, which is overexpressed in more than 50% of breast cancers 
and can be activated by MAPKs (Anzick et al., 1997). In vitro studies have shown 
that overexpression of AIB1 in cultured cells enhances the partial-agonist activity of 
tamoxifen, more particularly in cells that also exhibit overexpressed levels of the 
HER-2 receptor (Osborne et al., 2003). Interestingly, Osborne et al. (2003) have 
also showed that patients receiving adjuvant tamoxifen therapy while having high 
levels of HER-2/AIB 1 had a lower disease free survival than patients with low levels 
of HER-2 and/or AIB1. For this reason, the same authors have suggested that 
overexpression of HER-2 represent a poor prognostic factor for tamoxifen therapy 
only if high levels of AIB1 are also present in patients.
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Figure 1.8 Model depicting signaling molecules implicated in anti­
hormone resistance. Inappropriate activation of growth factor (GF) 
signaling pathways can result in anti-hormone resistance. CoAs, 
coactivators; GTFs, general transcription factors (adapted from Nicholson 
& Johnston, 2005).
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1.5.3.2 Loss of ERa expression
Lack of ERa expression at the time of diagnosis represent the major cause of 
de novo resistance to tamoxifen, affecting approximately 30% of all breast cancers. 
Although most ERa-positive breast tumours retain ERa expression over the course of 
endocrine therapy, some can progress to ERa-negative tumours. In the metastatic 
setting, for example, approximately 30% of patients lose ERa expression on 
tamoxifen relapse (Holloway et al., 2004). In endocrine therapy, loss o f ERa 
expression is a major clinical problem because ERa-negative breast tumours are 
associated with a more aggressive phenotype and increased disease spread, which 
ultimately means a worse clinical outcome for the patients (Gruvberger et al., 2001).
There is a continuing debate as to the origins of ERa-negative breast cancers. On 
one hand, evidence present in the literature supports the idea that ER-negative breast 
tumours may evolve either from ERa-positive cells that stop expressing the receptor 
as tumours “naturally” progress and enlarge or in response to prolonged anti- 
hormonal treatments like tamoxifen (adaptive mechanism). Kuukasjarvi & 
coworkers (1996) have reported the loss of ERa expression in metastatic lesions in 
the absence of intervening treatments. In contrast, other studies carried out from 
tumour biopsies (before and after intervening tamoxifen treatments) have 
demonstrated a significant decrease of ERa levels in a proportion of tumours that 
have relapsed on tamoxifen (Johnston et al., 1995). In contrast to the adaptive 
mechanism, it is also believed that a selective mechanism may also underlie both de 
novo and acquired ERa-negative breast cancers. Breast tumours are notoriously 
heterogeneous diseases and may therefore contain a small and stable population of 
ERa-negative progenitor cells, which can become independent of the oestrogen 
environment within the breast tumours and achieve a growth advantage over ERa- 
positive cells as tumours progress or, in the context of anti-hormone therapy, these 
ERa-negative progenitor cells may be naturally selected by tamoxifen, which 
primarily decrease proliferation of ERa-positive cells (Allred et al., 2004; 
Bachleitner-Hofmann, 2002).
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The mechanisms underlying both de novo and acquired ERa-negative breast 
cancers remain poorly defined. However, epigenetic silencing o f the ERa gene has 
been shown to be one contributing factor in approximately 25% of de novo ERa- 
negative breast cancers (Yan et al., 2001). Two extensively studied epigenetic 
mechanisms that might lead to loss of ERa expression is methylation o f CpG islands 
by DNMTs and histone deacetylation by HDACs. CpG islands represent 
cytosine/guanine (GC)-rich areas, which are located within the promoter regions of 
about 40% of mammalian genes (Egger et al., 2004). As described in section 1.6.1, 
the formation of a transcriptional repression complex including DNMT1 and 
HDAC1 has been shown to be present in the proximal promoters of the ERa gene 
and cause ERa silencing in ERa-negative breast cancer cell lines (Macaluso et al., 
2003 and 2007). Hypermethylation of CpG islands within the promoters A and C o f 
the ERa gene is now known to be directly correlated with lack of ERa expression in 
some ERa-negative breast cancer cells including MDA-MB-231 as well as in human 
primary ERa-negative breast cancers. Interestingly, the demethylating agent 5-aza- 
2-deoxycytidine, which inhibits DNMT1, has been shown to re-induce ERa 
expression and function in ERa-negative cell lines (Yan et al., 2001; Yang et al., 
2001). In addition, the loss of critical positive transcription factors involved in ERa 
transcription, such as ERBF-1, has also been suggested to contribute to ERa loss in 
vitro (Yoshida et al., 2000).
Because epigenetic silencing of the ERa gene is a mechanism that can only explain a 
fraction o f ERa-negative breast cancers, other mechanisms are likely to be involved 
in loss of ERa expression. It is now well acknowledged that sustained and 
hyperactivated growth factor signalling may promote significant reduction or even 
loss of ERa expression (Gee et al., 2004; Massarweh & Schiff, 2006; Oh et al., 
2001). In fact, it has been known for some time that an inverse relationship exist 
between EGFR/HER-2 expression and ER levels in clinical breast cancer, with 
overexpression of these growth factor receptors also being associated with decreased 
sensitivity to endocrine therapy and poor prognosis (Ciocca et al., 1992; Nicholson et 
al., 1994; Konecny et al., 2003). These clinical observations have been confirmed 
by a number of in vitro studies. Stoica & co-workers have shown that exogenous 
challenge of the highly ER-positive MCF-7 cells with the ligands EGF, IGF-1 and
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TGF/? results in the significant downregulation of ERa mRNA and protein via 
mechanisms involving EGFR, IGF-IR, and PI3K/Akt (Stoica et al., 1997; Stoica et 
al., 2000a; Stoica et al., 2000b; Stoica et al., 2003a). TPA-induced activation o f the 
protein kinase C (PKC) has also been shown to result in downregulation o f ERa 
expression in MCF-7 cells (Martin et al., 1995). Also, overexpression o f PKC 
isoforms a in ERa-positive cells has been associated with a more aggressive 
phenotype including enhanced cell proliferation and anchorage-independent growth 
(Ways et al., 1995, Tonetti et al., 2000). Overexpression of PKC isoforms a  and 5 
have now been associated with the growth of tamoxifen-resistant cell lines (Frankel 
et al., 2007).
Additional evidence for a negative regulation of ERa expression by hyperactivated 
growth factor signalling pathways have been drawn by transfection studies in MCF-7 
cells. Oh et al. (2001) have shown that transient transfection of constituvely active 
HER-2, MAP3K (Rafl) and MAPK kinase (MEK1) in MCF-7 cells results in 
hyperactivation of the downstream MAPKs Erkl/2 and concomitant downregulation 
of ERa (mRNA and protein), which is reversible by pharmacological inhibition of 
MEK or transfection with dominant negative Erkl/2. In this transfection study, loss 
of ERa expression has been shown to result in oestrogen-independence growth and 
significant reduction in anti-hormone sensitivity. In an attempt to define the 
molecular mechanism underlying loss of ERa, Holloway et al. have demonstrated 
that downregulation of ERa induced by hyperactivated Erkl/2 is mediated, at least in 
part, by the nuclear transcription factor NF-kB (Holloway et al., 2004). 
Interestingly, NF-«B activity is found elevated in ER-negative breast cancer cell lines 
such as MDA-MB-231 (Nakshatri et al., 1997).
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1.6 Src family kinases
1.6.1 Structure and function
Src kinase, the first oncogene to be discovered, was initially identified by
t l iPeyton Rous in the early 20 century as the transforming agent in chicken sarcomas 
(Martin, 2004). It is now known to be a member of the largest family o f non­
receptor tyrosine kinases which, in humans, includes Fyn, Yes, Yrk, Lyn, Hck, Fgr, 
Blk and Lck. Src-family kinases (SFKs) all share a common structure o f six distinct 
functional domains (Figure 1.9): an N-terminal Src Homology (SH) 4 domain 
containing a myristylation site that is involved in anchorage of SFKs to the cell 
membrane, a poorly-conserved unique region, the SH3 and SH2 domains which act 
as “docking” sites for the intracellular substrates of SFKs. The SHI domain 
harbours the tyrosine kinase activity of SFKs at tyrosine residue 419 (Y419), the 
auto-phosphorylation of which is required for the full kinase activity of SFKs. The 
C-terminal negative-regulatory tail contains a highly conserved tyrosine at position 
530 (in human) whose phosphorylation causes a conformational change and 
inactivation of SFKs (Yeatman, 2004).
1.6.2 Src in breast cancer
A considerable amount of data have been generated supporting the role of Src 
as a key signalling molecule in many important cellular pathways including cell 
proliferation, differentiation, survival, motility, and angiogenesis (Yeatman, 2004). 
Elevated Src kinase activity is also known to regulate the development and 
metastatic progression of many types of human cancer including breast cancer 
(Summy et al., 2003). Also, Src kinase activity is greatly increased in breast cancer 
tissue compared to normal breast tissue (Verbeek et al., 1996). Interestingly, 
however, c-Src by itself has not been shown to be a dominant transforming oncogene 
in human cancers (Shalloway et al., 1984). Most importantly, Src acts as key 
mediator of cross-talk between ERa and the EGFR family members, a cross-talk 
known to be important in the acquisition of endocrine resistance (see section 1.5.3.1). 
Indeed, Src can physically interact with both membrane-ERa and EGFR family 
receptors thus relaying the non-genomic action of oestrogen, as described in section
1.3.5.3 (Song & Santen 2006). As such, Src acts as an important mediator of many
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downstream effects of receptor tyrosine kinases (RTKs). Furthermore, previous 
studies have shown that c-Src transfection potentiates EGFR-induced oncogenesis 
(Maa et al., 1995). A Src-dependent phosphorylation of EGFR at tyrosine 845 is 
important for such neoplastic induction (Morgan et al., 2008). Indeed, activation of 
the tyrosine kinase domain leads to auto- and transphosphorylation of the 
intracellular domain of EGFR. Phosphorylated tyrosine residues then serve as 
docking sites for Src, which subsequently phosphoyrlate EGFR at tyrosine 845 and 
activate a complex network of downstream cell-signaling components. These 
include paxillin, phosphoinositol-3-kinase (PI3K), Crk-associated substrate (CAS), 
and STATs (Silva, 2004; Thomas & Brugge, 1997). Furthermore, Src can also be 
activated by various cytoplasmic proteins including focal adhesion kinases (FAKs), 
which play a prominent role in relaying integrin signalling (Brunton et al., 2005).
Y419 Y530
N - SH4 UR SH3 SH2 SHI (kinase) - C
Figure 1.9 Structural organisation of human Src family 
kinases (adapted from Yeatman, 2004). UR, unique region.
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1.6.3 Therapeutic targeting of Src in breast cancer
The role of Src in proliferation, invasion, angiogenesis and metastasis, has led to the 
development of Src inhibitors in breast cancer. Blocking Src activation may slow 
disease progression and potentially play an important role in the adjuvant setting to 
prevent disease recurrence and the development o f metastases. In preclinical models 
of acquired tamoxifen resistance, elevated levels of EGFR activity have been shown 
to be accompanied by an increase in Src activity and sensitivity to the Src inhibitor 
AZD0530 (Hiscox et al., 2006).
AZD0530 (AstraZeneca, Wilmington, Delaware) is a highly selective, dual-specific, 
and orally available small-molecule currently in phase I studies (Hennequin et al., 
2006). It inhibits Src and Abl kinase activity by competing for binding at the ATP 
binding pocket of Src/Abl proteins. AZD0530 was shown to inhibit both anchorage- 
dependent and -independent growth in several cell lines and to also increase cell 
sensitivity to growth inhibition by tamoxifen (Herynk et al., 2006). There are two 
other orally-active competitive ATP inhibitors currently in Phase I clinical trials: 
Dasatinib (BMS354825, Bristol Myers Squibb) and SKI-606 (Wyeth Research, 
Lombardo et al., 2004).
Dasatinib is currently approved for second-line treatment of chronic myelogenous 
leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic 
leukaemia. Encouragingly, preclinical studies in breast cancer have shown that 
breast cancer cell lines representing the basal/triple-negative subtype are uniquely 
sensitive to growth inhibition by Dasatinib (Finn et al., 2007). Furthermore, 
treatment of the ER-negative MDA-MB-231 human breast cancer cells with SKI-606 
also resulted in a dose-dependent inhibition of cellular proliferation and invasion 
(Jallal et al., 2007).
A number of other Src-inhibitory small molecules exist, which inhibit Src protein- 
protein interactions by blocking the SH2 and SH3 domains of Src (Oneyama et al.,
2002), while some other Src-inhibitory agents, such as the benzoquinone antibiotics, 
interfere with the stability of Src protein by inhibiting the molecular chaperone Heat 
Shock Protein 90 (Hsp90, Beliakoff & Whitesell, 2004).
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1.7 AIMS
ERa expression remains a strong predictor of good primary response to 
tamoxifen. However, one great challenge in breast cancer prevention and treatment 
is to prevent a drift towards more aggressive cancer cell behaviour as exemplified by 
both the de novo and acquired ERa-negative forms of the disease. Current hormonal 
therapies like tamoxifen are almost entirely ineffective in ERa-negative breast 
cancers, which are ultimately treated with cytotoxic chemotherapies. Although the 
development of acquired resistance to tamoxifen is mainly associated with 
maintained ERa expression, previous in vivo studies carried out from tumour 
biopsies (before and after intervening tamoxifen treatments) have demonstrated a 
significant decrease of ERa levels in tumours that have relapsed on tamoxifen. 
Although less commonly observed, the same studies have also shown that a 
proportion of breast tumours evolve from an ER-positive to an ER-negative status on 
relapse to tamoxifen in the adjuvant and metastatic settings (Johnston et al., 1995; 
Kuukasjarvi et al., 1996). The exact molecular mechanisms underlying ERa 
expression and loss over the course of anti-hormone treatments are still unclear. In 
light of the aforementioned clinical observations regarding ERa loss, this project 
aimed to develop an in vitro model of tamoxifen resistant cells in order to investigate 
whether long term tamoxifen treatment can induce loss of ERa expression in vitro 
thereby allowing one to study the underlying mechanisms. The present work was 
associated with two main study arms, which were:
• Analysis of ERa expression using in vitro models of MCF-7-derived
tamoxifen resistant breast cancer cells (TamRs), which were cultured in the
presence of 4-hydroxy-tamoxifen (4-OHT) up to a 30 month period. Using 
quantitative PCR, the expression of total ERa mRNA and its constituent 
mRNA variants were quantified in the endocrine-sensitive MCF7 cells, and 
TamR cells. Expression of ERa protein was also assessed by western blot 
and immunocytochemical analyses.
■ Investigation of the molecular mechanisms involved in the regulation o f ERa
expression in TamR cells by means of pharmacological challenges.
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Unless otherwise stated, all tissue culture medium and their chemical constituents 
were purchased from Gibco®-Invitrogen (Paisley, UK). All tissue culture plastic 
ware was purchased from Nunc (Roskilde, Denmark), supplied by Fisher Scientific 
(Loughborough, UK). All general molecular grade chemicals, organic solvents and 
molecular biology reagents were obtained from Sigma-Aldrich® (Poole, Dorset, UK) 
unless otherwise stated.
2.1 Routine cell culture maintenance
All cell culture procedures were carried out in MDH Class II laminar-flow 
safety cabinets (BIOQUELL UK Ltd, Andover, UK). Cells were routinely grown in 
75 cm2 flasks and incubated at 37°C in a humidified 5% CO2 atmosphere using 
Sanyo MCO-17AIC incubators (Sanyo Gallenkamp, Loughborough, UK). Culture 
media were changed every 3 to 4 days and cell confluency was routinely assessed 
using the Nikon Eclispse TE200 phase-contrast microscope (Nikon Ltd, Kingstom- 
upon-Thames, UK). All cell lines were passaged when 80% confluency was 
reached. Throughout this study, the cell lines MCF-7, FasR and Tam/TKI-R were 
cultured for a maximum number of 20-25 passages (~ 12 weeks). TamR cells were 
passaged to a maximum of 10 times (~ 8 weeks) to avoid overlapping between the 
different TamR sub-variants (see section 2.1.1.2). When required, frozen cell stocks 
were thawed as described in section 2.1.2.2.
2.1.1 Cell lines
2.1.1.1 MCF-7 cells
The endocrine-sensitive MCF-7 wild-type cell line was kindly provided by 
AstraZeneca Pharmaceuticals (Cheshire, UK). MCF-7 cells were routinely 
maintained in phenol red-containing RPMI 1640 medium (rRPMI), supplemented 
with 5% (v/v) foetal calf serum (FCS), penicillin (100 u/ml), streptomycin (10 
pg/ml), and fungizone (2.5 pg/ml). For all experimental procedures, MCF-7 cells 
were washed three times with pre-warmed Dulbecco’s PBS and transferred in 
phenol-red-free RPMI (wRPMI) supplemented with 5% charcoal-stripped FCS
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(SFCS), L-glutamine (200 mM), the aforementioned antibiotic and anti-fungal 
agents. The charcoal stripping procedure was carried out in order to deplete any 
steroidal compounds present in the serum (see section 2.1.2.3).
2.1.1.2 TamR cells
The tamoxifen-resistant cells (TamR) were originally derived from MCF-7 
cells, which were continuously exposed to 10‘7 M 4-hydroxytamoxifen (4-OHT, 
AstraZeneca Pharmaceuticals) over a period of 6 months in wRPMI medium 
containing 5% SFCS and the aforementioned L-glutamine, antibiotic and anti-fungal 
agents (referred to as wRPMI + 5% SFSC). After an initial period o f growth 
inhibition (~ 2 months), outgrowth of resistant cells occurred (Knowlden et al.,
2003). In the present study, TamR-3, TamR-11 and TamR-18 cells corresponded to 
cells that were exposed to 4-OHT for 3-, 11-, and 18 months, respectively. Long­
term TamR-24 and TamR-30 cells were generated by continuous exposure o f TamR- 
18 cells with 4-OHT for an extended period of 6 months and 12 months, 
respectively. All TamR cells were routinely maintained in wRPMI + 5% SFSC 
medium supplemented with 4-OHT (10‘7 M, in ethanol).
2.1.1.3 FasR cells
The Faslodex-resistant cell line (FasR) was originally derived from 
continuous exposure of MCF-7 cells tolO’7 M fulvestrant (ICI 182, 780/faslodex®, 
AstraZeneca Pharmaceuticals) in wRPMI + 5% SFCS over a period of approximately 
6 months (McClelland et al., 2001). In the present study, long-term FasR cells, 
which have been cultured in the presence of ICI 182, 780 (10'7 M in ethanol) for 24 
months, were used.
49
Chapter 2. Material and Methods
2.1.1.4 Tam/TKI-R cells
Tam/TKI-R cells were originally established by continuous exposure of 
TamR-11 cells to the specific EGFR inhibitor gefitinib/Iressa® (1 pM in DMSO, 
AstraZeneca Pharmaceuticals) for 6 months in wRPMI + 5% SFCS (Jones et al.,
2004). In the present study, Tam/TKI-R cells were maintained wRPMI + 5% SFCS 
supplemented with 4-OHT (10‘7 M) and gefitinib (1 pM).
2.1.2 Routine technical procedures for cell culture
2.1.2.1 Cell passaging
At ~ 80% confluency, medium was removed from the flask and cells were 
detached by incubation with 10 ml of pre-warmed trypsin/EDTA (0.05%/0.02% v/v 
in PBS) for 3-5 minutes in the incubator, or until cells were in suspension. 
Trypsin/EDTA was neutralized by adding an equal volume of cell medium in the 
flask (rRPMI + 5% FCS, or wRPMI + 5% SFCS depending on cell lines). The cell 
suspension was transferred to a sterile universal container and cells were then 
pelleted by centrifugation at 1,000 rpm for 5 minutes (Mistral 3000i centrifuge, 
Sanyo Gallenkamp, Loughborough, UK). Using a pipette, the cell pellet was 
thoroughly but gently re-suspended in 10 ml of the appropriate medium. Cells were 
then seeded into fresh flasks at a split ratio of 1:10 (MCF-7, TamR-3, TamR-11, 
TamR-18), 1:20 (TamR-24), or 1:30 (TamR-30) in 15 ml medium (per 75 cm2 flask).
2.1.2.2 Cryo-preservation of cell lines
Freezing procedures were carried out as follows: cells were trypsinized as 
previously described and re-suspended in 10 ml of the appropriate medium and 
counted as described in section 2.1.5. Cells were then pelleted by centrifugation 
(1,000 rpm, 5 minutes) and re-suspended at a density of lx l0 6 cells/ml in the 
appropriate medium supplemented with 10% FCS or SFCS and containing 7.5% 
DMSO (v/v). 1 ml cell aliquots were then prepared in cryo-vials and immediately 
put at -80°C for 24 hours. Cells were then transferred to liquid nitrogen for long-
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term storage. For thawing procedures, cryo-vials were removed from liquid nitrogen 
and thawed as quickly as possible to limit cell exposure to DMSO. Vials were then 
sprayed with 70% ethanol in a sterile laminar-flow cabinet and allowed to evaporate 
completely prior to opening of the vials. Cells were transferred to a sterile universal 
container, washed with 9 ml of the appropriate medium and pelleted by 
centrifugation (1, 000 rpm, 5 minutes). Cells were re-suspended in the appropriate 
medium containing 5% FCS or SFCS and transferred into 12.5 cm2 flasks for 
overnight incubation at 37°C. Medium was changed and cells cultured as normal.
2.1.2.3 Charcoal stripping procedure for 100 ml FCS
A charcoal solution (2 g activated charcoal, 0.01 g dextran T70 in 18 ml 
dFhO) was stirred vigorously for at least one hour. FCS was adjusted to pH = 4.2 
using HC1 (5 M) and allowed to equilibrate for 30 minutes at 4°C. 5 ml o f charcoal 
solution was added to 100 ml FCS and the solution stirred gently for 16 hours at 4°C. 
Charcoal was then removed by centrifugation (12, 000 rpm for 40 minutes) and the 
supernatant coarse-filtered through Whatman filter paper No. 4 to ensure total 
removal of of charcoal. The solution was re-adjusted to pH = 7.2 using NaOH (5 M) 
and filter-sterilized using a 0.2 pM Supor Vacucap® membranes (Gellman 
Laboratory Pall, Ann Arbor, USA). Charcoal-stripped FCS was aliquotted in sterile 
universal container and stored at -20°C.
2.1.2.4 Cell counting
To seed cells for experimental analysis, cell monolayers were washed twice 
in pre-warmed PBS, trypsinized and re-suspended in the appropriate medium, as 
described in section 2.1.2.1. Cells were then passed through a sterile 25G syringe 
needle in order to obtain a single-cell suspension. 50 pi of this suspension was added 
to 10 ml of Isoton® II solution and cell number was determined using a Coulter™ 
Multisizer II (Beckam Coulter UK Ltd, High Wycombe, UK). Cells were then 
seeded into flasks or dishes in the appropriate medium at the required cell densities.
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For basal growth curve analysis and growth responses to faslodex and gefitinib, cells 
were seeded into a 24-well plate at the appropriate densities and carried out as 
described in Chapter 2-Results (Figure 3.17 and Figure 3.18). Following growth of 
cells, the medium was removed from wells prior to the addition of 1 ml 
trypsin/EDTA per well. Plates were incubated at 37°C in the aforementioned Sanyo 
MCO-17AIC incubator for 5 minutes, or until the cells detached from wells. Cells 
were transferred into a 5 ml syringe by passing through a 25G needle three times in 
order to obtain single-cell suspensions. 3 x 1 ml of Isoton® solution was added in 
each well and also transferred to the same 5ml syringe to make up a 4 ml cell 
suspension. The latter was mixed with 6 ml of Isoton® solution in a counting cup to 
give a total 10 ml cell suspension, which was counted using the Coulter™ Multisizer 
II according to the manufacturer’s instructions. The counts obtained were multiplied 
by 20 to give the total number of cells per well.
2.1.3 Treatments
Throughout this study, cells were subjected to treatments with various 
compounds including hormones, anti-hormones, and signal transduction inhibitors 
(STIs). Details of these treatments (durations and compound concentrations) are 
indicated in figure legends throughout Chapter 3-Results.
2.2 Gene expression analysis
2.2.1 Total RNA extraction
All the centrifugation steps were performed at 13, 000 rpm for 10 minutes at 
4°C (Labofuge 400R centrifuge, Heraeus, Germany). Cells were grown in the 
appropriate routine medium in 100 mm dishes at a seeding density o f 1 x 106 or 0.5 x 
106 (TamR-30 cells) unless otherwise stated in Chapter 2-Results. Total RNA 
extractions were performed using the TRI REAGENT® according to the 
manufacturer’s instructions (Sigma-Aldrich®, Poole, UK). Briefly, cells were
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washed twice with pre-warmed PBS and lysed directly on the dish by adding 1 ml of 
TRI REAGENT®. After 5 minutes, the viscous solution was transferred to sterile 
eppendorf tubes (Elkay, Galway, Ireland) to which 0.2 ml o f chloroform was added 
(per ml of TRI REAGENT®). The solutions were vigorously but gently mixed for 15 
seconds and allowed to stand at room temperature for 10 minutes prior to 
centrifugation. The upper aqueous phase (containing total RNA) was transferred into 
a fresh eppendorf tube to which 0.5 ml isopropanol (per ml of TRI REAGENT®) 
was added to precipitate RNA. Samples were vigorously mixed and incubated at 
room temperature for 10 minutes prior to centrifugation. RNA pellets were then 
washed with 1 ml 75% ethanol (per ml of TRI REAGENT®) followed by 
centrifugation. The supernatant was discarded and RNA pellets were air-dried for 10 
minutes and dissolved in 20-50 pi of nuclease-free water (Sigma-Aldrich®). 
Samples were routinely stored at -70°C.
2.2.2 Nucleic acid quantification by spectrophotometry
Nucleic acids were diluted 1:200 in Tris/EDTA buffer (10 mM Tris-Cl, 1 mM 
EDTA; pH = 8) and transferred to quartz cuvettes. Nucleic acid concentrations were 
determined by measuring the optical density (OD) of the diluted nucleic acid 
solutions at 260 nm and 280 nm using the Cecil CE 2041 spectrophotometer 
(Cambridge, UK). RNA or DNA concentrations (pg/ml) were calculated according 
to the formulas below. Pure DNA and RNA samples are expected to have a 
A260/A280 ratio of approximately 1.8 and 2.0, respectively (Sambrook et al., 1989).
(A260) x (50pg/ml) x dilution factor = pg/ml DNA 
(A260) x (40pg/ml) x dilution factor = pg/ml RNA
2.2.3 cDNA synthesis by reverse-transcription PCR (RT-PCR)
Complementary DNA strands (cDNA) were generated from total RNA using 
the Molony-murine leukaemia virus (MMLV)-reverse transcriptase enzyme 
(Invitrogen, Paisley, UK) and random hexamer oligonucleotides (Amersham
53
Chapter 2. Material and Methods
Bioscience, Buckinghamshire, UK). RT-PCR reactions were carried out on ice in a 
final volume of 20 pi as follows: 1 pg total RNA was adjusted to a volume of 7.5 pi 
with nuclease-free dfhO and mixed with 11 pi of a master-mix containing:
- 2 pi random hexamers (100 pM stock, Pharmacia Biotechnologies, Hertz, UK)
- 5 pi dNTP mix (2.5 mM stock containing 0.625 mM of each dNTP, Invitrogen),
- 2 pi DTT (0.1 M stock),
- 2 pi 10X PCR buffer (100 mM Tris-HCl, 500 mM KC1, 15 mM MgCl2, 0.01% v/v 
gelatine).
Reaction mixtures were incubated at 95°C for 5 minutes (denaturation step) using the 
PTC-100 thermocycler (MJ Research Ltd., Massachusetts, USA) and were then 
rapidly cooled on ice prior to brief centrifugation. 1 pi of MMLV enzyme (200 
U/pl) and 0.5 pi of RNasin™ RNAse inhibitor (40 U/pl) were added to the reaction 
mixtures, bringing the final volume to 20 pi. RT-PCR reactions were run in the 
PTC-100 thermocycler using the following standard cycle conditions: step 1, 
22°C/10 minutes; step 2, 42°C/40 minutes; step 3, 95°C/5 minutes.
2.2.4 Real time quantitative PCR (qPCR) analysis of total ERa and ERa 
mRNA variants
Using cDNA samples as templates, expression levels of total ERa mRNA and 
ERa mRNA variants were quantitatively assessed by qPCR analysis with the 
DyNAmo™ SYBR® Green qPCR Kit (Finnzymes, Espoo, Finland). All real-time 
qPCR reactions were carried out in the DNA Engine® Opticon 2 system (MJ 
Research Ltd., Massachusetts, USA), which combined a continuous fluorescence 
detector and a traditional thermal cycler. All qPCR reactions were set up on ice in a 
Labconco Purifier PCR enclosure (GRI, Rayne, UK).
54
Chapter 2. Material and Methods
2.2.4.1 Primers
Primer pairs for /Tactin and total ERa were as previously reported and were 
originally designed to span introns/exon borders for the detection of any potential 
genomic DNA contamination (Knowlden et al., 1997). Primer sequences are shown 
in Table 2.1. Primers for specific qPCR amplifications of each ERa mRNA variant 
were designed similarly to previous studies (Donaghue et al., 1999; Flouriot et al., 
1998). Primer pairs consisted of a forward oligonucleotide designed to specifically 
bind a region within the 5’UTR (untranslated region) that is unique to each ERa 
mRNA species; and a common reverse oligonucleotide (used in all qPCR reactions) 
designed to anneal to a region within the 5’ end of the protein coding region exon 
1 (Figure 2.1). Primers were designed with the online Primer3-web 0.3.0 software 
package using the default settings (Rozen & Skaletsky, 2000). The input DNA 
sequences corresponding to the different ERa promoters (A to F) were retrieved from 
the Ensembl gene sequence ENSG00000091831 (ESR1, http://www.ensembl.orgk 
Specificity of all primers was checked using the NCBI-BLASTN program (Altschul 
etal., 1990).
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Table 2.1 Primer sequences for /?-actin, total ERa and ERa variants
Gene Primer sequence Amplicon size (bp)
/?-actin forwardreverse
5'-GGA GCA ATG ATC TTG ATC TT-3’ 
3'-CCT TCC TGG GCA TGG AGT CCT-5’ 204
total ERa forward 5 ’ -GGAG AC ATG AGAGCTGCC AAC-3 ’ 432reverse 3’-CCAGCAGCATGTCGAAGATC-5’
variant A forward 5 ’ - AT G AGCTCGGG AG ACC AGT A-3 ’ 242reverse* 3 ’ - AGGGC AGAAGGCTC AGAAAC-5 ’
variant B forward 5 ’ -GGC AC AT AAGGC AGC AC ATT-3 ’ 190reverse* 3 ’ - AGGGC AG A AGGCTC AG AA AC-5 ’
variant C forward 5’-TTCACACACTGAGCCACTCG-3’ 150reverse* 3 ’ - AGGGC AGAAGGCTC AG AAAC-5 ’
variant D forward 5 ’ - AGC AG ACCGCT GG AAAAGT-3 ’ 116reverse* 3 ’ - AGGGC AG AAGGCT C AG AAAC-5 ’
variant E forward 5 ’-ACC AAATATC AGC AC AGC ACTTC-3 ’ 102reverse* 3 ’ - AGGGC AG AAGGCT C AG AAAC-5 ’
variant F forward 5 ’ -GGTCC ATGCTCCTTTCTCCT-3 ’ 100reverse* 3’-AGGGCAGAAGGCTCAGAAAC-5’
* common reverse primer
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s'H >- exon 5 +y
(i) common reverse primer
(ii) universal primers
(i) (ii)
(B)
E l
D
B
...GGATTT TACCAAAACT GAAAATGCAGGCTC CATGCTCAGAAGCTC TTTAACAGGC TCGA 
AAGGTCCATGCTCCTTTCTCCTGCCCATTCTATAGCATAAGAAGACAGTCTCTGAGTGAT 
AATCTTCTCTTCAAGGTGGCCCGCCGGTTTCTTCTCAATTTATTTTTTCCTTTTTGATAT
  — —  / / ----------------------------------------------------------------------------------
TAATTAAGGAAATCTGT AGAAATCAC CCACATCTCC CTTTC CTTCT CTGTT AAAAAAACA 
AAAGGAA GAAGA AAACT AGGA AGGAG T AAGC AC AAA GAT CT CTTCACATTC TCCGG GACT 
GCGGTACCAAATATCAGCACAGCACTTCTTGAAAAAGGATGTAGATTTTAATCTGAACTT 
TGAACCATCACT GAGGT ATGT GTGAACATAC TAGTT TCCTC TTTCT CTCTC CTGAC TTTG
 / /  -----
CACGGGGAAGTTGAGAGGAACACCATGTTTGAGAATGGTGACTCATATTTGAACAAGCCT 
GCAATGCCCAGCAGACCGCTGGAAAAGTGGGGCTGGAGACACATTCAACGG AGGAG CCAG 
ATCAATCTTTACCCTTCTTCACCTGAGAGAGCCAGTAAGTCACGGCTGGAACGTGT GTGT 
CCAGCAGGAGAGGGTAGGGAGGGAAGCCAAGAGAGCTGGGAGCCCGAGTGAAGTTTTTGC
 / / _  -----------------------------
ACAAACA CATCC ACACA CTCT CTCTG CCT AG TTCAC ACACT GAGCC ACTCGCACAT GCGA 
GCACATTCCTTCCTTCC TTCTCACTC TCTCGGCCCT TGACT TCTACAAGCC CATGGAACA 
TTTCTGGAAAGACGTTCTTGATCCAGCAGGGTAGGCTTGTTTTGATTTCTCTCTCTGTAG / / ------------------------------------------------
CGAGGAG GGGGA AT C AA AC AG AAAGA GAGAC AAACA GAGAT AT AT C GGAGT CTGGCACGG 
GGCACATAAGGC AGCAC ATTAGAGAAAGCCG GCCCC TGGAT CCGTC TTTCG CGTTT ATTT 
TAAGCCC AGTCT TCCCT GGGC CACCT TT AGC AGATC CTCGT GCGCC CCCGC CCCCT GGCC 
GTGAAAC TCAGC CTCTATCCA GCAGC GACGA CAAGT AAAGT AAAGT TCAGG GAAGC TGCT 
CTTTGGG ATCGC TCCAA AT CGAGTTGTGCCT GGAGT GATGT TTAAG CCAAT GTCAG GGCA 
AGGCAAC AGTCC CTGGC CGTCCTCCAGCACCTTTGTAATGCATATGAGCTCGGGAGACCA 
GTACTTAAAGTT GGAGG CCCG GGAGC CCAGG AGCTG GCGGAGGGCG TTCGT CCTGG GACT 
GCACTTG CTCCC GTCGG GTCG CCCGG CTTCACCGGA CCCGC AGGCT CCCGG GGCAG GGCC 
GGGGCCAGAGCTCGCGTGTCGGCGGGACATG CGCTGCGTCGCCTCTAACCT CGGGCTGTG 
CTCTTTTTCCAGGTGGCCCGC CGGTTTCTGAGCCTTCTGCCCTGCGGGGACACGGT CTGC
ACCCTGC CCGCG GCCAC GGAC CATG...
*
Figure 2.1 Location of prim ers specific for ERa mRNA variants. (A)
Schematic location of primers on the ERa gene promoter and protein coding 
region. Short coloured arrows indicate forward primers specific for ERa 
mRNA variants and the short black arrow represents the common reverse 
primer used in all qPCR reactions for the amplification of ERa transcript 
variants. As indicated by the short dotted arrows, universal primers were used 
to amplify total levels of ERa transcript. (B) Genomic sequence of the 5’-end 
of the ERa gene (Ensembl gene ID: ENSG00000091831) with the exact 
location and sequence of ERa variant-specific primers. Each promoter region 
is highlighted in grey. The exact location and sequence of the transcript- 
specific primers is shown in bold red font. The common reverse primer is 
located at the 5’-end of exon 1 as indicated by underlined black bold font. The 
translation start site is indicated by an asterisk.
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2.2.4.2 Preparation of cDNA standards
For quantitative assessment of total and variant-ERa mRNA expression in the 
various cell lines, standard curves were generated during each qPCR run and 
corresponded to a range of known concentrations of total ERa cDNA amplicons. 
The latter were produced by semi-quantitative PCR {section 2.2.5) using total ERa 
primers and analyzed by agarose gel electrophoresis {section 2.2.6) prior to their 
purification by gel extraction according to the manufacturer’s instructions (QIAquick 
Gel Extraction Kit, Quiagen Ltd., Crawley, UK). Total ERa cDNA amplicons were 
quantified by spectrophotometry using the GeneQuant RNA/DNA Calculator 
(Biochrom Ltd., Cambridge, UK) and were then serially diluted in nuclease-free 
dFUO to generate a known concentration range of total ERa cDNA standards, which 
were included in each qPCR run. The same protocol was also used to generate 
cDNA standards for quantitative measurements of /?-actin signals, against which all 
qPCR data were normalized. Using a serial dilution factor of 10, the optimized 
concentration range was 10 pg/pl-0.0001 pg/pl and 100 pg/0.001 pg/pl for total ERa 
cDNA and /?-actin standards, respectively.
2.2.4.3 Real-time qPCR reaction set ups
Real-time quantification of total and variant-ERa mRNA expression in 
unknown samples was carried out using the total ERa cDNA standards. Real-time 
qPCR reactions for the assessment of /Lactin signals (using the /?-actin cDNA 
standards) in the same unknown samples were performed alongside but in different 
wells since SYBR Green is unable to discriminate between different double-stranded 
DNA fragments. All qPCR reactions were set up in 96-well multiplate low-profile 
PCR plates (Bio-Rad Laboratories Ltd., Hertz, UK), in a total volume of 25pi 
containing the following reagents: 12.5 pi of IX DyNAmo PCR solution (containing 
dNTPs, PCR buffer, hot-start Taq polymerase and SYBR Green dye), 0.375 pi 
forward primer (20 pM stock), 0.375 pi reverse primer (20 pM stock), 11.3 pi 
nuclease-free dH20, and 0.5 pi cDNA template (standard or unknown sample). To 
reduce experimental errors, a master mix (containing all the reagents except cDNA) 
was routinely prepared and distributed evenly (24.5 pi) across the wells prior to the
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addition of 0.5 pi of the appropriate cDNA template. Negative controls (24.5 pi + 
0.5 pi nuclease-free dH20) and blanks (12.5 pi IX DyNAmo PCR solution + 12.5 pi 
nuclease-free dt^O ) were systematically included in all qPCR runs. Wells were 
sealed tightly using flat cap strips (Bio-Rad Laboratories Ltd., Hertz, UK) and mixed 
prior to brief centrifugation for 30 seconds at 2,000 rpm (Labofuge 400R centrifuge, 
Heraeus, Germany). qPCR Cycling conditions were as follows:
Step 1: initial denaturation (hot-start)
Step 2: denaturation
Step3: annealing
Step 4: extension
Step 6: melting curve analysis
95°C/15 minutes 
94°C/1 minute 
58°C/30 seconds 
72°C/1 minute 
from 50°C to 95°C
x 40
2.2.4.4 Data analysis
At the end of each qPCR run, a “Data” graph of Fluorescence (or log 
fluorescence) versus Cycle number, and a “Standards” graph of Log Quantity versus 
c(t) Cycle were automatically generated and plotted by the DNA Engine® Opticon 2 
software (Figure 2.2). The c(t) or cycle threshold refers to the cycle at which a 
sample’s fluorescent signal surpass background fluorescence “noise”. As described 
by the manufacturer’s instructions, the c(t) line was manually positioned on the 
“Data” graph of baseline and blank subtracted data prior to any quantitation of 
cDNA amplicons in standards and samples. The c(t) line was positioned just above 
background noise (whereby fluorescent signals start to increase) and adjusted so that 
the R value associated with the “Standards” graph be at least 0.996 in order to 
ensure the accuracy of quantity data. The “Standards” graph of known initial amount 
of cDNA templates was then automatically used by the DNA Engine® Opticon 2 
software in order to calculate the quantity (pre-set in pg/pl) of initial cDNA template 
in unknown samples. PCR product homogeneity in standards and unknown samples 
was routinely checked by “Melting curve” analysis, which was performed at the end 
of the cycling protocol (step 6). The “Melting curve” analysis was set up so that 
continuous fluorescent reading in samples was performed every 1 °C (for 10 seconds)
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from 50°C to 95°C. The “Melting curve” was automatically plotted at the end of 
each qPCR run by DNA Engine® Opticon 2 software.
(A)
o -
0.01
0.001
0.0001- 2 . 5 -
20 30
|C(T) Cycle
(B)
10 20 30 40
Cycle
Figure 2.2 Example of a (A) Standard and (B) Data 
graph for total ERa cDNA standards, as generated by the 
Opticon 2 software. The concentration range of total ERa 
cDNA amplicons (run in duplicate) are indicated (10-0.0001 
pg/jil). C(t), cycle treshold line.
60
Chapter 2. Material and Methods
2.2.5 Semi-quantitative PCR
All semi-qPCR reactions were carried out in the aforementioned PCR 
enclosure. PCR reactions were performed in a total volume of 25 pi by adding 0.5 pi 
of cDNA templates to the following master-mix in a sterile 0.5 ml eppendorf tube:
- 18.6 pi nuclease-free dfCO (adjusted to 18 pi for /?-actin amplification) 
-2.5 pi 1 OX PCR buffer
- 2 pi dNTPs (2.5 mM stock)
- 0.6 pi forward-primer (20 pM stock) or 0.3 pi (for /?-actin)
- 0.6 pi reverse-primer (20 pM stock) or 0.3 pi (for /?-actin)
- 0.2 pi BIOTAQ™ DNA polymerase (5 U/pl; Bioline Ltd., London, UK)
Reaction mixtures were thoroughly but gently mixed and briefly centrifuged (IEC 
Micromax RF, Thermo Electron, Hampshire, UK). Semi-qPCR reactions were 
performed in the aforementioned PTC-100 thermocycler pre-set with a heated lid to 
prevent any volume loss through evaporation. PCR running conditions were as 
follows:
step 1 (initial denaturation): 94°C/5 minutes 
step 2 (denaturation): 94°C/1 minutes
step 3 (annealing): 58°C/1 minutes
step 4 (Extension) 72°C/1 minutes
step 5 (final extension): 72°C/5 minutes
x 25 (/7-actin) 
x 28 (total ERa) 
x 35 (ERa variants)
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2.2.6 Agarose gel electrophoresis
Electrophoretic separations of nucleic acids were run in agarose gels cast in 
IX Tris-Acetate EDTA/TAE buffer (40 mM Tris-acetate, 1 mM EDTA) in the 
presence of 0.2 pg/pl ethidium bromide. For a 3% agarose gel, 3 g o f agarose 
(Bioline Ltd., London, UK) was dissolved in 100 ml IX TAE buffer and the solution 
heated in a microwave for ~ 2 minutes. The solution was allowed to cool prior to the 
addition of 2 pi ethidium bromide (10 mg/ml), gently mixed and poured into a tray 
containing the appropriate comb. The polymerized gel was placed into the Mini- 
Sub® Cell GT electrophoretic tank (Bio-Rad Laboratories Ltd., Hertz, UK) filled 
with IX TAE buffer. Appropriate volumes of PCR products were mixed with IX 
DNA loading buffer (60% w/v sucrose, 0.05% w/v bromophenol blue) and dispensed 
into the wells. 5 pi of a molecular-weight DNA marker was also included in the gel 
for assessment of DNA fragment sizes (HyperLadder IV, Bioline Ltd., Hertz, UK). 
Electrophoreses were carried out at 70 V constant voltage for approximately 40-60 
minutes (Bio-Rad Power-PAC 1000). Gels were then visualized on a standard UV 
transilluminator and pictures taken using the AlphaDigiDoc™ System 1000 (Genetic 
Technologies Inc., Miami, USA).
2.3 Protein expression analysis
2.3.1 Protein cell lysis
Cells were grown in the appropriate routine medium in 60 mm dishes at a 
seeding density of 5 x 105 cells/dish (MCF-7, TamR-3, TamR-11, TamR-18, TamR- 
24 cells) or 0.25 xlO5 cells/dish (TamR-30 cells), unless otherwise stated in Chapter 
3. Culture medium was then removed and cells were washed twice with pre-warmed 
PBS prior to cell lysis with ice-cold Triton-XlOO lysis buffer pH 7.5 (50 mM Tris 
base, 150 mM NaCl, 5 mM EGTA, 1% v/v triton-XlOO) containing a freshly-added 
cocktail of protease and phosphatase inhibitors at the following final concentrations: 
sodium orthovanadate (Na3V0 4 , 2mM), sodium fluoride (NaF, 200 mM), sodium 
molybdate (10 mM), phenylmethylsulfonyl fluoride (PMSF, 1 mM), phenylarsine 
oxide (20 pM), aprotinin (10 pg/ml) and leupeptin (10 pg/ml). A total volume of
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250 pi of lysis buffer was added per 60 mm dish, which were left on ice for 
approximately 5 minutes. Cells were scrapped off the dish with a sterile cell scraper 
(Fisher Scientific, Loughborough, UK) and transferred to fresh eppendorf tubes, 
which were left on ice for approximately 10 minutes. Tubes were then centrifuged at 
13, 000 rpm for 15 minutes at 4°C (IEC Micromax RF, Thermo Electron, Hampshire, 
UK), and supernatants (crude cell extracts) were aliquoted for storage at -20°C.
2.3.2 Determination of protein concentration
The concentration of solubilised proteins in crude cell extracts was 
determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories Ltd., Hertz, UK). 
As described by the manufacturer’s instructions, serial dilutions o f the protein 
standard BSA (1 mg/ml stock solution) were prepared in duplicates as shown in 
Table 2.2. Crude cell extracts were diluted 1:200 in dH20, also in duplicates. 800 
pi of standard or sample dilution was thoroughly mixed with 200 pi of Protein Assay 
Dye Reagent Concentrate (Bio-Rad Laboratories Ltd., Hertz, UK) in a semi-micro 
cuvette (Bio-Rad), which was incubated for 5-15 minutes at room temperature. 
Absorbance of standards and samples was then measured at a wavelength o f 595 nm 
using the Cecil CE 2041 spectrophotometer, which automatically generated a 
standard curve with a relative quantification of protein concentration (in pg/pl) 
corrected with the dilution factor.
Table 2.2 Serial dilutions of BSA protein standard
BSA final concentration (pg/ml) Volume BSA, 1 mg/ml (pi) Volume dHiO (pi)
0 0 1000
5 5 995
10 10 990
15 15 985
20 20 980
25 25 975
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2.3.3 SDS-polyacrylamide gel electophoresis (SDS-PAGE)
All SDS-PAGE experiments were carried out using the Bio-Rad Mini- 
Protean® 3 Cell system. Protein samples (50 pg) were denatured by boiling for 5 
minutes in appropriate volumes of 2X Laemmli loading buffer (8% w/v SDS, 40% 
glycerol, 0.25 M Tris base, 0.02% w/v bromophenol blue, and 0.3 M DTT added 
freshly). Samples were collected by pulse-centrifugion at 13,000 rpm. Proteins were 
loaded into a 7.5% resolving gel overlaid with a 4% stacking gel, as described by the 
manufacturer’s instructions (see Table 2.3 for polyacrylamide gel preparations). The 
electrophoresis tank was half-filled with IX Tris/Glycine running buffer, which was 
routinely prepared from a 10X stock solution (Tris base, 250 mM; glycine, 192 mM; 
SDS, 1% w/v, solution adjusted to pH 8.3). Gel electrophoresis was run under a 
constant voltage of 170 V for approximately 90 minutes (Bio-Rad Power-PAC 
1000), or until the bromophenol blue dye front reached the bottom of the gel. The 
Full Range Rainbow™ molecular weight marker was routinely included in the gel 
alongside protein samples (Amersham Bioscience, Buckinghamshire, UK).
Table 2.3 Composition of resolving and stacking SDS-polyacrylamide gels
Reagents 7.5% resolving gel (10 ml) 4% stacking gel (10 ml)
dH20 4.8 ml 6.1 ml
1.5 M Tris-Hcl, pH 8.8 
(Bio-Rad) 2.5 ml -
0.5 M Tris-Hcl, pH 6.8 
(Bio-Rad) - 2.5 ml
30% acrylamide/bis- 
acrylamide solution 
(Sigma-Aldrich®) 2.5 ml 1.3 ml
10% w/v SDS 100 pi 100 pi
10 % w/v APS 100 pi 50 pi
TEMED (added last) 6 pi 10 pi
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2.3.4 Western blotting
Proteins were transferred to the PROTAN® nitrocellulose membranes (0.2 
pM pores, Scheilcher & Schuell, Dassel, Germany) using the Mini Trans-Blot® 
transfer system powered by the Bio-Rad Power-PAC 1000. Membranes were 
washed under shaking using the platform rocker STR6 (Stuart Scientific Bibby 
Sterilin Ltd., Stone, UK). Both gels and membranes were equilibrated in IX transfer 
buffer (25 mM Tris base, 192 mM glycine, 20% v/v methanol) for 10 minutes under 
gentle shaking. Two Whatman 3MM filters and two fibre pads were also pre-soaked 
in IX transfer buffer and assembled in cassettes together with the equilibrated gel 
and membrane according to the manufacturer’s instructions. Any air bubbles that 
formed between the different layers were removed by gentle pressure with a 
serological pipette as they can disrupt protein transfer from gel to membrane. The 
cassette was then placed into the transfer apparatus according to the manufacturer’s 
instructions. A frozen cooling unit and stir bar were place inside the buffer tank, 
which was filled with IX transfer buffer. Protein transfer was carried out at constant 
voltage (100 V) for 1 hour under constant stirring. After transfer, membranes were 
briefly washed in IX TBS-Tween buffer, which was routinely prepared from a 10X 
stock solution (Tris, 100 mM; NaCl, 1 M; Tween 20, 0.5% v/v; solution adjusted to 
pH 7.6). Membranes were then reversibly stained with Ponceau-S solution (Ponceau 
S, 0.1% w/v; Acetic Acid, 5% v/v) to verify that proteins were successfully 
transferred and also to check for equal protein loading across samples. Ponceau S 
staining was removed by washing membranes with IX TBS-Tween buffer for 5 mins 
with shaking. Membranes were blocked in 5% w/v non-fat dried milk (prepared in 
IX TBS-Tween buffer) for at least 2 hours with gentle shaking, followed by a brief 
wash in IX TBS-Tween buffer. Membranes were subsequently subjected to 
immunodetection or were alternatively stored at 4°C in IX TBS-Tween buffer.
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2.3.5 Immunoblotting
Blocked membranes were washed in IX TBS-Tween for 5 mins and were 
then incubated with the appropriate dilution o f primary polyclonal antibody 
overnight at 4°C. All primary antibodies were prepared in IX TBS-Tween 
containing 5% v/v of Western Blocking Reagent (Roche Diagnostics, Mannheim, 
Germany) and 0.05% (w/v) sodium azide, except for phospho-specific antibodies 
against EGFR (Tyrl068), which were diluted in IX TBS-Tween containing 1% w/v 
non-fat dried milk and 0.05% (w/v) sodium azide. Dilutions of all primary antibodies 
used in this study are shown in Table 2.4.
After incubation with the primary antibody, membranes were washed three times in 
IX TBS-Tween for 10 minutes and incubated at room temperature for 1 hour with 
HRP-linked anti-rabbit IgG antibody (Cell signalling Technology™, New England 
BioLabs®, UK). The latter was diluted 1:10,000 in IX TBS-Tween containing 5% 
v/v of Western Blocking Reagent. For /?-actin signals, an anti-mouse IgG HRP- 
linked antibody was used and diluted 1:20,000 (Cell signalling Technology™). 
Membranes were then washed three times in IX TBS-Tween for 10 minutes and 
processed for luminol-based chemiluminescence detection of the protein of interest 
using Supersignal™ West Pico, Supersignal™ West Dura or Supersignal™ West 
femto (Pierce & Warriner Ltd., Cheshire, UK) according to the abundance of the 
target proteins in cells. Each Supersignal™ chemiluminescent reagent was prepared 
according to the manufacturer’s instructions and -250-500 pi was applied to each 
membrane and allowed to incubate at room temperature for 5 minutes. X-Ray films 
were then exposed to membranes placed in autoradiography cassettes for times 
ranging from 15 seconds to 3 hours depending on signal strength. X-Rays were 
developed using an X-O-graph Compact X2 developer (X-O-graph Imaging system, 
Tetbury, UK) and scanned using the AlphaDigiDoc™ System 1000 (Genetic 
Technologies Inc., Miami, USA).
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Table 2.4 Primary antibodies for western blot analysis.
All antibodies were polyclonal anti-rabbit IgGs except for y8-actin (anti-mouse monoclonal IgG) and
total PKCa (anti-rabbit monoclonal IgG).
Antibody Dilution Company CatalogueNo.
ERa (H-184) 1 :1 0 , 0 0 0 Santa Cruz Biotechonology, CA, USA sc-7207
EGFR-Tyrl068 1 :1 ,0 0 0 Cell signalling Technologies™ #2234
Total EGFR 1 :2 , 0 0 0 Santa Cruz Biotechonology, CA, USA sc-03
c-erB2-Tyrl248 1 :2 , 0 0 0 BioSource International, Inc., CA, USA 44-904
Total c-erbB2 1 :2 , 0 0 0 Cell signalling Technologies™ #2242
IGF-IR-Tyrl316 1 :1 ,0 0 0 AstraZeneca, Macclesfield, UK gift
Total IGF-IR 1 :2 , 0 0 0 Santa Cruz Biotechonology, CA, USA sc-712
PKCa-Ser657 1 :2 , 0 0 0 Upstate Biotechnologie Inc. (NY, USA) #06-822
Total PKCa 1 :2 , 0 0 0 Transduction Laboratories (KY, USA) P-16520
Src-Tyr418 1 :1 ,0 0 0 BioSource International, Inc., CA, USA 44-660G
Total Src 1 :1 ,0 0 0 Cell signalling Technologies™ #2105
Erkl/2- 1 :2 , 0 0 0 Cell signalling Technologies™ #9101
Total Erkl/2 1:4,000 Cell signalling Technologies™ #9102
Akt-Ser473 1 :2 , 0 0 0 Cell signalling Technologies™ #9271
Total Akt 1:4,000 Cell signalling Technologies™ #9272
p- actin 1:50,000 Sigma-Aldrich®, Poole, Dorset, UK A2228
Total Foxo3A 1 :1 ,0 0 0 Cell signalling Technologies™ #9467
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2.3.6 Immunocytochemical analysis
Cells were routinely grown on sterile 3-aminopropyltriethoxysilane 
(TESPA)-coated coverslips, which were put in 35 mm dishes. Cells were grown to 
60-70% confluency in the appropriate routine medium as described in section 2.1.1 
or allowed to grow for 24 hours prior to treatments with the Src inhibitor AZD0530, 
as described in Chapter 2-Results (Figure 3.32). Unless otherwise stated in Chapter 
2-Results, cells were seeded at 1 x 105 cells/dish (MCF-7, TamR-3, TamR-11, 
TamR-18 cells) or 0.5 x 105 cells/dish (TamR-24 and TamR-30 cells). The PBS 
solution used for antibody dilutions and washing steps was prepared in house (5L 
solution: 42.5 g NaCl, 7.15 g K2HPO4, and 1.25 g KH2PO4 in dFEO). Prior to 
immunodetection, cells were fixed by the ER-ICA or formal saline method 
depending on the protein target. Visualisation of immunostainings and subsequent 
HScore analysis were carried out using an Olympus BH-2 light microscope 
connected to an Olympus DP 12 digital camera.
2.3.6.1 ER-ICA fixation
Coverslips were removed from culture medium and immersed in a freshly 
prepared 3.7% v/v formaldehyde solution (30 ml of 37% formaldehyde in 270 ml 
PBS) and allowed to incubate for 15 minutes at room temperature. Coverslips were 
then washed in PBS for 5 minutes at room temperature prior to incubation in 
methanol for 5 minutes (between -10°C and -30°C), followed by acetone for 3 
minutes (between -10°C and -30°C). They were then washed in PBS for 5 minutes at 
room temperature, transferred to 35 mm dishes filled with a sucrose storage medium 
(42.8 g sucrose, 0.33 g MgCl2, 250 ml PBS, 250 ml glycerol) and stored at -20°C.
2.3.6.2 Phenol formal saline fixation
Coverslips were removed from culture medium and fixed for 5 minutes at 
room temperature with a 2.5% phenol formal solution (2 ml per coverslip), which 
was prepared by dissolving the appropriate amount of phenol in a 3 .7 % formal saline 
solution (NaCl, 4.5 g; 37% formaldehyde, 50 ml; dFEO, 450 ml). Cells were then
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washed with 1 0 0 % ethanol ( 1 x 5  minutes followed by a brief rinse in 1 0 0 % ethanol) 
and PBS ( 1 x 5  minutes followed by a brief rinse in PBS). Coverslips were stored in 
the sucrose storage medium at -20°C for at least 24 hours before use for 
immunodetection.
2.3.6.3 ERa
Cells were ER-ICA fixed, as described previously. Detection of nuclear ERa 
was carried out using the Vector-6 F ll  mouse monoclonal antibodies (Vector 
Laboratories, Burlingame, CA, USA), which was diluted 1:200 in PBS. First, the 
sucrose storage medium was discarded and coverslips were briefly washed in dFLO 
followed by a PBS wash ( 3 x 3  minutes). A PBS-Tween solution (0.02% v/v Tween- 
20) was applied to the coverslips for 3 minutes in order to facilitate even spreading of 
the diluted antibody solution. Excess PBS-Tween solution was then removed and 50 
pi of the diluted Vector-6 F ll  antibody was applied to each coverslip, which were 
then incubated at 23°C in a humidified atmosphere for 90 minutes. Following a wash 
in PBS ( l x l  minute) and PBS-Tween ( 2 x 5  minutes), coverslips were incubated 
with 1 drop/coverslip of EnVision HRP-linked anti-mouse antibodies (Dako Ltd., 
Ely, UK) for 75 minutes at room temperature. Coverslips were washed in PBS ( l x l  
minute) and PBS-Tween ( 2 x 5  minutes), and incubated with 70pl/coverslip of 
EnVision DAB chromagen solution (Dako ltd.) for 10 minutes, at room temperature. 
Coverslips were washed in dH2 0  ( 2 x 5  minutes) prior to counter-staining in methyl- 
green (0.02% v/v) for 5-10 minutes. Coverslips were rinsed in dH2 0  and air-dried 
prior to mounting onto slides using DPX mountant.
2.3.6.4 AP2y
Nuclear AP2y was detected using the specific 6E4 anti-mouse monoclonal 
antibodies (Gee et al., 2008). Cells were ER-ICA fixed and the sucrose storage 
medium was removed from coverslips by a brief wash with dH2 0 , and PBS (3 x 3 
minutes). As described in section 2.3.6.3, a PBS-Tween solution (0.02% v/v Tween- 
20) was applied to the coverslips for 3 minutes and discarded. 60 pi (per coverslip) 
of 6E4 antibodies diluted 1:50 (in PBS) was applied to the coverslips and incubated
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overnight at 23°C in a humidified atmosphere. Coverslips were washed in PBS (3 x 
4 minutes) and PBS-Tween ( 1 x 4  minute) and were then incubated at room 
temperature for 30 minutes with EnVision HRP-linked anti-mouse antibodies (1 
drop/coverslip, DAKO). 70pl (per coverslip) of EnVision DAB chromagen solution 
was applied and allowed to incubate for 1 0  minutes at room temperature. Coverslips 
were washed in dH2 0  ( 2 x 5  minutes) prior to counter-staining in methyl-green 
(0.02% v/v) for 5-10 minutes. Coverslips were rinsed in dH2 0  and air-dried prior to 
mounting onto slides using DPX mountant.
2.3.6.5 Total Foxo3A, phospho-Foxo3A (Ser 253)
The same protocol described for ERa (section 2.3.6.3) was followed. Total 
levels of Foxo3A were detected using anti-rabbit Foxo3a antibodies (Cell signalling 
Technologies™, #9467) diluted 1:250 in PBS. Phosphorylated/inactive Foxo3A was 
detected with anti-rabbit phospho-Fox03a (Ser253) antibodies (Cell signalling 
Technologies™, #9466) diluted 1:20 in PBS. EnVision HRP-linked anti-rabbit 
secondary antibodies were used (Dako Ltd., Ely, UK).
2.3.6.6 Total EGFR, phospho-EGFR (Tyrl068)
The sucrose storage medium was removed from coverslips, which were 
washed in dH2 0  and PBS, as described in section 2.3.6.3. A PBS-Tween solution 
was applied for a few seconds, discarded and coverslips were incubated overnight 
with Neomarkers EGFR anti-mouse primary antibodies diluted 1:140 (in PBS) for 
the detection of total EGFR (Lab Vision, Fisher Scientific, Loughborough, UK), or 
with EGFR (Tyrl068) phospho-specific anti-rabbit antibodies diluted 1:40 (in PBS 
containing 1% v/v BSA; BioSource International, Inc., CA, USA). Coverslips were 
washed in PBS ( l x l  minute) and PBS-Tween ( 2 x 5  minutes) prior to incubation 
with 1 drop/coverslip of EnVision HRP-linked anti-mouse antibodies (Dako Ltd., 
Ely, UK) for 60 minutes at room temperature. Coverslips were washed in PBS ( l x l  
minute) and PBS-Tween ( 2 x 5  minutes), and incubated with 70pl/coverslip of 
EnVision DAB chromagen solution (Dako ltd.) for 10 minutes, at room temperature. 
Coverslips were washed in dH2 0  ( 2 x 5  minutes) prior to counter-staining in methyl-
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green (0.02% v/v) for up to 15 minutes. Coverslips were rinsed in dlr^O and air- 
dried prior to mounting onto slides using DPX mountant.
2.4 Haematoxylin & Eosin staining
The sucrose storage medium was discarded and coverslips were briefly 
washed in dH20 followed by a PBS wash ( 3 x 3  minutes). A 10% Haematoxylin 
solution (Raymond A Lamb, Eastbourne UK) was applied to the coverslips for 5 
minutes followed by a brief rinse in dH20. A 1% Eosin solution (Raymond A Lamb) 
was applied for 10 minutes; coverslips were briefly rinsed with dH2 0  and allowed to 
dry at room temperature prior to mounting onto slides using DPX mountant.
2.5 Cell migration assay
Cell migration assays were performed using 6.5 mm Transwell® inserts 
(Coming Life Sciences) with an 8 pm membrane pore size. Under sterile conditions, 
membranes were coated with fibronectin by placing Transwell® inserts in wells of a 
24-well plate (supplied by the manufacturer) containing 200pl of a fibronectin 
solution (10 pg/ml in wRPMI containing no supplements). The plate was incubated 
at 37°C for 2 hours; inserts were washed in sterile PBS and air-dried. Cells were 
trypsinized as described previously and seeded (in duplicate) into the inner 
compartment of the Transwell® inserts at a density of 5 x 104 cells/insert in 200 pi of 
the appropriate routine medium. 650 pi of the same routine medium was added to 
the outer compartments (wells) of the Transwell® inserts and the 24-well plate was 
incubated at 37°C for 48 hours in a Sanyo MCO-17AIC incubator. The medium 
containing non-migratory cells was removed from the inner compartment, which was 
swabbed with a cotton bud. Migratory cells were fixed by incubating the inserts in a 
3.7% (v/v) formaldehyde solution (prepared in PBS) for 10 minutes. Fixed 
migratory cells were washed in PBS and stained with crystal violet (0.5% w/v in 
dH20) for 15-30 minutes. Excess crystal violet stain was removed; inserts were 
washed with PBS and air-dried at room temperature. Migratory stained cells were 
counted at x20 magnification using an Olympus BH-2 light microscope.
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2.6 Cell invasion assay
Invasion assays were carried out using the aforementioned 6.5 mm/8 pm 
membrane pore size Transwell® inserts (Coming Life Sciences), which were coated 
with 50 pi of Matrigel™ basement membrane matrix solution diluted 1:3 in ice-cold 
wRPMI containing no supplements (Matrigel™ sock solution: 12 mg/ml, BD 
Biosciences). The 24-well plate, containing the Matrigel™-coated inserts, was 
incubated at 37°C for 2 hours to allow the Matrigel™ to set. Cells were trypsinized 
as described previously and seeded (in duplicate) into the inner compartment of the 
Transwell® inserts at a density of 5 x 104 cells/insert in 200 pi of the appropriate 
routine medium. 650 pi of the same routine medium was added to the outer 
compartments (wells) of the Transwell® inserts and the 24-well plate was incubated 
at 37°C for 72 hours in a Sanyo MCO-17AIC incubator. The medium was removed 
from the inner compartment (non-invasive cells) and the polymerised Matrigel™ 
removed with a cotton bud. Invasive cells on the membrane of the inserts were fixed 
in a 3.7% (v/v) formaldehyde solution (prepared in PBS) for 10 minutes, followed by 
a wash with PBS and air-dried at room temperature. The membranes were excised 
from the inserts using a scalpel blade and mounted, cell-side up, onto glass sides 
using 1 drop of VectaShield® Hard-set™ mounting medium with DAPI nuclear stain 
(Vector Laboratories, Burlingame, CA, USA). Slides were wrapped in foil and stored 
at 4°C. The number of DAPI-stained invasive cells on the membranes was assessed 
using the DMIRE2 Leica fluorescent microscope (Leica Microsystem, Arizona, 
USA), fitted with a digital camera (Orca-285, Hamamatsu, Japan).
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2.7 Statistical analysis
For direct comparisons between two cell lines or between controls and 
treatments, the statistical significance was calculated using independent, two-tailed 
Student’s /-test. Overall differences between control and treatment groups (or 
between more than two cell lines) were examined by one-way ANOVA with post- 
hoc tests. For immunocytochemical analysis, the Mann-Whitney U test was 
employed to compare median HScore values between cell lines. Differences were 
considered significant at the P < 0.05 level for all tests.
2.8 AliBaba2.1
Approximately 1-kb of upstream DNA sequences of the different ERa 
promoters was screened for transcription factor binding sites using the web-based 
AliBaba2.1 software (httpi/Avww.gene-regulation.coni). DNA sequences were 
pasted in the text box and the default parameters were used for analysis of 
transcription factor binding sites.
I
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Chapter 3. Results
3.1 Validation of primers used for real-time qPCR analysis of 
variant-ERa mRNA expression
3.1.1 Verification of primer-specific PCR products by semi-qPCR and melting 
curve analysis
Throughout this study, the expression of total ERa mRNA and its constituent 
variants were quantified in various anti-hormone responsive and resistant cell lines 
using real-time quantitative PCR (qPCR) based on SYBR® Green fluorescence. As 
depicted in Figure 2.1 of Material and Methods, amplifications of the different ERa 
isoforms were carried out using sets of primers with forward oligonucleotides 
specifically annealing to the 5’UTRs, which are unique to each ERa mRNA variant. 
A common reverse primer was also used and was designed to anneal to the 5’ end of 
ERa exon 1. Also, expression levels of total ERa mRNA were assessed using 
“universal” primers specific to a region within exon 5 of the ERa gene (Knowlden et 
al., 1997). These “universal” primers were not flanking intron-exon boundaries and 
therefore potential contamination from amplified genomic DNA could occur during 
PCRs. However, routine use of these primers in this study and others (Knowlden et 
al., 1997; McClelland et al., 2001) has shown that genomic contamination was not 
apparent in PCR products. In order to experimentally evaluate the effectiveness and 
specificities of all primers, conventional semi-quantitative PCR reactions were 
carried out using cDNA prepared by RT-PCR from MCF-7 cells and run on a 3% 
agarose gel. As shown in Figure 3.1A, each PCR reaction produced a single 
fragment of the expected molecular weight for total ERa mRNA and the mRNA 
isoforms A-F. The specificity of all primers and the homogeneity of the PCR 
products were further verified by melting curve analysis, which was automatically 
carried out by the analysis software of the DNA Engine® Opticon 2 system used in 
this study, as described in Material and Methods {section 2.2.5). All ERa isoform 
were distinguished by the melting point of their corresponding PCR products. The 
melting temperature of nucleic acids is affected, amongst other factors, by length and 
GC contents. As exemplified in Figure 3.1B, real-time PCR amplicons 
corresponding to total ERa mRNA and ERa mRNA variants were consistently 
generated with a distinguishable melting curve signature containing a single peak of
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fluorescence. This strongly suggests PCR product homogeneity and the absence of 
primer-dimers or other non-specific products that could affect the efficiency of the 
PCR reactions.
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Figure 3.1 Validation of prim er sets for total ERa mRNA and 
ERa mRNA variants by (A) semi-quantitative PCR and (B) melting 
curve analysis in MCF-7 cells. (A) cDNA was prepared by RT-PCR 
from MCF-7 cells grown to 70% confluency, as described in Material 
and Methods. Semi-qPCR reactions were carried out using universal 
primer sets for total ERa, and primers specific for ERa mRNA variants 
A-F. PCR products were then separated on a 3% agarose gel containing 
ethidium bromide. The expected size of each PCR product is (in bp): 
total ERa. 432; A, 242; B, 190; C, 150; D, 116; E, 102; F, 100. A/, 
Molecular weight marker. (B) cDNA from MCF-7 cells were also 
subjected to real-time qPCR during which a melting curve was 
generated. The representative graph shows the negative first derivative 
of the fluorescence intensity (-dl/dT) versus temperature. As indicated, 
each ERa transcript is associated with a specific melting curve 
containing a single fluorescent peak.
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3.1.2 E2-induced downregulation of ERa mRNA expression in MCF-7 cells
Transcriptional regulation o f the ERa gene by oestrogen (E2) has long been 
established in MCF-7 cells, in which treatment with the steroid hormone results in a 
time dependent decrease o f ERa mRNA steady-state levels (Saceda et al., 1988). 
This reduction has later been shown to affect all ERa mRNA isoforms in a similar 
manner in MCF-7 cells (Flouriot et al., 1998). In light of these observations and in 
order to further validate the identity o f all amplified ERa transcripts, the effect o f E2 
on expression levels of all ERa mRNA isoforms was measured in MCF-7 cells. 
Real-time qPCR was performed with cDNA templates prepared from MCF-7, which 
were cultured in the presence or absence o f 17/?-oestradiol for 24 h (10‘9 M). 
Previous studies have shown that this time point can result in a significant decrease 
in steady-state levels of ERa mRNA isoforms (Flouriot et al., 1998; Berthois et al., 
1990). As expected, oestrogen treatment resulted in approximately 40% reduction in 
expression levels of total ERa mRNA, and 40-60% decrease o f the different ERa 
mRNA variants (Figure 3.2). Transcripts generated from the proximal (A/B) and 
distal (C) promoters have been shown to be the most predominantly expressed in 
breast cancer cells overexpressing ERa protein. Accordingly in this study, the ERa 
mRNA isoforms A, B and C were detected as the most prevalent variants in MCF-7 
cells. The liver- and bone-specific variants E and F, respectively, were expressed at 
lower levels whereas transcripts generated from the promoter D were almost non- 
detectable.
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Figure 3.2 Effects of oestrogen on steady state expression 
levels of (A) total ER a mRNA and (B) ERa mRNA variants in 
MCF-7 cells. MCF-7 cells were grown to 70% confluency in wRPMI 
+ 5% SFCS prior to treatment with 10'9 M 17/?-oestradiol (MCF-7 
+E2) for 24 hours. Control treatments (MCF-7 -E2) were carried out 
in EtOH (vehicle for 17/?-oestradiol). Error bars represent the S.D. 
of at least three independent experiments, each carried out in 
duplicate. *, P < 0.01, **, P < 0.001, versus MCF-7 (-E2).
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3.2 Loss of ERa expression in response to anti-hormone 
treatments: Proof of principle with fulvestrant in vitro
As described in Chapter 1 (section 1.5.3.2), a proportion of initially ERa- 
positive breast tumours become ERa-negative on tamoxifen relapse, and for those 
that remain ERa-positive, a significant reduction in ERa expression has been 
revealed (Johnston et al., 1995; Kuukasjarvi et al., 1996; Holloway et al., 2004). In 
light of these clinical observations, this study addressed the questions of whether, 
and through which molecular mechanisms, could long-term tamoxifen treatment 
induce loss of ERa expression (adaptive mechanism) using in vitro models of 
tamoxifen-resistant cells.
Previous in vitro studies have already provided proof of principle that loss of ERa 
expression can occur following long-term anti-hormone treatment with the pure anti­
oestrogen fulvestrant (Faslodex®, ICI 182, 780; Liu et al., 2006). The same authors 
have generated a faslodex-resistant cell line with an irreversible ERa-negative 
phenotype, by culturing the ERa-positive MCF-7 cells with faslodex-containing 
medium for approximately 18 months. In order to validate the observations made by 
Liu et al., ERa mRNA and protein expression levels were also assessed using in 
house faslodex-resistant cells (FasR). The latter were generated by continuous 
exposure of the MCF-7 breast cancer cells with fulvestrant (10‘7 M) over a period of 
24 months (Julia Gee, personal communication). As shown in Figure 3.3, ERa 
expression could not be detected in FasR cells both at the mRNA and protein levels, 
as determined by real-time qPCR and immunocytochemistry (ICC), respectively. 
The ERa-negative phenotype exhibited by FasR cells was irreversible as withdrawal 
of faslodex from culture medium over a 6 months period did not result in re­
expression of ERa (Dr. Martin Giles, personal communication). These results are in 
agreement with studies by Liu et al. and provide in vitro evidence that ERa 
expression can be lost in response to long term anti-hormone treatments of initially 
ERa-positive cells.
79
(A)
JS 4 Total ERa mRNA
Q.
Xa>
<
2
E
<u2
MCF-7 FasR
(B)
MCF-7 FasR
OL
• 9*
rv 
#  ^
Figure 3.3 Analysis of total ER a expression levels in M CF-7 and FasR 
cells. (A) Real-time PCR analysis o f total ERa mRNA expression levels. Total 
RNA was extracted from cells grown to 70% confluency in their routine medium, 
as described in Material and Methods. Expression levels o f total ERa were 
normalized against f i-actin expression, and results o f the experiments are reported 
as relative mRNA expression levels. Error bars represent S.D. o f at least three 
independent experiments, each carried out in duplicate. (B) Immunocytochemical 
analysis of total ERa nuclear protein. MCF-7 and FasR cells were grown to 70% 
confluency on glass coverslips in their routine medium followed by ER-ICA 
fixation, as described in Material and Methods. Total expression levels o f nuclear 
ERa protein were detected with polyclonal mouse antibodies. The picture is 
representative of two independent experiments (Original magnification 20x).
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3.3 Analysis of ERa expression in TamR cells
3.3.1 TamR-18 cells
A starting point for investigating whether prolonged exposure to tamoxifen 
can induce loss of ERa in vitro was the assessment of the receptor expression using 
the in house cell model o f acquired-tamoxifen resistance TamR-18. As described in 
Material and methods, TamR-18 cells were generated by continuous exposure of 
MCF-7 cells with 4-OHT over a period o f 18 months. Total ERa mRNA and protein 
expression levels were measured in TamR-18 cells and compared to those of the 
parental cells. As shown in Figure 3.4A, TamR-18 cells showed a significant 
decrease in total ERa mRNA expression levels compared to MCF-7 cells. In this 
study, it was initially hypothesised that progression from an endocrine-responsive to 
a resistant phenotype may be accompanied with a change in the prevalence o f ERa 
mRNA isoforms. This hypothesis was based on previous studies, which have 
established that there was a tissue and cell specificity in the level o f expression of the 
different isoforms (Gannon et al., 2001; Flouriot et al., 1998). Therefore, steady- 
state levels of all the ERa transcript variants were also analysed in TamR-18 cells by 
real-time qPCR.
Results showed that downregulation of ERa expression affected all the variants in 
TamR-18 cells in which, like in MCF-7 cells, the isoforms A/B and C were identified 
as the most predominant variants (Figure 3.4B). Most notably, however, expression 
levels of transcript variants C were significantly reduced by more than 70% in 
TamR-18 compared to MCF-7 cells (P < 0.001). It should also be noted that the 
overall decrease in expression o f all the ERa mRNA variants in TamR-18 is 
reminiscent of that observed in MCF-7 cells treated with 17/?-oestradiol, suggesting 
that both cells may use similar molecular mechanisms to regulate ERa gene 
expression. Also in correlation with the mRNA data was the reduction in expression 
levels of total ERa protein in TamR-18 cells, as measured by Western blot analysis 
(Figure 3.5A). This was further confirmed by immunocytochemical analysis, in 
which the intensity of nuclear ERa staining was noticeably reduced in TamR-18 
compared to MCF-7 cells (Figure 3.5B). Expression levels o f /?-actin protein 
remained constant for all Western blot samples, which verified equivalent sample
81
Chapter 3. Results
loading. Taken together, these results show that emergence of tamoxifen resistance 
in vitro is accompanied with a small attenuation of ERa expression over an 18 
months period. Furthermore, immunocytochemical analysis of nuclear ERa 
indicates that this attenuation occurred across the entire cell population rather than 
being the result of an out-growth o f an ERa-negative cohort. It is important to note 
that despite this downregulation, ERa protein levels still remain high in TamR-18 
cells with the receptor retaining an important functional role in regulating cell growth 
(Hutcheson et al., 2003).
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Figure 3.4 Real-time qPCR analysis of steady state mRNA levels 
of (A) total ER a and (B) E R a transcrip t variants in MCF-7 and 
TamR cells. Total RNA was extracted from 70% confluent cells grown 
in the appropriate routine medium as described in Material and 
Methods. Error bars represent the S.D. of at least four independent 
experiments, each carried out in duplicate. *, P < 0.05, **, P < 0.001, 
versus TamR-18.
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Figure 3.5 (A) W estern blotting and (B) immunocytochemical
analysis of total ERa protein expression in MCF-7 and TamR-18 
cells. Western blotting analysis was carried out from whole cell extracts 
prepared from 70% confluent cells grown in their routine medium. Total 
ERa expression was detected using rabbit polyclonal antibodies specific 
to the full length form of ERa (66 kDa). /?-actin signals were used as 
internal controls to monitor equal protein loading. Immunocytochemical 
analysis was performed on ER-ICA fixed cells grown to 70% 
confluency. Original magnification, x20. Data are representative o f at 
least three independent experiments for each methodology.
HScore analysis (median values): HScore (MCF-7) = 195; HScore 
(TamR-18) = 169. P < 0.05 for ERa levels in MCF-7 versus TamR-18.
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3.3.2 Effects of short-term tamoxifen treatment on ERa expression levels
To establish whether loss of ERa was an early response to tamoxifen therapy, 
expression of ERa was examined in tamoxifen-resistant cell lines cultured in the 
continuous presence of 4-OHT for 3 (TamR-3) and 11 months (TamR-11). Real­
time qPCR analysis revealed that total ERa mRNA expression was significantly 
downregulated in TamR-3 and TamR-11 cells compared to MCF-7 cells, and to 
levels similar to those observed in TamR-18 cells (Figure 3.6A). All the ERa 
mRNA variants were also significantly downregulated in all o f the tamoxifen- 
resistant variants compared to MCF-7 cells (Figure 3.6B). In agreement with the 
mRNA data, Western blot analysis showed a noticeable decrease in expression levels 
of total ERa protein after 3- and 11 months exposure with tamoxifen. Similar to 
ERa mRNA, ERa protein levels in TamR-3 and TamR-11 cells were equivalent to 
those measured in TamR-18 cells (Figure 3.7A). As expected, parallel 
immunocytochemical analysis and subsequent HScore analysis showed a significant 
reduction in the intensity of nuclear-localized ERa staining in all the TamR cells 
compared to the parental MCF-7 cells (Figure 3.7B).
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Figure 3.6 Effects of short-term tamoxifen treatm ents on steady 
state levels of (A) total ERa mRNA and (B) ERa mRNA variants.
Parental MCF-7 cells and the sequentially acquired TamR cell lines 
were grown to 70% confluency in their routine medium and harvested 
for total RNA extraction for subsequent RT-PCR and real-time qPCR 
analysis of ERa mRNA levels (n = 3 ± S.D.). *, P < 0.001 versus 
MCF-7
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Figure 3.7 (A) W estern blotting and (B) immunocytochemical
analysis of total ERa protein levels in TamR cells. Data are 
representative of at least three independent experiments for each 
methodology. Original magnification, x 20.
HScore analysis (median values): HScore (MCF-7) = 195; HScore 
(TamR-3) = 159; HScore (TamR-11) = 166; HScore (TamR-18) = 169; 
HScore (TamR-24) = 145. P < 0.05 for ERa levels in MCF-7 versus each 
TamR cell line.
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3.3.3 Effects of long-term tamoxifen treatment on ERa expression levels
The effects o f long-term tamoxifen therapy on ERa levels were also 
examined by using TamR-24 and TamR-30 cell models. As described in Material 
and Methods, TamR-24 and TamR-30 cells were generated by continuous culture of 
TamR-18 cells in the presence of 4-OHT for 6- and 12 months, respectively. As 
shown in Figure 3.8A, real-time qPCR analysis revealed that total ERa mRNA 
levels were significantly reduced in TamR-24 cells compared to TamR-18 cells (P < 
0.01, TamR-24 versus TamR18). This downregulation was further exacerbated in 
TamR-30 cells, in which total ERa mRNA levels were significantly reduced 
compared to TamR-24 cells (P < 0.05 TamR-30 versus TamR-24). Expression levels 
of all ERa mRNA variants were also significantly downregulated in the long-term 
TamR cells (Figure 3.8B). Interestingly, however, mRNA isoforms C was the most 
severely affected and expressed to almost non-detectable levels in TamR-24 and 
TamR-30 cells, thus suggesting that transcription from the promoter C may be 
particularly important in maintaining adequate levels of ERa gene expression in 
these cells. In corroboration with the mRNA data, total levels o f ERa protein were 
drastically reduced in TamR-24 and TamR-30 cells, as demonstrated by Western blot 
analysis (Figure 3.9A). A significant decrease in the intensity of nuclear ERa 
staining was also observed in the long-term TamR cells, particularly so in TamR-30 
cells, as demonstrated by immunocytochemical analysis (Figure 3.9B). As 
mentioned previously, this decline in nuclear ERa staining was seen across the vast 
majority of the ERa-positive cells, further indicating that loss o f ERa during 
tamoxifen therapy is unlikely to be due to an out-growth o f ERa-negative progenitor 
cells.
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Figure 3.8 Real time qPC R  analysis of (A) total ER a and (B) 
ERa mRNA variant levels in the late Tam R cells. Error bars 
represent the S.D. of three independent experiments, each carried out 
in triplicates. *, P < 0.01 versus TamR-18; **, P < 0.001 versus 
TamR-18; f ,P <  0.05 versus TamR-24.
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Figure 3.9 Effects of long-term  tamoxifen treatm ents on 
expression levels of total E R a protein, as demonstrated by (A) western 
blotting and (B) immunocytochemical analysis (original magnification, 
x20). Data are representative o f at least four (western blotting) or three 
(ICC) independent experiments.
HScore analysis (median values): HScore (MCF-7) = 191; HScore 
(TamR-18) = 148; HScore (TamR-24) = 128; HScore (TamR-30) = 79. 
P < 0.05 for ERa levels in MCF-7 versus each TamR cell line; P < 0.05 
for ERa levels in TamR-30 versus TamR-18, and TamR-30 versus 
TamR-24 .
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3.3.4 Sensitivity to fulvestrant and basal growth rate of TamR-30 cells
Based on the observations that both TamR-24 and TamR-30 cells contain 
very low levels of ERa, it was hypothesised that these cells might be drifting towards 
an ER-negative phenotype. In order to investigate this further, the influence of the 
ER down-regulator fulvestrant on growth o f TamR-24 and TamR-30 cells was 
examined and compared to that of TamR-18 cells. The latter have previously been 
shown to respond sensitively to the growth inhibitory properties of fulvestrant at the 
optimal concentration of 10' M (Hutcheson et a l., 2003). In this study, the growth 
of TamR cells in response to increasing concentrations of fulvestrant (10'8 M and 10' 
7 M) was assessed by means of cell counts on day 7 from initial treatments with the 
pure anti-oestrogen. Although the growth of TamR-24 and TamR-30 cells was 
significantly reduced compared to their respective controls at the optimal 
concentration (P < 0.05), results clearly demonstrated that these cells have become 
less sensitive to the growth inhibitory action o f fulvestrant compared to TamR-18 
cells, whose growth was reduced by nearly 60% compared to -20%  for TamR-24
n  #
and TamR-30 cells at the 10' M dose (Figure 3.10). In view of this data, it would 
be of interest to further analyze ERa levels following a 7-day treatment regime of 
TamR cells with fulvestrant.
ERa-negative cells often exhibit increased rates o f cell proliferation, which is driven 
by increased growth factor signalling particularly Erkl/2 (Oh et al., 2001). In view of 
this and to provide further evidence for a drift of TamR-24 and TamR-30 cells 
towards an ER-negative phenotype, the basal growth rate of these cells was assessed 
and compared to that of TamR-18 cells. Proliferation of TamR cells in the presence 
of 4-OHT was compared by means o f growth curves over a period o f 11 days. 
Results showed that the growth rate of TamR-30 cells was considerably and 
significantly higher than that observed for TamR-18 and TamR-24 cells, by over 
200% on day 11 of cell proliferation (Figure 3.11). Surprisingly, TamR-24 cells 
exhibited an almost similar growth pattern to that of TamR-18 cells.
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Figure 3.10 Comparative assessment of TamR-18, TamR-24, 
and TamR-30 cell growth in response to ICI 182,780. Cells were 
preliminarily grown to 70% confluency in their routine medium and 
re-seeded in 24-well plates at a density of 30,000 cells/well. Cells 
were allowed to grow for 24 hours in their routine medium 
(supplemented with 4-OHT) before treatment with increasing 
concentrations of ICI 182,780 or the vehicle EtOH (control) for 7 
days (medium was changed at day 3). Results are expressed as % 
of control values on day 7 and are the means ± S.D. of three separate 
experiments carried out in triplicate wells for each dose. *, P < 0.05 
versus control; f , P < 0.05 versus TamR-18 at the 10'8 M and 10‘7 M 
doses.
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Figure 3.11 Basal growth rates of TamR-18, TamR-24 and 
TamR-30 cells. Cells were grown to 70% confluency in their routine 
medium, trypsinized and re-seeded in 24-well plates at a density of 
40,000 cells/well (TamR-18) or 20,000 cells/well (TamR-24, TamR- 
30). The experiment was carried out in routine medium, which was 
changed every 4 days. Cell number was assessed 1-, 4-, 6-, 8- and 11 
days after seeding, as described in Material and Methods. Results are 
expressed as % of control values on day 1, which were derived from 
the mean cell number ± S.D. of three separate experiments carried 
out in triplicate wells for each time point. *, P <0.001 TamR-30 
versus TamR-18, and TamR-30 versus TamR-24.
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3.4 Molecular mechanisms for ERa loss in TamR cells
3.4.1 Role of EGFR signalling
As described in Chapter 1 (section 7.5.3.2), there is compelling evidence in 
the literature to suggest that hyperactivated growth factor signalling, can result in 
downregulation of ERa expression. Most notably, preclinical and clinical data have 
shown that overexpression of EGFR and hyper-activation o f its downstream 
signalling elements is associated with ERa negativity. In view o f this, the potential 
involvement of EGFR signalling in attenuating ERa levels was investigated in TamR 
cells. Basal expression and activity o f EGFR signalling was first assessed in the 
early TamR cell lines (TamR-3, TamR-11, and TamR-18) which, as described 
previously, exhibited reduced levels of ERa mRNA and protein. Whole cell lysates 
from MCF-7 and TamR cells were prepared and subjected to Western blot analysis 
for the detection of total and activated EGFR, HER2, Erkl/2 and Akt. HER2 has 
previously been shown to be the preferred dimerization partner of EGFR (Knowlden 
et al., 2003).
As shown in Figure 3.12, a progressive increase in phosphorylated EGFR was 
observed as the exposure with 4-OHT was extended over the 18 month period. 
Although specific antibodies were used against activated EGFR, the latter were 
experimentally difficult to detect under basal growth conditions. Therefore, in house 
positive control samples were routinely used and prepared from TamR-18 cells 
treated with the EGFR-activating ligand EGF for 5 min (10 ng/ml). Total levels of 
EGFR protein appeared relatively similar across the different TamR cells but, as 
expected, were increased in comparison with MCF-7 cells. Levels o f both total and 
activated HER2 were also similar across the different TamR cells but all were 
similarly increased compared to MCF-7 cells, which is in agreement with previous 
studies (Knowlden et al., 2003). Consistent with the enhanced activity o f EGFR was 
a clear and progressive increase in levels o f phosphorylated Akt and E rkl/2 . In 
agreement with the Western blot data, immunocytochemical analysis o f total EGFR 
protein also revealed a noticeable increase in membrane and cytoplasmic staining for 
this protein in TamR-18 cells compared to MCF-7 cells (Figure 3.13). 
Immunostaining of activated EGFR (Tyrl068) revealed that staining was
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predominantly cytoplasmic. The cytoplasmic staining of EGFR (Tyrl068) was 
likely due to the fact that upon activation, the growth factor receptor is rapidly 
internalized into the endocytic compartment of the cells for subsequent recycling or 
degradation in lysosomes (Harari & Yarden, 2000).
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Figure 3.12 Basal expression levels and activity of EGFR, 
HER2, Erkl/2 and Akt in MCF-7 cells and the sequentially 
acquired TamR cells. Results are representative of at least three 
independent experiments except for p-EGFR (Tyrl068), n=l.
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Figure 3.13 Im m unocytochemical analysis of basal EG FR activity 
and expression in M CF-7 and TamR-18 cells. Cell were fixed using 
the phenol formal saline method and stained with phospho-specific 
antibodies against EGFR (Tyrl068), as described in Material and 
Methods. Original magnification, x40; n = 1.
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In view of the increased activity of EGFR in TamR-18 cells, the effects o f the 
specific EGFR tyrosine kinase inhibitor (TKI) gefitinib (Iressa®/ZD1839) on ERa 
mRNA and protein expression was investigated. Using an optimal concentration of 
1 pM, this compound has successfully been used by other studies to modulate EGFR 
activity in TamR-18 cells (Britton et al., 2002; Knowlden et al., 2003; Hutcheson et 
al., 2007). As shown in Figure 3.14A, treatments of TamR-18 cells with TKI for 24 
h resulted had no significant effect on levels of total and variant-ERa mRNA. Of 
note, only the breast cancer-specific ERa mRNA variants (A/B/C) were measured 
from this point onward since they were, as stated previously, the predominant 
isoforms in TamR-18 cells. In contrast to the mRNA data, a noticeable reduction in 
ERa protein expression was observed by Western blot analysis (Figure 3.14B).
In order to validate the efficacy of gefitinib in inhibiting EGFR signalling, the 
activity of the tyrosine kinase receptor and its downstream signalling components 
were also assessed by Western blotting. As expected, levels o f phosphorylated 
EGFR, Erkl/2 and Akt were completely abrogated upon TKI treatments in TamR-18 
cells (Figure 3.14B), and this was not due to a reduction in total levels of these 
proteins. Extending the gefitinib treatment regime over a 48 h period resulted in a 
significant reduction in both total and variant-ERa mRNA expression levels in 
TamR-18 (Figure 3.15A). Expression levels of total ERa protein clearly corroborate 
the mRNA data and were considerably reduced upon treatment with TKI after 48 h. 
Assessment of phospho-EGFR, Akt and Erkl/2 again clearly showed the strong 
inhibitory effects of gefitinib on activity of the EGFR signalling pathway (Figure 
3.15B).
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Figure 3.14 Effects of 24-hour gefitinib treatm ents on E R a expression 
and EGFR signalling in TamR-18 cells. (A) Real-time qPCR analysis of 
total ERa mRNA and ERa mRNA variants A-C. Cells were grown to 70% 
confluency in routine medium before treatment with gefitinib (Gef, 1 pM) or 
with the vehicle DMSO (control) for 24 hours. Error bars represent the S.D. 
of three independent experiments, each performed in duplicate. (B) Western 
blot analysis of total ERa protein expression and basal activity o f EGFR cell 
signalling components. Phospho-specific antibodies against EGFR (Tyrl068), 
Erkl/2 (Thr202/Tyr204), and Akt (Ser473) were used as described in 
Material and Methods. Blots were also probed for total EGFR, Erkl/2, Akt, 
ERa and /?-actin signals. Results are representative of three separate 
experiments.
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Figure 3.15 Effects of 48-hour gefitinib treatm ents on E R a expression 
and EGFR signalling in TamR-18 cells. (A) Real-time qPCR analysis of 
total ERa mRNA and ERa mRNA variants A-C. Cells were grown to 70% 
confluency in routine medium before treatment with gefitinib (Gef, 1 pM) or 
with the vehicle DMSO (control) for 48 hours. Error bars represent the S.D. 
of three independent experiments, each performed in duplicate. (B) Western 
blot analysis of total ERa protein expression and basal activity o f EGFR cell 
signalling components. Results are representative o f three separate 
experiments. *, P < 0.05 versus control.
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The effect o f long-term EGFR inhibition on ERa expression was also 
investigated with TamR-18 cells being treated with gefitinib over a period of 10 
days. As shown in Figure 3.16, steady-state levels of total and variant-ERa mRNAs 
remained significantly reduced after 10 days of gefitinib treatment although much 
less markedly when compared to the 48 h period. These results indicate that ERa 
mRNA levels may start to recover upon sustained EGFR inhibition. This was further 
suggested by Western blot analysis o f ERa protein levels, where expression appeared 
to be re-instated in the gefitinib-treated samples compared to the control samples 
(Figure 3.17). Although there was abrogation of basal phosphorylated EGFR, there 
appears to be a partial recovery o f Akt and Erkl/2  signalling activity after a 10 day- 
gefitinib treatment. Furthermore, total levels o f the same proteins were also up- 
regulated, thus reflecting a compensatory mechanism in response to the sustained 
inhibitory action of gefitinib on EGFR signalling.
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Figure 3.16 Effects of 10-day gefitinib treatm ents on ER a mRNA 
expression levels in TamR-18 cells. Cells were grown to 70% confluency 
in their routine medium and re-seeded into 60mm dishes (0.25 million 
cells/dish). Cells were allowed to grow for 24 hours before treatment with 
gefitinib (lpM ) or with the vehicle DMSO (control) for 10 days. Real-time 
qPCR analysis of total ERa mRNA and ERa mRNA variants A-C is 
shown. Error bars represent the S.D. of three separate experiments, each 
performed in duplicate. *, P < 0.05 versus control.
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Figure 3.17 Effects of 10-day gefitinib treatm ents on E R a protein
m
levels and basal activity and expression of EGFR cell signalling 
components in TamR-18 cells. Cell culture conditions and treatments 
with gefitinib were as described in Figure 3.16. Results are 
representative o f three separate experiments.
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In view of the results observed with long-term gefitinib treatments, it was 
interesting to investigate whether ERa expression was maintained in TamR-18 cells 
that have been continuously exposed to Gefitinib and have subsequently gained 
resistance to the growth inhibitory effects o f this agent. Therefore, ERa mRNA and 
protein levels were measured in the double tamoxifen/gefitinib-acquired resistant cell 
lines Tam/TKI-R. These cells were previously generated by continuous exposure of 
TamR-18 cells with Gefitinib (l|iM ) over a period o f 6 months (Jones et al., 2004). 
Real-time qPCR analysis revealed that expression levels of total ERa mRNA is 
significantly higher in Tam/TKI-R cells compared to TamR-18 cells, and to almost 
equivalent levels to those observed in MCF-7 cells (Figure 3.18A). Surprisingly, the 
increase in total ERa mRNA levels was only reflected by an increase o f the ERa 
mRNA variant A in Tam/TKI-R cells, suggesting for the first time in this study that a 
potential promoter-specific regulation o f the ERa gene expression may occur in these 
cells. In agreement with the mRNA data, immunocytochemical analysis showed that 
there was also a considerable increase in ERa nuclear staining o f wild-type (MCF-7) 
equivalence in Tam/TKI-R cells compared to TamR-18 cells (Figure 3.18B).
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Figure 3.18 Analysis of total E R a expression levels in MCF-7, TamR- 
18 and the double resistant cells Tam /TKI-R. (A) Real-time PCR analysis 
of total and variant ERa mRNA levels. Error bars represent the S.D. of four 
separate experiments, each performed in duplicate. (B) Immunocytochemical 
analysis of total ERa protein expression (n=l, original magnification, x20). 
*, P < 0.05 versus TamR-18.
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Overall, the gefitinib experiments would strongly suggest that EGFR 
signalling, although being considerably increased in TamR-18 cells, is not involved 
in the downregulation o f ERa expression. In order to investigate this further, the 
activity of EGFR and its modulation by gefitinib was examined in the long-term 
TamR cells. Western blot analysis revealed that basal phosphorylated EGFR was 
increased in TamR-30 compared to TamR-24 and TamR-18 cells which only 
exhibited a faint signal of the activated growth factor receptor, while MCF-7 cells 
exhibited no apparent signals (Figure 3.19A). Because EGFR expression levels are 
very often inversely related to ERa levels in clinical breast cancers, an increase in 
total EGFR signals was initially expected in TamR-30 cells compared to TamR-18 
cells. However, Western blot analysis showed that total levels o f EGFR remained 
similar between TamR-18, -24, and -30 cells, but were increased compared with 
MCF-7 cells. Furthermore, no robust changes in levels of total and activated HER2 
was observed between TamR-18, TamR-24 and TamR-30 cells, as demonstrated by 
Western blot analysis (Figure 3.19A). As expected and in agreement with previous 
studies (Knowlden et al., 2003), all three TamR cells (-18, -24 and -30) contained 
elevated levels of phosphorylated HER2 compared to the parental MCF-7 cells, and 
this appeared to be due to an increase in total expression of the protein. As depicted 
in Figure 3.19B, immunocytochemical analysis o f total EGFR further confirmed the 
Western blot data with both TamR-18 and TamR-30 cells exhibiting no obvious 
changes in cytoplasmic and membrane staining o f the tyrosine kinase receptor.
Given that phosphorylated EGFR (Tyrl068) was most noticeably increased in 
TamR-30 cells, the effect of gefitinib treatments on ERa mRNA and protein levels 
was assessed. As shown in Figure 3.20, real-time qPCR and Western blot analysis 
showed, respectively, that ERa mRNA and protein expression was not affected by 
the gefitinib treatment regime in TamR-30 cells, thus further demonstrating that 
EGFR signalling does not contribute to ERa downregulation in TamR cells.
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Figure 3.19 (A) W estern blotting analysis of basal expression and
activity of EGFR and HER2 in MCF-7 and the late T am R  cells. (B) 
Immunocytochemical analysis of total EG FR  levels in TamR-18 and 
TamR-30 cells. (A) Cells were grown to 70% in their routine medium 
and harvested for total protein extraction as described in Material and 
Methods. Phospho-specific antibodies against EGFR (Tyrl068) and 
HER2 (Tyrl248) were used to detect the activated form of the proteins. 
Blots were also probed for total EGFR and HER2. A positive control 
sample for the detection of p-EGFR(Tyrl068) was used (+). Results are 
representative of two separate experiments. (B) Immunocytochemical 
detection of total EGFR. The image is representative of two separate 
experiments (original magnification, x40).
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Figure 3.20 Effects of gefitinib on expression levels of 
total ERa (A) mRNA and (B) protein in TamR-30 cells.
Cells were seeded into 75cm2 flasks (750,000 cells/flask) and 
allowed to grow for 24 hours in their routine medium before 
treatment with gefitinib (1 pM) or the vehicle DMSO (control) 
for 3 days. Error bars represent the S.D. o f three independent 
experiments, each performed in duplicate.
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Despite EGFR signalling not being involved in the progressive loss of ERa 
expression, it was interesting to investigate the role of EGFR in the growth of TamR 
cells. Previous studies have demonstrated that the increased activation of EGFR 
correlates with the enhanced proliferative activity o f TamR-18 cells compared to 
MCF-7 cells (Knowlden et al., 2003). Given that TamR-30 cells exhibited higher 
levels of activated EGFR (Tyrl068) in comparison with TamR-18 cells, it was 
therefore feasible to suggest that TamR-30 cells may also exhibit an increased 
reliance on EGFR signalling to mediate cell growth compared to TamR-18 cells. To 
investigate this further, the effect o f increasing concentrations o f gefitinib on growth 
of TamR-18 and TamR-30 cells was examined. As shown in Figure 3.21, no 
difference in sensitivity to gefitinib was observed between TamR-18 and TamR-30 
after 5 days. However, the growth o f both cell lines was significantly reduced by 
more than 50% compared to their respective control at the optimal gefitinib 
concentration (1 pM). These results suggest that although EGFR signalling remains 
important for the growth of both TamR-18 and TamR-30 cells, the enhanced EGFR 
activity exhibited by TamR-30 cells is not associated with an increased reliance of 
these cells on the growth factor receptor to mediate cell growth. Therefore other yet- 
to-be identified signalling pathways are likely be involved.
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Figure 3.21 Basal grow th response of TamR-18 and Tam R- 
30 cells to increasing concentrations of gefitinib. Cells were 
preliminarily grown to 70% confluency in their routine medium 
and re-seeded in 24-well plates at a density o f 30,000 cells/well. 
Cells were allowed to grow for 24 h before treatment with 
increasing concentrations o f gefitinib (0.1-1 pM) or DMSO 
(control) for 5 days; medium was changed at day 3. Results are 
expressed as % of control values on day 5 and are the means ± 
S.D. of three separate experiments carried out in triplicate wells 
for each dose. *, P < 0.05 versus control.
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3.4.2 Role of epigenetic mechanisms
Early experiments were performed in TamR-18 cells (prior to the 
development of TamR-24 and TamR-30 cells) to investigate whether methylation of 
the ERa gene promoter could be a potential contributory factor to the downregulation 
of ERa expression in these cells. Therefore, the effects o f the DNA-demethylating 
agent 5-azadeoxycytidine (5-AZA) on levels o f total and variant-ERa mRNAs were 
examined in TamR-18 cells. As shown in Figure 3.22, Real-time qPCR analysis 
demonstrated no effects of 5-AZA on expression levels of total ERa mRNA and ERa 
mRNA variants A-C, therefore suggesting that methylation o f the ERa gene is an 
unlikely mechanism responsible for the significant reduction o f ERa expression in 
TamR-18 cells.
The effects of tamoxifen withdrawal on the receptor levels were also examined in 
TamR-24 and TamR-30 cells. 4-OHT was omitted from routine medium and cells 
were maintained in this condition for 4 weeks in order to ensure total clearance of 4- 
OHT from the residual levels o f ERa present in the cells. As depicted in Figure 
3.23, tamoxifen withdrawal from culture medium resulted in a significant increase of 
total ERa mRNA levels in both TamR-24 and TamR-30 cells. In TamR-24 cells, this 
increase was accompanied by a significant increase in expression o f all three ERa 
mRNA variants. In TamR-30 cells, steady-state levels o f the ERa mRNA variants A 
and C were also significantly recovered following 4-OHT withdrawal. Western blot 
analysis of ERa expression also revealed a noticeable recovery of ERa protein levels 
in TamR-24 and TamR-30 cells, to approximately TamR-18 equivalents (Figure 
3.24A). A strong increase in nuclear staining o f ERa was also observed by 
immunocytochemical analysis in TamR-24 and TamR-30 cells, to levels comparable 
to that of TamR-18 cells but not MCF-7 cells, in which nuclear ERa staining 
remained considerably stronger (Figure 3.24B). These results clearly indicate that 
the reduction of ERa expression in TamR-24 and TamR-30 cells was not permanent, 
therefore further excluding the possibility o f epigenetic modifications (particularly 
DNA methylation) as a mechanism for ERa loss in these cells.
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Figure 3.22 Effects of 5-AZA treatm ents (5 days) on expression 
levels of (A) total ER a mRNA and (B) E R a mRNA varian ts in 
TamR-18 cells. Cells were seeded on 60 mm dishes (0.5 million 
cells/dish) and allowed to grow in their routine medium for 24 h. Cells 
were then treated with an initial 5 pM-dose of 5-AZA (+ 5-AZA) or the 
vehicle DMSO for controls without 5-AZA (-5-AZA). After 48 h, 
media was changed and cells were then maintained in culture for a 
further 3 days in the presence o f 1 pM 5-AZA. Cells were harvested for 
total RNA extraction, and subsequent real-time qPCR analysis o f ERa 
mRNA expression was performed (n = 1).
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Figure 3.23 Effects of 4 weeks-tam oxifen w ithdraw al on E R a 
mRNA expression levels in (A) Tam R-24 and (B) Tam R-30 cells.
Cells were preliminarily grown to 70% confluency and passaged by 
trypsinization in their routine medium (containing 4-OHT) as described 
in Material and Methods. Cells were allowed to grow for 24 h before 4- 
OHT was omitted from the medium (-Tam). Cells were then maintained 
in culture without tamoxifen for 4 weeks prior to cell harvest for total 
RNA extraction. Expression levels o f both total ERa mRNA and ERa 
transcript variants were then assessed by real-time qPCR. Error bars 
represent the S.D. of three independent experiments, each carried out in 
triplicate. *, P < 0.05 versus TamR-24 (-Tam); f ,  P < 0.05 versus 
TamR-30 (-Tam).
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Figure 3.24 Effects of 4 weeks-tamoxifen w ithdraw al on total 
levels of ER a protein in TamR-24 and TamR-30 cells. Cell 
culture conditions were as described in Figure 3.23. (A) Western 
blot analysis of total ERa protein expression. Data are representative 
of two separate experiments. (B) Immunocytochemical analysis of 
total ERa protein levels (n=l); Original magnification, x20.
Chapter 3. Results
3.4.3 Role of alternative growth factor signalling pathways
In an attempt to identify the mechanisms underlying loss o f ERa expression 
in TamR cells, the basal expression and activity o f other cell signalling components 
were analysed. A cross-talk mechanism between IGF-IR and EGFR, whereby the 
IGF-IR regulates basal-activated EGFR signalling and cell proliferation, has been 
shown in TamR cells (Knowlden et al., 2005). Given that levels o f EGFR (Tyrl068) 
were increased in TamR-30 cells, it was interesting to assess basal levels o f activated 
IGF-IR in these cells. In line with the increased levels of EGFR (Tyrl068) in TamR- 
30 cells as described earlier, basal levels o f phosphorylated IGF-IR (Tyrl316) were 
also markedly enhanced in these cells (Figure 3.25). In contrast, levels o f total IGF- 
IR were progressively and markedly reduced as cells progressed through to TamR-30 
cells, further reflecting the loss of ERa expression in these cells since IGF-IR is a 
well known ER-dependent gene product. The enhanced basal activity o f the receptor 
tyrosine kinases EGFR and IGF-IR in TamR-30 cells was further validated by the 
marked increase in basal activity of their two common downstream signalling 
elements Akt and Erkl/2 which, as described in Chapter 1 {section 1.5.3.2), have 
been linked with the downregulation of ERa expression in breast cancer. 
Interestingly, levels of total Akt were visibly reduced in TamR-24 and TamR-30 
cells.
As described in Chapter 1 {section 1.5.3.2), an inverse relationship between PKCa 
activity and ERa expression is well known in breast cancer. Overexpression of 
PKCa has also been involved in the development o f tamoxifen resistance, ERa- 
independent tumour growth as well as tumour aggressiveness and metastasis in vivo 
(Ways et al., 1995; Tonetti et al., 2000; Frankel et al., 2006). Furthermore, elevated 
activity of the non-receptor tyrosine kinase Src has recently been associated with a 
significant proportion of ERa-negative primary breast cancers, and the reduced 
stability of ERa protein in ERa-positive breast cancer cell lines (Chu et al., 2007). 
In light of these observations, the basal expression and activity of both PKCa and Src 
was analyzed in TamR cells. As depicted in Figure 3.26, Western blot analysis 
revealed a slight but noticeable increase in levels o f phosphorylated PKCa in TamR- 
24 compared to TamR-18 cells. MCF-7 cells exhibited no apparent signals of the 
activated protein kinase. In contrast, a considerable increase of phosphorylated
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PKCa was observed in TamR-30 cells, which also displayed the lowest levels o f total 
expression of the protein, thus reflecting a hyper-phosphorylated state for PKCa in 
these cells. Src kinase activity was not apparent in MCF-7 cells but was 
progressively and noticeably increased as tamoxifen-resistance developed, and 
reached maximum levels in TamR-30 cells. The increase in phosphorylated Src was 
not due to an increase in expression levels o f the protein.
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Figure 3.25 Basal expression and activity of IG F-IR , E rk l/2  
and Akt in MCF-7 and the late Tam R  cells. Cells were grown to 
70% in their routine medium and harvested for total protein 
extraction as described in Material and Methods. Phospho-specific 
antibodies against IGF-IR (Tyrl316), E rkl/2  (Thr202/Tyr204 ) and 
Akt (Ser473) were used to detect the activated form of the proteins. 
Blots were also probed for total levels o f the proteins. Results are 
representative of three separate experiments.
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Figure 3.26 Basal expression and activity of PK C a and Src in 
MCF-7 and the late TamR cells. Phospho-specific antibodies 
against PKCa (Ser657) and Src (Tyr418) were used to detect the 
activated form of the proteins. Total expression levels of the same 
proteins were also assessed. Results are representative o f three 
independent experiments.
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In light of the increased activity of PKCa, Src, Akt and Erkl/2 in TamR-30 
cells, and their reported link with downregulation o f ERa expression in breast cancer, 
a panel of signal transduction inhibitors targeting specifically each o f these proteins 
individually were used in TamR-30 cells in order to examine the effects on ERa 
mRNA and protein expression. ERa expression levels were first examined following 
a short-term inhibition (24 h) with the inhibitors. As shown in Figure 3.27A, 
inhibition of Src kinase activity by AZD0530 resulted in a significant increase of 
total ERa mRNA levels (p<0.001 control vs AZD0530). This increase could also be 
clearly seen at the protein levels, as demonstrated by Western blot analysis (Figure 
3.27B). In contrast, no significant changes in total ERa mRNA levels were observed 
following treatment of TamR-30 cells with the PKC inhibitor bisindolylmaleimide 
IX (Bis), and the PI3K inhibitor wortmannin (Wort). Although not significant, a 
slight but visible reduction in ERa mRNA steady-state levels could be seen upon 
inhibition of Erkl/2 signalling by the MEK1/2 inhibitor U0126. In agreement with 
the mRNA data, ERa protein levels remained unchanged in TamR-30 cells treated 
with Bis, suggesting that PKCa may not be involved in downregulation o f ERa 
levels in TamR-30 cells. Although no change in total ERa mRNA levels was 
observed with wortmanin, the latter induced a visible recovery o f ERa protein but 
not to the same extent as with AZD0530 treatments. Interestingly, a total loss of 
ERa protein was observed following treatment with the inhibitor U 0126, and this 
was confirmed by overexposure o f the blots.
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Figure 3.27 Short term  effects of various signal transduction 
inhibitors on (A) ERa mRNA and (B) protein expression in Tam R- 
30 cells. Cells were seeded into 60mm dishes (TamR-30 cells, 
0.25x10s cells/dish; TamR-18 cells, 0.5x10s cells/dish) and grown to 
70% in their routine medium before treatment with the various 
inhibitors for 24 hours. (A) real-time qPCR analysis o f total ERa 
mRNA expression. Error bars represent the S.D. of three independent 
experiments, each carried out in duplicate. (B) Whole cell extracts 
were also prepared for western blot analysis of total ERa protein 
expression. C, control; AZD, AZD0530 (lpM ); Bis, 
bisindolylmaleimide (0.5 pM); U 0126 (10 pM); Wort, wortmanin 
(lOOnM). Western blot data are representative o f two separate 
experiments. *, P < 0.01 versus control, C.
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In an attempt to confirm more robustly the results presented in Figure 3.27, 
the pathway inhibition study was extended to a period of 3 days. As depicted in 
Figure 3.28A, a significant increase in total ERa mRNA levels was observed 
following treatments o f TamR-30 cells with AZD0530 (p<0.001 control vs 
AZD0530, n=3). This increase was noticeably stronger (-6.5 fold vs. control) than 
that observed at the 24 h period with the same inhibitor (~ 2-fold vs. control). Again, 
no apparent changes in total ERa mRNA levels were observed upon inhibition with 
Bis, or wortmannin. There was a slight but non-significant reduction of ERa mRNA 
steady-state levels following treatment o f TamR-30 cells with U 0126. However, at 
the protein level, treatment with the inhibitor U 0126 resulted in a total loss of ERa 
protein signals. In contrast to the observations made at the 24 h-period, treatment of 
TamR-30 cells with wortmannin for 3 days resulted in only a very slight increase of 
ERa protein levels. Most importantly, Western blot analysis confirmed the effects of 
AZD0530 on ERa mRNA expression, with total ERa protein levels being 
considerably increased in TamR-30 cells treated with the inhibitor, to levels similar 
to that of TamR-18 cells (Figure 3.28B). In line with the Western blot data, 
immunocytochemical analysis revealed that AZD0530-treated TamR-30 cells 
exhibited intense nuclear staining for ERa to levels surprisingly comparable to wild- 
type MCF-7 cells (Figure 3.29). In light o f the results obtained with AZD0530, 
steady-state levels o f ERa mRNA variants (A-C) were also assessed in TamR-30 
cells treated with the Src inhibitor for 3 days. As shown in Figure 3.30, a significant 
increase in expression levels o f all three transcripts was observed following Src 
inhibition in TamR-30 cells.
These results strongly implicate Src kinase activity as one potential mechanism 
underlying the considerable loss o f ERa expression levels in TamR-30 cells. Akt 
activity may also be involved in the progressive reduction o f ERa, at least at the 
post-translational level, since treatment with wortmannin did result in a slight but 
visible increase o f ERa protein (particularly at 24 h) but not ERa mRNA expression. 
Although in disagreement with the literature, the U0126-induced downregulation of 
ERa protein expression would suggest that hyperactivation o f Erkl/2 may have a 
positive regulatory function on ERa expression at least at the post-translational levels 
in TamR-30 cells
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Figure 3.28 Long term  effects of various signal transduction 
inhibitors on (A) ER a mRNA and (B) protein expression in TamR-30 
cells. Cells were seeded into 75cm2 flasks (750,000 cells/flask) and 
allowed to grow for 24 hours in their routine medium before treatment 
with the various inhibitors for 3 days. Error bars represent the S.D. of 
three independent experiments, each performed in duplicate. Western 
blot data are representative of two separate experiments. *, P < 0.001 
versus control, C.
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Figure 3.29 Immunocytochemical analysis of total ER a protein expression 
in MCF-7 cells and TamR-30 cells treated or not with AZD0530 for 3 days.
Cells were seeded onto coverslips (75,000 cells/coverslips) and allowed to grow 
for 24 h in their routine medium before treatment with 1 pM AZD0530 or with 
the vehicle DMSO (control: TamR-30 (-AZD)) for 3 days (except MCF-7 cells). 
Cells were then ER-ICA fixed for immunocytochemical detection of nuclear ERa 
(n=l).
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Figure 3.30 Effects of 3 day-AZD0530 treatm ents on steady-state 
levels of ER a mRNA varian ts  in Tam R-30 cells. cDNA samples from 
TamR-30 cells treated with AZD for 3 days were also used to assess 
expression levels o f ERa mRNA variants. Error bars represent the S.D. 
of at least 3 separate experiments carried out in duplicate. *, P < 0.05 
versus TamR-30 (-AZD).
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Because ERa expression was partially restored in TamR-30 cells when 
tamoxifen was omitted from culture medium (section 3.4.2), the effect o f tamoxifen 
withdrawal on the kinase activity o f Src, Akt and Erkl/2 was also examined. To this 
end, the same whole cell lysates used to detect total ERa protein after 4-weeks o f 
tamoxifen withdrawal from culture medium (see Figure 3.27) were used. Western 
blot analysis revealed that levels o f phosphorylated Src and phosphorylated Akt were 
reduced upon tamoxifen withdrawal in TamR-30 cells. In contrast, the levels of 
activated and total Erkl/2 proteins remained unchanged in the tamoxifen-withdrawn 
samples (Figure 3.31).
In order to confirm the inhibitory action o f AZD0530 on Src kinase activity, the 
latter was analyzed before and after treatments o f TamR-30 cells with the inhibitor. 
As expected, levels of phosphorylated Src were reduced to almost non-detectable 
levels following a 3 day treatment with the inhibitor (Figure 3.32A). Furthermore, 
TamR-cells with elevated Src activity have previously been shown to display poor 
cell-cell contacts when grown in culture in vitro (Hiscox et al., 2006). Therefore, the 
morphology of live TamR-30 cells was also examined following treatments with the 
Src inhibitor using an inverted microscope fitted with a Hoffman condenser. As 
illustrated in Figure 3.32B, inhibition o f Src activity in TamR-30 cells restored cell­
cell contacts and resulted in reorganization o f the cells into a tightly packed epithelial 
cell colony similar to that of the parental MCF-7 cells. The increase in cell-cell 
contacts as a result of Src inhibition was further confirmed by Haematoxylin/Eosin 
staining (Figure 3.32C).
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Figure 3.31 Effects of 4 weeks-tamoxifen w ithdraw al on 
activity and expression of Src, Akt and E rk l/2  in TamR-30 cells.
Data is representative of two separate experiments.
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Figure 3.32 Effects of AZD0530 treatm ents on Src activity and 
cell morphology in TamR-30 cells. (A) The inhibitory effects of 
AZD0530 (lpM , 3 days) on Src activity was assessed by western 
blotting. Control sample were treated with the vehicle for AZD0530, 
DMSO. Data are representative o f two separate experiments. (B) 
Representative HMC® images o f TamR-30 cells with or without (C, 
control) AZD0530 (1 pM) for 3 days. (Original magnification, x20). 
(C) Haematoxylin & Eosin staining of TamR-30 cells grown in the 
presence or absence o f AZD (lpM , 3 days). Cell seeding densities 
were as described in Figure 3.29.
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3.5 Analysis of cell motility and invasiveness in TamR-30 cells
Using the in house TamR-18 cells, previous studies have shown that the 
acquisition of endocrine resistance is associated with the development of a more 
aggressive cell phenotype essentially due to elevated Src activity. This was 
demonstrated by TamR-18 cells exhibiting increased cell motility and invasion 
capabilities in vitro (Hiscox et al., 2004; 2006). In view of this and the findings 
herein that TamR-24 and TamR-30 cells contain a noticeable increase of activated 
Src, it was expected that the invasion and motility would be enhanced in these cells 
compared to TamR-18.
Using fibronectin-coated porous membranes, the in vitro migratory capacity of 
TamR-24 and TamR-30 cells was first assessed and compared to that of TamR-18 
cells over a period of 48 h, and under basal conditions. As shown in Figure 3.33, the 
migratory capacity of TamR-24 and TamR-30 cells was significantly increased 
compared to TamR-18 cells (TamR-18, 36 ± 8; TamR-24, 102 ± 20; TamR-30, 151 ± 
16 mean cell number/field o f view). TamR-30 cells were also significantly more 
migratory when compared to TamR-24 cells. A representative picture of crystal- 
violet stained cells that have migrated through the membrane is shown (Figure 
3.33A).
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Figure 3.33 In  vitro m igration assay in TamR-18, TamR-24, 
and TamR-30 cells. Cells were seeded onto fibronectin-coated 
porous membranes (Transwell™), as described in Material and 
Methods. After 48 h, migratory cells were fixed, stained and 
counted. (A) Representative images o f crystal-violet-stained 
migratory cells. Original magnification, x40. (B) Quantitative
assessment of the number o f migratory cells. The latter were counted 
in 10 random fields o f view per membrane using an Olympus BH-2 
light microscope, as described in Material and Methods (Original 
magnification, x20). Results are expressed as mean cell number/field 
of view ± S.D. of three separate experiments carried out in triplicates. 
*, P < 0.001 versus TamR-18; *j\ P < 0.001 versus TamR-24.
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As depicted in Figure 3.34, basal cell invasion was also significantly 
increased in TamR-24 and TamR-30 cells compared to TamR-18 over a 3 day period 
(TamR-18, 25 ± 6; TamR-24, 64 ± 12; TamR-30, 103 ± 28 mean cell number/field of 
view). These results are in agreement with the causative role o f Src activity in the 
development of a more aggressive and invasive cell phenotype, since the increase of 
cell motility and invasion in the late TamR cells correlate robustly with the increase 
of Src activity in those cells compared to TamR-18. The aggressive properties of 
TamR-30 cells were also visibly apparent when routinely grown in their culture 
medium, as shown by their rapid adhesion to uncoated Petri-dishes. Although it was 
only assessed qualitatively, the cell adhesion rate on plastic surfaces was visibly 
higher in TamR-30 cells compared to TamR-18 cells, as shown by the Hoffman 
Modulation Contrast (HMC®) images o f the live cells taken at different time shots 
after seeding (Figure 3.35).
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Figure 3.34 In vitro cell invasion assay in TamR-18, TamR-24, 
and TamR-30 cells. An artificial basement membrane (Matrigel) 
was used to assess the invasive capacity o f the cells, as described in 
Material and Methods. After 72 h, invasive cells were fixed, stained 
and counted. (A) Representative images of DAPI-stained invasive 
cells. Original magnification, x40 (inverted microscope DMIRE2 
Leica, Arizona, USA). (B) Cell invasion was quantified by viewing 
DAPI-stained-cells on five separate fields of view per membrane and 
counting the number of cells in each field using magnification x20. 
Data were then plotted as mean cell number/field of view ± S.D. o f at 
least three separate experiments, each performed in duplicate. *, P < 
0.001 versus TamR-18; f ,  P < 0.05 versus TamR-24.
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Figure 3.35 Com parative assessment of cell spreading on 
uncoated plastic surfaces between TamR-18 and TamR-30 cells.
Cells were grown to 70% confluency in their routine medium, 
trypsinized and re-seeded onto uncoated 60mm Petri-dishes ( lx l0 6 
cells/dish) for incubation at 37°C for up to 24 h. Hoffman 
Modulation Contrast (HMC®) images o f live cells were taken 1-, 3-, 
6-, and 24 h after seeding using an inverted microscope (DMIRE2 
Leica, Arizona, USA) and a digital camera (Orca-285, Hamamatsu, 
Japan). Original magnification, x20.
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3.6 Potential Transcription factors regulating ERa expression in 
TamR cells: preliminary studies
3.6.1 AliBaba2.1 and Affymetrix database
The loss o f critical transcription factors involved in the positive regulation of 
ERa transcription has been suggested as one potential mechanism that could 
contribute to the loss o f ERa expression in vitro (Yoshida et al., 2000). Similarly, 
loss of ERa expression can also be due to the predominant expression of 
transcriptional repressors (Yoshida et al., 2000; Macaluso et al., 2007). In the 
present study, TamR-18 cells have been shown to exhibit a significant reduction of 
ERa mRNA steady-state levels compared to MCF-7 cells. In a preliminary attempt 
to identify transcription factors involved in the downregulation of ERa gene 
expression in TamR cells, potential transcription factor binding sites were mapped to 
both the proximal (A/B) and distal promoters (C) o f the ERa gene using AliBaba 2.1 
software (Grabe 2002; http://www.gene-regulation.comT
As described in Material and Methods, the nucleotide sequence of each promoter and 
approximately 1-kb of upstream DNA sequences (relative to the originally described 
transcription start site, +1) were subjected to the AliBaba2 algorithm. The list of 
potential transcription factors as predicted by AliBaba2 are represented in Table 3.1. 
The prediction of transcription factor binding sites performed by AliBaba2.1 
software is based on the TRANSFAC® database, which contains amongst other data 
those of experimentally-proven binding sites for eukaryotic transcription factors 
(Matys et al., 2006). However, at the time o f the analysis, the AliBaba2 program 
was based on an outdated version o f TRANSFAC® (version 4.0). Therefore, the 
candidate list of transcription factors generated by AliBaba 2.1 was further extended 
with additional transcriptional regulators (outlined below), which were shown in the 
literature to regulate ERa transcription either through protein/DNA interactions or 
through protein-protein interactions at the ERa promoter.
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Table 3.1 List of potential transcription factors (TFs) for ERa proximal 
(-1000 to +245)* and/or distal (-3000 to -1977)* promoters as 
predicted by AliBaba 2.1 software.
TFs GeneCard ID f ERa promoter
HNF-1/TCF1 GC12P119900
MYC GC08P128817
Proximal
EGR2/Krox20 GC10M064241
MYOD1 GC11P017697
C/EBPp GC20P048240
CREB2 GC02M 175645
HSF1 GC08P145486
Distal
RARa GC17P035718
SOX2 GC03P182912
HSF1 GC08P145486
C/EBPa GC19M038482
HNF4a GC20P042463
POU2F1 GC01P165456
POU2F3 GC11P119616
Pu.l GC11M047332
NFkBI GC04P103641
Proximal/Distal
AP2a GC06M 010503
FOS GC14P074815
JUN GC01M058958
IRF-1 GC05M131846
ZEB1 GC 10P031648
SP1 GC12P052060
*, relative to the originally described transcription start site (Green et al., 
1986); f , www.genecards.org
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As described in Chapter 1 {section 1.4.1), these transcriptional regulators 
include the pRb2/SUV39Hl/HDACl/DNM Tl/E2F4/E2F5 and p300/CBP complex 
(Macaluso et al., 2003; 2007), p53 (Angeloni et al., 2004) and AP2y (Schuur et al., 
2001); all of which have been shown to regulate ERa transcription as part o f a 
multiprotein complex that bind to the proximal promoter. In addition, Fox03a were 
also added to the list since it was shown to positively regulate ERa gene transcription 
through direct binding to the C promoter (Guo & Sonenshein, 2004). Next, the gene 
expression profiles of all the candidate transcription factors were examined using a 
gene array database in TamR-18 cells (vs. MCF-7 cells), which has previously been 
generated from the Affymetrix U133A Genechip (see Appendix A for protocol 
overview). A heat map representing the gene expression level o f each candidate 
transcription factor is shown in Figure 3.36. As first cut-off criteria, only the 
expression profiles associated with a p-value o f less than 0.1 were considered in 
order to select relevant candidate transcription factors, whose expression were either 
up- or downregulated in TamR-18 cells compared to MCF-7 cells.
As a result of the cut-off criteria, 7 transcriptional regulators were short-listed and 
these are shown in Table 3.2 (see Appendix B for Log-intensity plot corresponding 
to the gene expression of these transcription factors). Statistical significance (P < 
0.05, MCF-7 versus TamR-18) was only found for Affymetrix probes corresponding 
to the transcription factors c-JUN (heat map number 47 and 54), C/EBPp (heat map 
number 1) and the transcriptional co-activator CBP/p300 (heat map number 46). 
Using the Pubmed-Medline resource (http://www.ncbi.nlm.nih.gov/sites/entrez), a 
literature search was carried out in order to identify whether each o f these 
transcription factors was a positive or negative regulator of ERa transcription. As 
outlined in Chapter / ,  the transcription factors p53, Fox03a, AP2y and c-Jun (part o f 
API complex) have been reported to positively regulate ERa transcription. Also, the 
transcriptional coactivator CBP/p300 has been identified as part o f a multi-protein 
complex found on the promoter A to activate transcription o f the ERa gene (See 
Table 3.2 for references). Binding sites for both C/EBPa and C/EBP(3 transcription 
factors on ERa proximal and distal promoters were suggested by AliBaba2 in the 
present study. However, no literature has been reported that implicate regulation of
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ERa gene transcription with these transcription factors, whose gene expression were 
found elevated in TamR-18 compared to MCF-7 cells.
In light of the substantial amount of evidence that exist in the literature implicating 
AP2y, p53 and Fox03a in the positive regulation o f ERa gene transcription, loss of 
one or several o f these transcription factors could potentially be involved in the 
downregulation of ERa in TamR cells. Indeed, the Affymetrix database showed 
reduced gene expression levels of these transcription factors in TamR-18 compared 
to MCF-7 cells (Figure 3.36). However, due to time constraints, the gene expression 
profiles o f these transcription factors could not be verified by semi-quantitative PCR. 
However, an optimized in house immunocytochemical assay for the detection of 
nuclear AP2y was available and thus, expression levels o f AP2y was examined in the 
long-term TamR cells. Fox03a were also assessed by both Western blot and 
immunocytochemical analysis in TamR cells.
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Rank Gene name Rank Gene name
* *  1 C/EBPp
2 ATF2/CREB2 29 HNF4a
3 C/EBPa 30 HNF1
4 F0XM1/FKHL16 31 MYOD1
5 dRB2/d130 * 32 F 0X 03a
6 HNF4a 33 TCF8/ZEB1
7 SUV39H1 34 HSF1
8 MYC 35 TCF8/ZEB1
9 EGR2/Krox20 36 TCF8/ZEB1
10 HNF1a 37 SOX2
11 HNF4a * 38 TP53
12 P0U2F1 39 JUN
13 SPM/Pu.1 40 RARa
14 HDAC1 41 RARa
15 NFkB1 * 42 AP2v/ERF1
16 HSF1 * 43 TP53
17 AP2a 44 RARa
18 E2F4 45 ATF2/CREB2
19 AP2a * * 46 CBP/D300
20 DNMT1 * * 47 JUN
21 AP2a 48 POU2F3
22 RARa 49 SP1
23 CBP/D300 * 50 F0X 03a
24 SOX2 51 E2F5
25 FOS * 52 JUN
26 E2F4 53 dRB2/d130
27 AP2V/ERF1 * * 54 JUN
38 IRF1
Figure 3.36 G ene a rra y  expression profiles of 
potential transcrip tio n a l regulators of the E R a gene. The
heat map represents comparative gene expression analysis 
between MCF-7 and TamR-18 cells, which was performed 
using median-normalised, log-transformed data using the 
online software package GeneSifter® (www.genesifter.net). 
Colour key is shown at the bottom o f the map and represents 
the Log expression intensity with red and green colours 
indicating higher and lower relative expression, 
respectively. Underlined gene names represent potential 
regulators o f  ERa gene transcription as suggested by the 
literature (see Table 3.2  for references). *, P  < 0.1; **, P  <  
0.05
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Table 3.2 Short-list of potential transcriptional regulators of ERa gene expression.
Red font indicate gene array expression profiles associated with P < 0.05 (MCF-7 versus TamR-18).
Gene Name Gene ID Probe No. Heat map No. Direct regulator of ERa transcription in BrCa? References
p53/TP53 NM 000546 211300 s at 
201746_at
38
43
Y, positive regulator of ERa transcription through protein- 
protein interaction on A/B promoter.
Mutated form present in high proportion of ERa-negative 
advanced BrCa.
Bems e ta l., 1996; 
Bems eta l., 2000; 
Angeloni et al., 2004
Foxo3A/
FKHRL1 NM_001455 204132 s at 210655_s_at
32
50
Y, positive regulator of ERa transcription (C promoter). Guo & Sonenshein, 2004
AP2y/ERFl NM 003222 205286 at 
205287_s_at
27
42
Y, positive regulator o f ERa transcription in vitro (A/B/C 
promoters) but lack of association between AP2y and ERa 
expression in clinical BrCa.
Schuur eta l., 2001
c-Jun NM 002228
213281 at
201464 x at 
201466 s at
201465 s at
39
47
52
54
Y, through binding of c-Jun to the ER-EH0 element 
(promoter D)
Tan g e t  al., 1997;
Table 3.2 ...continued
Gene Name Gene ID Probe No. Heat mapNo. Regulator of ERa gene transcription? References
C/EBP/? AL564683 212501 at 1
Not reported, but C/EBP/? shown to regulate transcription of 
other steroid receptors.
Correlation betweenC/EBP/?-3 (LIP) expression and ERa- 
negative status.
Dong et al., 2006 
Langosch et al., 
2003
C/EBPa NM 004364 204039_at 3 Not reported. No correlation found between C/EBPa expression and ER status in primary BrCa.
Gery et al., 2005 
Langosch et al., 
2003
CBP/p300 NM 004380 211808 s at
202160_at
23
46
Y, through interaction with large multi-protein complex involved 
in epigenetic regulation of ERa transcription (promoter A)
Macaluso et al., 
2005; 2007
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3.6.2 AP2y
Although no clear correlations has yet been found between AP2y and ERa 
expression in clinical breast cancers, in vitro studies using human mammary 
epithelial cells have shown that AP2y can activate ERa transcription through binding 
to the proximal promoter A (Schuur et al., 2001). Furthermore, a number o f highly 
ERa-positive breast cancer cell lines are known to overexpress AP2y (Schuur et a l , 
2001; Pellikaineno & Kosma, 2007). In light o f these observations and the fact that 
gene array analysis revealed that AP2y transcript levels were downregulated in 
TamR-18 cells compared to MCF-7 cells, it was hypothesised that downregulation of 
nuclear AP2y could, at least in part, underlie the significant reduction o f ERa 
expression levels in the late TamR cells. As a preliminary attempt to investigate this 
hypothesis, total levels o f nuclear AP2y protein were examined by 
immunocytochemical analysis.
As shown in Figure 3.37 and in agreement with the gene array data, 
immunocytochemical assessment o f AP2y expression and subsequent HScore 
analysis showed a reduction, although not statistically significant, o f nuclear AP2y 
staining in TamR-18 and TamR-24 cells compared with MCF-7 cells. No significant 
difference in AP2y nuclear staining was observed between TamR-18 and TamR-24 
cells. In contrast, AP2y expression was found to be significantly reduced in TamR- 
30 cells (median HScore, 132) compared with MCF-7 (median HScore, 170), TamR- 
18 (median HScore, 165) and TamR-24 cells (median HScore, 155). .
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Figure 3.37 Immunocytochemical analysis of AP2y expression 
in MCF-7 cells and the late Tam R  cells. Cells were grown to 70% 
confluency and ER-ICA fixed for the detection of total nuclear AP2y 
using the specific 6E4 antibodies, as described in Material and 
Methods. Data are representative o f at least three independent 
experiments (Original magnification, x20).
HScore analysis (median values): HScore (MCF-7) = 170; HScore 
(TamR-18) = 165; HScore (TamR-24) = 155; HScore (TamR-30) = 
132. P < 0.01 for TamR-30 versus MCF-7, TamR-30 versus TamR- 
18, TamR-30 versus TamR-24.
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3.6.3 Fox03a
As previously stated, Fox03a has been shown to positively regulate ERa 
gene transcription through binding to a region within the promoter C (Guo & 
Sonenshein, 2004). Interestingly, gene array analysis in the present study showed 
that Fox03a transcript levels were downregulated in TamR-18 cells compared to 
MCF-7 cells. It was initially hypothesised that reduced expression levels o f Fox03a 
proteins could, at least in part, be correlated with the progressive loss o f ERa 
expression levels (and more particularly steady state levels o f ERa mRNA variants 
C) in the different TamR cells. To examine this further, total levels o f Fox03a 
protein were analysed by Western blotting and immunocytochemical analysis in 
MCF-7, TamR-18 and the late TamR cells (TamR-24 and TamR-30). As shown in 
Figure 3.38A, Western blotting showed no robust changes in levels o f total Fox03a 
protein between the TamR cells, which exhibited similar levels o f the protein 
compared to MCF-7 cells.
Fox03a activity is negatively regulated by the PI3K signalling pathway, whereby 
Akt-mediated phosphorylation of Fox03a on specific threonine and serine residues 
result in nuclear export and concomitant inhibition o f the transcription factor since it 
is no longer able to interact with DNA (Brunet et a l ,  1999). Interestingly, levels o f 
phosphorylated/active Akt were shown in the present study to be dramatically 
increased in TamR-30 cells (see Figure 3.25). In view of this, it was therefore 
feasible to anticipate that the very low ERa content exhibited by TamR-30 cells 
could correlate with low levels of nuclear Fox03a, as a result o f the Akt-mediated 
phosphorylation/nuclear exclusion o f Fox03a. In order to test this hypothesis 
further, immunocytochemical analysis o f total Fox03a was carried out using total 
Foxo3a antibodies that detect both nuclear/active- and cytoplasmic/inactive-Foxo3a. 
Results showed a very slight but visible decrease in Fox03a nuclear staining in 
TamR-30 cells compared to MCF-7 and TamR-18 cells (Figure 3.38B). The 
cytoplasmic staining of Foxo3a was very weak in TamR cells and this could be due 
to the high dilution used with total Foxo3a antibodies (1:250).
It was also anticipated that cytoplasmic levels o f phosphorylated/inactive Fox03a 
(Ser 253) be increased in TamR-30 cells, since Akt activity was considerably 
elevated in these cells. Immunocytochemical analysis o f phospho-Fox03a (Ser 253)
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confirmed the cytoplasmic localization of the inactive protein. However, the 
cytoplasmic staining o f phospho-Fox03a appeared similar across the different cell 
lines (Figure 3.39).
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Figure 3.38 (A) W estern blot and (B) im m unocytochem ical
analysis of total Foxo3A expression in M CF-7 and the late T am R  
cells. Cells were grown to 70% confluency in their routine medium. 
Immunocytochemical detection o f total Foxo3A was carried out 
using specific polyclonal antibodies on ER-ICA fixed cells, as 
described in Material and Methods. Data are representative o f one 
(ICC) or two (WB) independent experiments.
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Figure 3.39 (A) W estern blot and (B) immunocytochemical
analysis of phosphorylated/inactive Foxo3A expression in 
MCF-7 and the late Tam R cells. Phospho-specific antibodies 
against Phosphorylated-Foxo3A (Ser253) were used, as 
described in Material and Methods (n=l).
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4.1 Rationale and aims of this study
ERa is a major contributor to the biology of breast carcinogenesis and is still 
currently considered as one o f the most powerful prognosis factors in breast cancer. 
Therefore, understanding the mechanisms controlling its expression during breast cancer 
development and following treatment with anti-hormones is of obvious clinical interest. 
Endocrine therapy is primarily aimed at blocking oestrogen-induced proliferation of ERa- 
positive breast cancer cells and is currently represented by three broad classes of agents: 
the SERMs (e.g.: tamoxifen), the SERDs (e.g.: fulvestrant) and the third-generation 
aromatase inhibitors (AIs; e.g.: anastrozole; Gradishar, 2004). A new therapeutic trend 
has been emerging in which AIs are progressively taking over from tamoxifen as the 
primary anti-hormonal agents in post-menopausal women with early or advanced ERa- 
positive breast cancer (Dixon & Bundred, 2006). This new trend has in part been initiated 
by data obtained from several phase III clinical trials, which have showed that AIs have a 
superior efficacy over tamoxifen when used as first-line endocrine agents for the 
treatment of early breast cancer in postmenopausal women. Most notably, the AT AC 
trial revealed that 5 years of anastrozole over tamoxifen improves disease-free survival by 
20% in the adjuvant setting (Howell et al., 2005; Younus & Vandenberg, 2005). 
Nonetheless, AIs have yet to be fully established into the routine clinical practise and 
thus, tamoxifen still remains widely used for the management of ERa-positive breast 
cancers. Unlike AIs, tamoxifen has proved itself as a flexible agent, being administered 
to breast cancer patients irrespective of their age, nodal or menopausal status. Moreover, 
while little is known about the long-term benefits and drawbacks of AIs, there is a 
substantial body of data available for tamoxifen whose clinical history spans over three 
decades, thus making it a relatively safe endocrine agent in systemic therapy for breast 
cancer. It is also worth to mention that the low cost of tamoxifen is of great relevance for 
its implemented use in developing countries.
Despite all these advantages, the efficacy of tamoxifen, like many other endocrine agents, 
is too often limited by the onset of resistance (intrinsic and acquired). Several underlying 
mechanisms for tamoxifen resistance have been proposed in the literature including 
mutations of ER, increased expression of ER splice variants, altered metabolism of 
tamoxifen, altered expression and activity of ER cofactors and increased activity of non- 
genomic/membrane ER (Riggins et al., 2007; Ring & Dowsett, 2004). Two other
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mechanisms that have also been identified, and which have been the subject of 
investigation in this study, are (i) the aberrant activation of alternative growth regulatory 
pathways, such as EGFR and HER-2, and (ii) loss of ERa expression.
In clinical disease, an inverse association between EGFR and/or HER-2 with ERa 
expression has been shown by many groups and is now a well acknowledged observation 
(Ciocca et al., 1992; Nicholson et al., 1994; Konecny et al., 2003; Gee et al., 2005). As 
previously stated in Chapter 1, loss o f ERa expression is a major issue since it is 
associated with a very poor prognosis, a more aggressive and metastatic breast cancer 
phenotype. Although the majority o f breast cancer patients retain ERa expression and 
function throughout endocrine therapy, concordant data from several clinical studies have 
shown that 15% to 30% of initially ERa-positive breast tumours can convert to an ERa- 
negative phenotype on tamoxifen relapse in the adjuvant or metastatic setting (Gutierrez 
et al., 2005; Johnston et al., 1995; Kuukasjarvi et al., 1996; Lower et al., 2005). A loss of 
ERa in as much as 50% of tumours at the time of progression on hormonal therapy has 
recently been quoted by the Johnston group (Johnston et al., 2008). In the adjuvant 
setting, Johnston et al. (1995) have also shown that there was a significant reduction in 
the quantitative expression of ERa in the ERa-positive recurrent tumour compared to the 
primary. In support of this, a recent clinical study has reported a proportion (~ 15%) of 
tamoxifen-relapsed breast tumours with “low-positive” ERa levels (Kennecke et al., 
2008). Cumulatively, these clinical data would suggest that loss of ERa expression may 
occur as a direct consequence o f tamoxifen therapy. The present study explored this 
possibility further by developing in vitro cell models of acquired resistance to tamoxifen 
in order to investigate whether ERa loss can indeed occur in response to prolonged 
tamoxifen treatments, and most importantly, elucidate the underlying molecular 
mechanisms together with their therapeutic implications.
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4.2 In vitro models of anti-hormone-resistance with depleted ERa levels
In the present study, MCF-7-derived fulvestrant-resistant (FasR) cells provided 
the first proof-of-principle that sustained exposure to anti-hormones can induce loss of 
ERa expression. Indeed, continuous exposure of MCF-7 cells with the pure anti­
oestrogen fulvestrant resulted in irreversible loss of ERa expression over a 24-month 
period. In agreement with the FasR cells in the present study, other studies have also 
reported a fully and irreversible ERa-negative phenotype following extended culture (~ 
18 months) of MCF-7 cells in fulvestrant-containing medium (Liu et al., 2006). In 
contrast to the fulvestrant-resistant subline, long-term treatment of MCF-7 cells with 4- 
OHT did not result in total loss o f ERa, even after a 30-month treatment regime, which 
generated TamR-30 cells. The FasR cell models seem therefore more susceptible to the 
generation of an ERa-negative phenotype than the acquired tamoxifen resistant variant. 
This observation in itself is not surprising considering that fulvestrant mode of action is 
based on its ability to rapidly downregulate ERa levels (Osborne et al., 2004), potentially 
via a nuclear matrix-associated proteasome mechanism (Long & Nephew, 2006). 
However, it has previously been shown that ERa expression (mRNA and protein) and 
function can be maintained in several MCF-7-derived models of fulvestrant resistance; 
yet ERa protein levels were still reduced by one-third compared to the parental cells 
(Larsen et al., 1997).
Although total loss o f ERa was not achieved after 30 months exposure with 4-OHT 
(TamR-30), the data presented herein clearly indicate that acquisition of tamoxifen 
resistance in MCF-7 cells is associated with a significant reduction o f both ERa mRNA 
and protein levels. Precisely, 18 months exposure with tamoxifen (TamR-18) was shown 
to reduce ERa expression by approximately 40%. Importantly, this fall was further 
exacerbated with a 24- (TamR-24) and 30 month (TamR-30) treatment regime, which led 
to a -90% reduction in ERa mRNA and protein steady state levels. Using in vitro models 
of early resistance to tamoxifen (TamR-3, TamR-11), this study also revealed that the 
decline in ERa expression occurs relatively quickly during in vitro acquisition of the 
tamoxifen-resistant phenotype. This is in agreement with previous in vitro studies by 
Badia et al. (2000) who have reported that ERa expression was reduced by -50%  in all of 
their eight variants of MCF-7-derived tamoxifen-resistant cells, which were exposed with 
4-OHT for 6 months. Preliminary in house experiments have shown that short-term
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treatments of MCF-7 cells with tamoxifen for 48 hours resulted in an increase of both 
ERa mRNA and protein levels (Dr Martin Giles, personal communication). This is in 
agreement with previous studies, which have shown a tamoxifen-induced accumulation 
of ERa protein in the nucleus o f MCF-7 cells treated with 4-OHT for up to 72 hours 
(Laios et al., 2003). In the same study, tamoxifen was shown to stabilize the receptor 
while oestrogen and faslodex caused rapid ERa degradation.
A number of tamoxifen resistant cell models that have been reported in the literature 
retain ERa expression at wild-type levels (Mullick & Chambon, 1990; Brunner et al., 
1993; Badia et al., 2000). However, almost two decades ago, van den Berg & colleagues 
were the first to report the development o f a tamoxifen-resistant phenotype associated 
with total loss of ERa protein (van den Berg et al., 1989). The same authors generated a 
ZR-75-1-derived cell line of tamoxifen resistance (ZR-75-9al), in which a total but 
reversible loss of detectable ERa protein was observed in a tamoxifen concentration- 
dependent manner over a 12 month period. The high concentration of tamoxifen used to 
maintain ZR-75-9al cells (i.e.: 8 pM) is in sharp contrast with that used to maintain 
TamR-30 in the present study (i.e.: 1 pM), in which the more potent metabolite 4-OHT 
was used. Furthermore, the more rapid decline o f ERa expression occurring in ZR-75- 
9al cells (i.e.: 12 months) compared to TamR-30 cells (i.e.: 30 months) can be attributed 
to the fact that the initial cellular levels o f ERa in the parental ZR-75-1 cells are 
considerably lower than in MCF-7 cells (Dr. Julia Gee, personal communication). 
Interestingly, previous clinical studies have shown that the duration of response to 
endocrine therapy tended to be longer in “ER-rich” primary breast tumours than those 
with lower levels of the receptor (Campbell et al., 1981). It is thus feasible to suggest that 
ERa-positive breast tumours with lower initial levels o f ERa may be more susceptible to 
become ERa-negative lesions culminating in an earlier anti-hormone relapse.
In contrast to this project’s findings, one study did claim that ERa protein was expressed 
at levels similar to those of parental MCF-7 cells in three tamoxifen-resistant variants 
(MTR1-3 cells), which were grown in the presence of 4-OHT (lpM ) for up to 2 years 
(Kilker et al., 2004). Using western blot analysis, the authors demonstrated that ERa was 
readily detectable in all three MTR cells. However, a more critical evaluation of the 
authors’ immunofluorescence data reveals that MTR cells exhibited a noticeable
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reduction in nuclear staining for ERa compared to the parental MCF-7 cells. Also in the 
same study, western blot analysis showed that cyclin D l, which is a classic ERa- 
regulated gene, was markedly reduced at the protein level in all three MTR cells 
compared to the parental MCF-7 cell line. Similarly in the current study, total levels of 
IGF-IR (another classic ERa-target gene) were shown to be downregulated as ERa levels 
were progressively lost during the development of the tamoxifen resistant cell models. 
Cumulatively, the immunofluorescence and cyclin D l data would therefore suggest that 
the development of MTR cells was in fact associated with a downregulation of ERa 
expression, thus in line with the results presented in this thesis.
Conclusively, TamR-30 cells and the other reported cell models of tamoxifen resistance 
like ZR-75-9al provide in vitro evidence that loss of ERa can occur as a direct 
consequence of tamoxifen therapy. These in vitro models are therefore in line with the 
aforementioned clinical data which showed that a proportion of breast tumours become 
ERa-negative on tamoxifen relapse (Johnston et al., 1995; Kuukasjarvi et al., 1996; 
Gutierrez et al., 2005). However, it is important to mention that other factors causing 
ERa downregulation may also exist independently to tamoxifen therapy. For example, 
previous clinical data have shown that ERa was lost in approximately one third of 
metastatic tumours, which originated from ERa-positive primary lesions treated with 
adjuvant chemotherapy without tamoxifen (Lower et al., 2005). Sustained oestrogen 
deprivation in vitro (mimicking the biological effect of AIs) has also been associated with 
the emergence of an ERa-negative phenotype from the ERa-positive T47D cells (Murphy 
et a l , 1990; Pink et a l , 1996), and hypoxia has also been demonstrated to result in 
downregulation of ERa expression in several ERa-positive breast cancer cell lines and 
breast tumours (Cooper et a l , 2004; Stoner et a l , 2002). It is noteworthy to mention that 
loss of ERa expression could also occur as part of the natural biological evolution of 
breast carcinoma. Whilst this hypothesis remains difficult to extrapolate from clinical 
data for obvious ethical reasons, a few studies have reported loss o f ERa in metastatic 
lesions that were associated with ERa-positive primary tumours in the absence of 
intervening treatments (Kuukasjarvi et al., 1996; Nedergaard et a l , 1995; Zheng et a l , 
2001).
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43 ERa promoter usage in TamR cells
In addition to assessing the overall transcriptional activity of the ERa gene 
(through measurements o f total ERa mRNA levels), this study also examined ERa gene 
promoter usage through expression analysis o f the different ERa mRNA variants in 
MCF-7 cells and in the tamoxifen-resistant cell models (TamR cells). The primaiy aim 
was to assess whether loss o f ERa in TamR cells was a result o f reduced usage of 
particular promoters. Based on the reports available in the literature to date, it appears 
that alternative promoter usage o f the ERa gene has only been investigated in the 
endocrine-sensitive phase in vitro but not during acquisition of the tamoxifen resistant 
phenotype. Herein, assessment o f ERa mRNA variant levels was first validated in 
oestradiol-treated MCF-7 cells which, in agreement with previous studies, exhibited 
reduced levels of all ERa mRNA variants but more significantly so for the breast-cancer 
specific variants A, B and C (Donaghue et al., 1999; Flouriot et al., 1998). Levels of the 
ERa mRNA variant C were as predominant as the variant A in control MCF-7 cells. This 
is in contrast to data from Flouriot et al. (1998) who have shown that ERa mRNA 
variants A were the most prevalent in MCF-7 cells. This discrepancy could be due to a 
natural variation in levels o f ERa mRNA isoforms across cell lines from different 
laboratories. Furthermore, expression levels of ERa mRNA variant C were associated 
with a large error bar in the present study, thus reflecting variation within the cells tested. 
Worthy of mention is the expression profiles o f ERa mRNA variants in TamR-18 cells, 
which closely resembled that o f MCF-7 cells treated with oestrogen. Interestingly, a 
previous study showed that tamoxifen treatment of MCF-7 cells for 6 days 
downregulated total ERa mRNA expression to levels similar to those observed in 
oestradiol-treated MCF-7 cells (Larsen et al., 1997). Because the effect of oestradiol on 
ERa expression has long been attributed to a decreased transcription rate of the ERa gene 
in MCF-7 cells (Saceda et al., 1988; Pink & Jordan, 1996), it is feasible to suggest that 
oestrogen and tamoxifen may act through similar mechanisms to regulate ERa gene 
transcription; possibly involving a similar repertoire of transcription factors in both MCF- 
7 and TamR cells.
Data presented in this study showed that the time-dependent reduction o f total ERa 
mRNA levels in response to prolonged tamoxifen treatments was attributable to a 
decreased expression of the entire population of ERa mRNA variants. However, this
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reduction was most dramatic for ERa mRNA variants C whose steady-states were 
reduced to almost non-detectable levels following a 30 month treatment regime with 
tamoxifen. This would therefore suggest that transcription of the ERa gene from the C 
promoter may play an essential role in maintaining adequate levels of total ERa mRNA 
in TamR cells. This is in agreement with previous studies, which showed a good 
correlation between overall ERa protein expression and the increased mRNA expression 
from the distal promoter C in MCF-7 cells (Tanimoto et al., 1999; Donaghue et al., 
1999). Interestingly, also, transcription from the promoter C was found to be 
dramatically increased in long-term oestrogen deprived MCF-7 cell models, which 
exhibited much higher ERa levels than their parental cells (Sogon et al., 2007). A more 
thorough examination of the ERa gene promoter activity (using for example a luciferase- 
based reporter gene assay) would be needed to conclusively confirm the predominant 
function of promoter C on ERa gene expression in TamR cells. Overall, the real-time 
PCR data obtained in this study would suggest that expression of the ERa gene does not 
occur through the selective use o f a specific promoter in the tamoxifen-resistant cells. 
Indeed, downregulation o f total ERa mRNA levels in TamR cells was associated with a 
declined expression of all the ERa mRNA variants. This is in line with previous studies 
carried out across different types o f ERa-positive breast cancer cells, in which ERa 
promoters were either all upregulated (e.g.: ZR-75-1) or downregulated (e.g.: MCF-7) by 
oestrogen treatments (Donaghue et al., 1999).
152
Chapter 4. Discussion
4.4 Mechanisms of ERa loss in TamR cells
4.4.1 A reversible and “adaptive” mechanism
The significant reduction in ERa mRNA and protein levels observed in TamR-24 
and TamR-30 cells was shown to be reversible upon tamoxifen withdrawal over a period 
of 4 weeks. This reversibility, thus, lends further support to this project’s hypothesis that 
tamoxifen therapy could be an active contributor o f ERa depletion. Reversibility of ERa 
expression upon tamoxifen withdrawal was also previously been demonstrated in the 
aforementioned ZR-75-9al cells, which were generated as ERa-negative tamoxifen- 
resistant breast cancer cells (Long et al., 1992; van den Berg et al., 1989). Significantly, 
however, it is important to note that the recovery o f ERa levels in TamR cells was only 
partial since expression levels o f both ERa mRNA and protein were not restored to wild- 
type levels (i.e.: MCF-7) under tamoxifen-withdrawn conditions. This would therefore 
imply that additional factors other than tamoxifen exist that would contribute additively to 
ERa loss during tamoxifen therapy. Furthermore, data from the tamoxifen-withdrawn 
experiments clearly indicate that downregulation o f ERa levels during prolonged 
tamoxifen treatments was not permanent, thus excluding epigenetic modifications as a 
mechanism responsible for the reduced ERa levels in TamR cells. This is further 
supported by the findings, herein, that ERa mRNA levels were not recovered with the 
DNA-demethylating agent 5-azadeoxycytidine (5-AZA) in TamR-18 cells. Interestingly, 
it was also shown that the irreversible loss o f ERa in FasR cells was not linked to 
epigenetic silencing o f the ERa gene, as suggested by DNA methylation studies on the 
proximal promoter o f the ERa gene (Dr. Martin Giles, personal communication).
It is noteworthy to mention that the tamoxifen-resistant phenotype exhibited by TamR-24 
and TamR-30 cells was not sustainable in tamoxifen-withdrawn conditions. Indeed, cell 
growth was noticeably reduced when TamR cells were routinely maintained in 4-OH- 
depleted medium for greater than 4 weeks. This observation is indicative of the acquired 
agonistic properties o f tamoxifen and its role as a growth promoting agent in TamR cells 
(Michalides et a l , 2004; Riggins et a l,  2007). Interestingly, in vitro and in vivo data from 
a recent report have suggested that unliganded ERa may have inhibitory effects on cell 
growth through its interaction with the cyclin-dependent kinase inhibitor p21/WAFl 
(Maynadier et a l, 2008). Assuming that the cellular pools of ERa have become fully
153
Chapter 4. Discussion
unliganded in TamR cells under the tamoxifen-withdrawn culture conditions, it is feasible 
to speculate that a mechanism, similar to that described by Maynadier et a l , may underlie 
the reduced growth of TamR-24 and TamR-30 cells when deprived of 4-OHT.
Immunocytochemical analyses have shown that the progressive downregulation of ERa 
levels (during the development o f the tamoxifen resistant phenotype) affected the entire 
cell population and was unlikely to be due to a clonal outgrowth from an initial ERa- 
negative cohort within the parental MCF-7 cell line. This observation together with the 
fact that downregulation of ERa was reversible in TamR cells provide in vitro evidence in 
support of an “adaptive” mechanism for the loss of ERa expression in response to 
prolonged tamoxifen therapy. In support of this adaptive mechanism, Beeram & co­
workers (2007) have recently reported that ERa was lost in 9 out o f 16 (56%) tamoxifen 
resistant cells, which have been clonally derived from ERa-positive MCF-7 breast cancer 
cell colonies that were cultured in the presence of 4-OHT (lpM ) over a 4 month-period. 
Furthermore, ERa mRNA levels were shown to be decreased by -50%  in tamoxifen- 
resistant cells that were also clonally derived from ERa-positive MCF-7 cells (Fan et al., 
2006). It should be noted, however, that a “selective” mechanism in which anti­
hormones would favour the growth of ERa-negative cells originally present in the 
primary tumour lesions, can not be entirely ruled out and has been quoted by others 
(Allred et al., 2004; Zheng et al., 2001).
4.4.2 An EGFR- independent mechanism
In the present work, it was clearly shown that a 24 hour- and 48 hour treatment 
regime with gefitinib induced downregulation of ERa mRNA and protein levels in 
TamR-18 cells. This would therefore imply that activation of EGFR signalling, with 
resultant stimulation of downstream components like Erkl/2 MAPKs, may have a 
positive regulatory effect on ERa expression in TamR cells. Also in this study, sustain 
inhibition of EGFR signalling over a 10-day period in TamR-18 cells resulted in what 
appeared to be a recovery o f ERa expression (most notably at the protein level), 
indicative of a compensatory mechanism. Interestingly, the recovery o f ERa expression 
also correlated with that of Erkl/2 activity (although not fully), thus lending further
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support to the possibility that Erkl/2 may maintain ERa steady-states levels in TamR 
cells. This possibility was further confirmed by the findings that inhibition of Erkl/2 
activity by U0126 resulted in total loss of ERa protein in TamR-30 cells. Taken 
together, these results are very surprising since the vast majority of reports present in the 
literature strongly favours the view that exaggerated EGFR/MAPK signalling promotes 
ERa downregulation. Most significantly, compelling data from the El-Ashry group have 
shown that hyperactivation o f MAPK in EGFR or HER-2-overexpressing breast cancer 
cell lines can directly induce loss of ERa expression in vitro (Holloway et a l , 2004; Oh et 
al., 2001). A hyperactivated-MAPK signature distinguishing ERa-negative from ERa- 
positive phenotypes has also been reported by the same group (Creighton et al., 2006). 
Also in contrast to the findings presented in this thesis, another study by the El-Ashry 
group has shown that ERa expression can be restored in ERa-negative breast cancer cell 
lines and ERa-negative tumours upon direct inhibition of hyperactive MAPK with the 
inhibitor U0126, but also via inhibition o f the upstream growth factor receptor EGFR 
(Bayliss et al., 2007)
Despite the overwhelming data in the literature demonstrating an MAPK-induced 
downregulation of ERa expression, a few studies are encouragingly in agreement with 
observations made in the current project. For example, it has recently been demonstrated 
that a 48 hour-treatment o f MCF-7 cells with U0126 also resulted in reduced levels of 
ERa protein (Chu et a l , 2007). Furthermore, Marsaud et a l  (2003) have shown that 
blockade of the Erkl/2 pathway by U 0126 resulted in a proteasome-mediated 
degradation of 4-OHT-bound ERa protein in MCF-7 cells. Perhaps most significantly for 
this study, the same authors further suggested that ERa levels may be maintained by the 
low basal activity of MAPKs normally exhibited by MCF-7 cells.
As outlined in Chapter 1, it is known that post-translational modifications o f the receptor, 
most notably phosphorylation on different serine residues of ERa, have a regulatory role 
on both ligand-dependent- and ligand-independent-degradation of the receptor (Alarid et 
a l , 1999; Laios et a l, 2005; Valley et a l, 2005). For example, phosphorylations of 
Seri 18 sites have been shown to contribute to ERa degradation by facilitating targeting of 
the receptor to the ubiquitin-proteasome pathway (Valley et a l, 2005). Furthermore, 
MAPKs are known to be involved in the phosphorylation of such serine sites on ERa 
(Kato et a l, 1995). In view of this and bearing in mind both Marsaud et ai: s  findings
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(2003) and those of the El-Ashry group, it is feasible to suggest that low levels of 
activated MAPKs may not efficiently initiate proteasome-mediated degradation of ERa, 
thus levels of the receptor appear to be maintained. However, hyperactivated MAPKs 
induce rapid receptor degradation, and thus reduce ERa steady-state levels. One would 
therefore expect Erkl/2 to induce degradation and thus downregulation of ERa levels in 
TamR cells since the latter have been shown in this study to contain considerably higher 
basal activity of Erkl/2 compared to MCF-7 cells. However, the U0126 experiment in 
TamR-30 cells suggested otherwise. Therefore, it is interesting to speculate that in TamR 
cells, levels o f phosphorylated/activated Erkl/2 proteins (although relatively high 
compared to MCF-7 cells) may not have yet reached a “threshold point” above which 
they would contribute to rapid degradation o f ERa. Indeed, the MAPK-induced loss of 
ERa suggested by the El-Ashry group is mainly based on experiments with constitutively 
active EGFR- and MEK-transfected MCF-7 cells in which the EGFR-Erkl/2 signalling 
reaches extreme levels of activity; far higher than that found in TamR cells, wherein the 
basal activity of EGFR signalling mainly depends on the autocrine production of EGFR 
ligands like amphiregulin (Britton et al., 2005; Hutcheson et al., 2003). In view of this 
and in order to further evaluate the potential role of the EGFR-Erkl/2 signalling in 
maintaining ERa levels in TamR cells; it would be interesting to assess the effect of 
exogenous EGFR-ligands on ERa expression.
4.43 A Src-dependent mechanism
Perhaps the most significant finding o f this work is that the elevated Src kinase 
activity exhibited by TamR-30 cells appears to be an important regulator of ERa loss in 
these cells. Indeed, modulation o f intracellular signalling pathways with various 
pharmacological inhibitors revealed that only the Src inhibitor AZD0530 rapidly and 
significantly restored both ERa mRNA and protein steady-state levels in TamR-30 cells. 
The recovery of ERa expression induced by AZD0530 was considerably higher and 
occurred much more rapidly (3 days) than that observed with withdrawal of tamoxifen 
from culture medium (4 weeks). ERa levels in TamR-30 cells were recovered to at least 
TamR-18-equivalent following Src inhibition for 3 days, as demonstrated by western blot 
analysis. However, the AZD0530-induced re-expression of ERa was shown to reach
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wild-type (MCF-7) levels by immunocytochemical analysis. The latter method is 
certainly more sensitive than western blotting in detecting ERa expression: there was a 
considerable decrease in the number of ERa-negative cells in the AZD0530-treated 
TamR-30 cells compared to the non treated cells. Also, a considerable increase in 
intensity of nuclear ERa staining was observed within the ERa-positive cells cohort. As 
described in Chapter 1 (section 1.6.2), Src is a key mediator o f cross-talk between EGFR 
and ERa signalling. In view o f this and the AZD0530-induced re-expression of ERa, it 
would be o f interest to investigate the effects o f Src inhibition on EGFR and HER-2 
activities in TamR-30 cells. Previous studies have indeed shown that although AZD0530 
does not affect phosphorylation o f EGFR at Y1068, it partially reduces phosphorylation 
of the growth receptor at Y845 (Hiscox et ah, 2006). It would be equally interesting to 
investigate Src activity in response to the inhibitory effects of gefitinib on EGFR activity 
which, as described in Chapter 3 (Figure 3.20), had no effects on ERa levels in TamR-30 
cells. The studies by Hiscox et al. (2006) have previously demonstrated only a partial 
inhibitory effects of gefitinib on Src kinase activity and suggested that mechanisms other 
than elevated EGFR expression and activity may contribute to increased levels of 
activated Src in TamR cells.
The restoration of ERa with AZD0530 is in strong agreement with the study by Chu et al. 
(2007) who provided for the first time compelling in vitro and in vivo evidence for a Src- 
mediated regulation of ERa expression in ERa-positive and ERa-negative breast cancer 
cell. These authors have established that Src-mediated phosphorylation of ERa targets 
the receptor for its ubiquitin-proteasome degradation in a ligand-dependent manner. 
Using a cohort of 18 ERa-negative primary breast tumours, the authors have also 
demonstrated an inverse clinical correlation between Src kinase activity and ERa- 
negativity. Furthermore, the same authors demonstrated that ERa protein stability was 
reduced in cells exhibiting high Src kinase activity with lower ERa levels compared to 
MCF-7 cells being observed. Similarly, preliminary in house studies with the protein 
synthesis inhibitor cycloheximide have revealed that ERa was less stable and thus more 
rapidly degraded in TamR-18 cells compared to wild-type MCF-7 cells. In view of this 
and the fact that TamR-18 cells have higher basal Src activity than MCF-7 cells, it would 
be anticipated that treatment o f TamR-18 cells with AZD0530 would result in an increase 
of ERa stability and expression in these cells.
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Data from Chu et al. (2007) mainly advocate a role for Src in regulating ERa expression 
at the post-translational level (i.e.: protein degradation). Surprisingly, herein, the 
AZD0530-induced upregulation of ERa mRNA steady states levels in TamR-30 cells 
also points to a transcriptional control of ERa gene levels by Src. Expression levels of the 
ERa mRNA variants A-C were significantly increased upon AZD0530 treatments in 
TamR-30 cells. These results would therefore suggest that Src kinase activity may 
indirectly inhibit ERa gene transcription from the proximal (A/B) and distal (C) 
promoters. In order to more convincingly ascertain this possibility, it would be interesting 
to assess the activity o f ERa promoter-based reporter genes (containing the firefly 
luciferase gene for example) that have been transfected into TamR-30 cells treated with 
the Src inhibitor. In support o f a Src-dependent modulation o f ERa gene expression, 
Longo et al. have provided convincing in vitro evidence for a Src-mediated regulation of 
the F promoter in the osteoblast-like Saos-2 cells (Longo et al., 2006). As outlined in 
Chapter 7, the F promoter is specifically activated in bones cells (Flouriot et al., 1998; 
Lambertini et al., 2003). The study by Longo et al. has also shown that PKCa was 
involved in mediating downregulation of ERa gene expression by acting upstream of Src 
in Saos-2 cells. Interestingly, an inverse relationship between PKCa overexpression 
/hyperactivation and ERa expression has been established in clinical breast cancer, breast 
cancer cell lines (Martin et al., 1995; Tonetti et al., 2000; Ways et al., 1995), and notably 
in models of tamoxifen-resistant cells (Frankel et al., 2006). In the present study, basal 
levels of activated PKCa were considerably increased in TamR-30 cells, as demonstrated 
by western blot analysis. However, treatments of TamR-30 cells with the widely used 
PKC inhibitor bisindolylmaleimide (Bis) did not restore ERa expression, thus suggesting 
that the PKC pathway may not be involved in the downregulation of ERa levels in TamR 
cells. Significantly, however, the inhibitory effect o f Bis (0.5pM) on the basal activity of 
PKCa in TamR-30 cells could not be checked due to time constraint; thus a regulatory 
role for PKCa on ERa expression in TamR cells can not be definitively ruled out herein. 
Similarly, the inhibitory effects o f U0126 and wortmanin on MAPK and Akt kinase 
activity, respectively, were not checked due to time constraints, thus other signalling 
pathways involved in downregulation o f ERa levels cannot be ruled out.
The prominent role o f Src in tamoxifen resistance has also recently been highlighted by 
the Santen group. The latter has shown that prolonged tamoxifen treatments in vitro (~12
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months) caused a fraction o f nuclear ERa to translocate to the cytoplasm and interact with 
EGFR in a Src-dependent manner (Fan et a l , 2007; Yue et a l , 2007). The extra-nuclear 
redistribution of ERa is thought to enhance the non-genomic action of ERa with 
EGFR/MAPK signalling to drive the growth o f tamoxifen-resistance cells. The same 
authors have showed that inhibition o f Src activity prevented cytoplasmic translocation of 
ERa and, importantly, restored the growth sensitivity o f TamR cells to tamoxifen. Most 
significantly, however, total levels o f ERa did not change during acquisition of the 
tamoxifen resistance in the studies by the Santen group. In contrast, the present work 
provides the first in vitro evidence, in a model o f acquired tamoxifen-resistance, for a link 
between Src kinase activity and ERa loss. It should be noted that the Src inhibitor 
AZD0530 used in the current study not only affect Src but also other members of the non­
receptor tyrosine kinase family including Fyn and Yes which, because of their high 
structural and functional redundancy with Src, could also play a role in the depletion of 
ERa levels in TamR cells (Hennequin et a l , 2006; Parsons & Parsons, 2004). siRNA 
experiments would certainly provide more clues regarding the extent to which each Src 
family kinase member may contribute to ERa downregulation in TamR cells. It is also 
noteworthy to mention that AZD0530 also inhibits the other non-receptor tyrosine kinase 
Abl (Hennequin et a l , 2006). Therefore, a potential involvement of the Abl signalling 
pathway in the downregulation o f ERa expression in TamR cells can not be entirely ruled 
out. While the role of Abl remains unclear in endocrine resistance, aberrant Abl kinase 
activity has been shown to be highly implicated in the invasion capacity of breast cancer 
cells; with Abl acting as downstream effectors o f the ErbB receptors, IGF-IR and the Src 
family (Srinivasan et al,. 2008; Srinivasan & Plattner, 2006).
Overexpression o f the non-receptor tyrosine kinase Src has now been established as a 
cmcial component o f growth factor signalling pathways that regulate the development 
and metastatic progression o f many types o f human cancer including breast cancer 
(Yeatman, 2004; Song & Santen, 2006). Importantly, recent emerging in vitro data have 
now also attributed a prominent role for Src in mediating the growth and invasion 
capacities of ERa-positive tamoxifen-resistant cells. Previous in house publications have 
shown that acquisition of the tamoxifen resistant phenotype (up to the 18 month-period) 
is associated with an elevation in Src kinase activity concomitant with an aggressive and 
invasive phenotype in vitro (Hiscox et a l , 2004; Hiscox et a l , 2006). Overexpression of
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activated c-Src has also been reported in other models of tamoxifen-resistant variants 
(Kilker et al., 2004; Planas-Silva et al., 2006). In the present study, the basal activity of 
Src, as determined by phosphorylation of the tyrosine residue Y418, was shown to be 
further enhanced when tamoxifen treatments were prolonged to a 30-month period, and 
as expected, this was associated with a further increase in cell motility and invasion. This 
would indicate that as cells progress towards ERa-negativity, this is associated with 
increase in aggressive behaviour mimicking what is seen with patients with ERa-negative 
breast cancers (Gruvberger et al., 2001; Gee et al., 2004).
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4.5 Therapeutic implications of the AZD0530-induced restoration of 
ERa expression
Regardless o f the molecular mechanisms governing ERa downregulation during 
tamoxifen therapy, re-expression of ERa must be that of a functional receptor that is still 
able to regulate growth in order to be clinically relevant. Therefore, it will be essential to 
conduct further studies investigating whether the AZD0530-induced upregulation of ERa 
expression in TamR-30 cells is accompanied with a restoration of the growth-inhibitory 
effect of tamoxifen or other anti-hormonal therapies. A growth response o f TamR-30 
cells in response to increasing concentrations of 4-OHT whilst in the presence of 
AZD0530 would be an appropriate initial experiment. Very encouragingly, in house 
preliminary studies have shown that sensitivity to tamoxifen could be restored in TamR- 
18 cells treated with AZD0530 (Hiscox et al., 2007). Importantly, the data presented in 
this thesis would indicate that inhibiting Src activity alongside anti-hormonal therapy may 
prove to be a valuable therapeutic strategy to retain ERa expression and function, thus 
preventing ERa-positive breast tumours to drift towards more aggressive cancer cell 
behaviour in clinical breast cancer. Furthermore, because epigenetic silencing of ERa can 
only be explained in -25%  of the de novo ERa-negative breast cancers, it is plausible to 
suggest that inhibition o f Src kinase activity in a proportion o f the remaining de novo 
ERa-negative tumours (for which cytotoxic chemotherapy is eventually used) might also 
be therapeutically beneficial in triggering anti-hormone response. Encouragingly, the 
aforementioned study by Chu et al. (2007) has shown that Src kinase activity was found 
elevated in as much as 78% of ERa-negative breast cancers.
In support of the results presented herein, pre-clinical data is now emerging which 
suggest that up-front combination therapies targeting Src activity and ERa have maximal 
inhibitory effects on growth o f ERa-positive breast cancer cell lines, thus delaying or 
preventing emergence of a resistant phenotype (Herynk et al., 2006; Planas-Silva & 
Hamilton, 2007; Hiscox et al., 2008). Significantly, the study by Hiscox et al. (2008) has 
shown that combining AZD0530 and tamoxifen treatments in the ERa-positive MCF-7 
and T47D cell lines prevented not only cell proliferation but also resulted in complete 
abrogation of their in vitro migratory and invasive behaviour. In light of this, it is 
anticipated that AZD0530 treatments would also reduce the highly motile and invasive
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characteristics of TamR-30 cells. In an attempt to identify the mechanisms underlying 
cell growth suppression following dual targeting of Src and ERa, pre-clinical studies have 
demonstrated that Src inhibition resulted in reduced expression of the key positive cell 
cycle regulators cyclin D1 and c-myc (Planas-Silva & Hamilton, 2007; Hiscox et al., 
2008). One potential explanation for the reduced expression of these cell cycle proteins 
could be the complete abrogation of EGFR signalling, which was shown to be essentially 
Src-dependent in a significant study by Knowlden et al. (2005). Importantly, in light of 
the novel data presented in this thesis, it is very plausible that the anti-proliferative effects 
of the AZD0530/tamoxifen combination treatments, as observed by the aforementioned 
studies, could now also be a consequence of an (AZD0530-induced) increase in ERa 
expression levels in TamR cells, thus restoring better response to tamoxifen.
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4.6 Potential upstream signalling elements for the Src-mediated loss of 
ERa expression
While data presented in this thesis are strongly suggestive of a Src-dependent 
mechanism causing ERa downregulation during prolonged tamoxifen treatments, it 
remains to be determined which growth factor receptors or other factors, acting upstream 
of Src, are involved. As previously stated in this chapter, EGFR signalling appears not to 
be involved in the downregulation of ERa expression in TamR cells. However, it 
remains possible that HER-2, although shown to be the preferred ally of EGFR in TamR 
cells (Knowlden et al., 2003), may contribute to ERa loss independently of EGFR. 
HER-2-inhibition by trastuzumab/Herceptin has been shown to restore ERa levels in 
ERa-negative breast cancer cell lines and ERa-negative tumours (Bayliss et al., 2007). 
Furthermore, a preliminaiy clinical study has shown for the first time that ERa expression 
could be reinstated with trastuzumab in a small cohort of patients with ERa-negative 
breast tumours overexpressing HER-2 (Munzone et al., 2006). In light of these clinical 
data, it would be equally interesting to investigate the effect o f HER-2 blockade by 
Herceptin on ERa expression in TamR-30 cells as it can be speculated that HER-2 
together with another member o f the ErbB family other than EGFR may be involved in 
ERa depletion. In support of this, Stoica et a l  (2003b) have shown that activation of 
HER-2/HER-3 heterodimerization with the exogenous ligands heregulin-/?l (HRG- /?1) 
results in downregulation of ERa mRNA and protein in MCF-7 cells, via the PI3K/Akt 
pathway. Such heterodimerization between HER-2 and HER-3 has been demonstrated in 
TamR-18 cells under HRG- /?1 challenge (Hutcheson et a l , 2007).
In the present study, the basal activity of Akt was dramatically increased in TamR-30 
cells and, interestingly, its inhibition by the PI3K inhibitor wortmanin did result in a slight 
but visible increase of ERa protein. It is therefore possible that Akt kinase activity may 
also have a contributory role in the downregulation of ERa levels in TamR cells. In 
support of this, Guo & Sonenshein (2004) have observed an increase of ERa protein 
levels when the low-ERa expressing NF639 cells were treated with wortmanin. Overall, 
it is very plausible that the Src-induced downregulation of ERa levels in TamR-30 cells 
could be mediated by the upstream signalling pathway elements HER2 and PI3K/Akt.
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One upstream growth factor receptor that could potentially be involved in the Src- 
mediated downregulation of ERa is IGF-IR. Indeed, Knowlden et al. (2005) have 
provided, for the first time, experimental evidence for a unidirectional cross-talk from 
IGF-IR to EGFR in a Src-dependent manner in TamR-18 cells. In the same study, Src- 
dependent phosphorylation of EGFR at tyrosine 845 was shown to be central for basal 
and ligand-mediated activation of the EGFR signalling and the resultant cell growth of 
TamR cells. Other upstream signalling elements that could also be involved in the Src- 
mediated loss of ERa, but which have not been investigated herein are the integrins. 
These so called cell adhesion molecules, consisting of a  and p subunits, are know to 
cooperate with growth factor receptors in the control of cell proliferation, cell survival and 
cell adhesion and migration (Hehlgans et al., 2007). pi and P4 integrins have been 
shown to be essential in breast tumour progression and invasion by amplifying EGFR and 
HER-2 signalling (Guo et al., 2006; Park et al., 2006). Most notably, in an attempt to 
elucidate the incompletely understood mechanisms of Src activation in human cancers, 
Huveneers et al. (2007) have identified avp3 integrins as a pivotal activator of Src kinase 
activity. Interestingly, in house preliminary studies have demonstrated a significant 
increase in avp3 expression levels in TamR cells (Dr. Steve Hiscox, personal 
communication). In view of these preliminary data, it would be interesting to analyse the 
protein expression levels of these integrins in TamR-30 cells.
164
Chapter 4. Discussion
4.7 Potential transcription factors regulating ERa expression in TamR 
cells
It is likely that the Src-mediated downregulation of ERa mRNA expression 
described in this study is exerted indirectly by the Src kinase activity through yet-to-be 
unveiled transcription factors that are regulated by upstream Src-dependent signalling 
pathways. In an attempt to identify such transcription factors and elucidate more 
thoroughly the Src-mediated regulation of ERa expression in TamR cells, Asymetrix 
studies are currently undergoing using RNA samples prepared from TamR-30 cells 
treated with the Src inhibitor AZD0530 for 3 days. Meanwhile, in a preliminary attempt 
to identify the mechanisms involved in the downregulation of ERa expression in TamR 
cells, the present study examined the protein expression and localization of the AP2y and 
Fox03a transcription factors which, as described in section 1.4.1, have been shown to 
exert a positive influence on ERa expression in vitro through their direct binding to the 
ERa promoter.
A correlation between nuclear Fox03a localization and ERa status has been described in 
several breast cancer cell lines (Guo & Sonenshein, 2004). However, 
immunocytochemical analysis in this study failed to convincingly demonstrate that 
decreased levels of nuclear/active Fox03a could be linked to the downregulation of ERa 
expression in TamR cells. Therefore, a relationship between Fox03a and ERa 
expression may not exist in these cells. In support o f this, Madureira et al. (2006) 
demonstrated a poor correlation between Fox03a and ERa expression using a panel of 
breast cancer cell lines that was considerably larger (n = 16) than the one used in the study 
by Guo & Sonenshein (n = 6). However, Madureira et al. did observe a much better 
correlation between FoxMl and ERa expression (13/16) compared with Fox03a (6/16). 
FoxMl is another member of the mammalian Forkhead Box family of transcription factor 
and is established as a key regulator of the G l/S  phase transition and progression into 
mitosis (Costa, 2005). Using siRNA and ChIP analyses, Madureira & colleagues (2006) 
have also shown that FoxMl, and not Fox03a, is the primary positive regulator of ERa 
expression through direct binding to the proximal promoter of the ERa gene. 
Interestingly, the same authors also demonstrated that U0126-inhibition of the Erkl/2- 
dependent activation of FoxMl resulted in a significant downregulation of ERa 
expression in MCF-7 cells. This is in agreement with the U0126-induced loss o f ERa
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protein levels described earlier in TamR-30 cells. In light o f Madureira et al.’s findings, it 
would be very interesting to investigate whether a relationship between FoxMl and ERa 
expression exist in TamR cells.
Although a convincing correlation between AP2y and ERa expression has yet to be 
reported in clinical breast cancer, several in vitro studies have identified AP2y as a 
positive regulator of ERa gene expression by directly interacting with the ERa promoter 
in human mammary epithelial cells and breast cancer cell lines (McPherson et al., 1997; 
McPherson et al., 1999; Schuur et al., 2001). In the present study, statistical analysis of 
immunocytochemically detected nuclear AP2y failed to demonstrate that a reduction in 
nuclear/active AP2y expression could be one contributing cause for the downregulation of 
ERa expression in TamR-18 and TamR-24 cells. However, this possibility can not be 
entirely ruled out in the case of TamR-30 cells, which exhibited a significant reduction in 
AP2y nuclear staining compared to MCF-7 and the other TamR cells. Furthermore, it is 
feasible to suggest that that reduced expression of the AP2a isoform could also be 
contributing to ERa downregulation in TamR-30 cells. The AP2a isoform has also been 
associated with the positive control of ERa promoter activity in vitro (McPherson et al.,
1999; Schuur et al., 2001). Moreover, in contrast to AP2y, previous studies have found a 
significant correlation between nuclear AP2a (and also the AP2p isoform) and ERa 
expression in clinical breast cancer materials (Gee et al., 1999; Friedrichs et al., 2005; 
Turner et al., 1998). However, recent siRNA studies in several models o f ERa-positive 
breast cancer cell lines revealed that endogenous expression o f ERa was specifically 
regulated by AP2y but not AP2a (Woodfield et al., 2007). In the same study, AP2y was 
also found to be the key regulator o f oestrogen-responsiveness while AP2a was involved 
in the regulation of genes involved in cell cycle inhibition and apoptosis. This is in 
agreement with previous studies in which AP2y mRNA expression was upregulated in 
response to oestrogen treatment of ERa-positive breast cancer cell lines, whilst AP2a 
mRNA levels were downregulated (Orso et al., 2004). Clearly, the regulatory loop 
existing between ERa and AP2 transcription factors is complex. Therefore, a more 
thorough analysis of the protein expression and localization of the three well-known AP2 
isoforms (AP2a, AP2p and AP2y) would be needed in order to better assess AP-2’s 
contribution to ERa expression in TamR cells.
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Deregulation of the expression and/or activity of the AP-1 transcription factor 
could be involved in ERa loss in TamR cells. AP-1 consists o f homodimers of the JUN 
family of proteins ( JunB and JunD) or the more stable heterodimers between JUN and 
members of the FOS family (c-Fos, Fra-1, Fra-2, FosB), which can not homodimerize. 
The AP-1 members can have opposite functions with c-Fos and c-Jun promoting growth, 
whereas JunB is a negative regulator o f cell proliferation (Shaulian & Karin, 2001). As 
described in Chapter 1 {section 1.4.1), Tang et al. (1997) demonstrated the existence of a 
dominant transcriptional enhancer containing a functional AP-1 site mapped within the 
distal promoter D of the ERa gene. The same authors have shown that the DNA-protein 
complexes specifically formed on this enhancer element could be supershifted by 
polyclonal antibodies against c-Fos and c-Jun, thus suggesting that these proteins may 
be involved in activation of ERa gene transcription. However, Smith et al. (1999) have 
demonstrated that overexpression of c-Jun in MCF-7 cells resulted in the downregulation 
of ERa gene expression. Furthermore, recent in vivo experiments using transgenic mice 
with overexpressing HER-2 breast tumours have shown that inhibition o f AP-1 activity 
could prevent the development of ERa-negative breast cancers (Shen et al., 2008). In 
light of these data and given that the AP-1 members can have antagonizing functions on 
cell profliferation, qualitative or quantitative changes in the protein composition of the 
AP-1 complex may change the overall transcriptional activity o f the transcription factor, 
and determine whether AP-1 act as an inhibitor or activator o f gene transcription. It 
would therefore be necessary to assess the expression and activity of all the AP-1 
members if a role of this transcription factor in the regulation of ERa expression was to 
be investigated in TamR cells.
As described in Chapter 1 {section 1.4.1), p53 has been shown to positively regulate ERa 
gene transcription in MCF-7 cells (Angeloni et al., 2004). Deregulation o f p53 
expression could therefore also be involved in ERa loss in TamR cells. Interestingly, 
previous clinical studies have demonstrated a significant correlation between mutation of 
p53 and ERa-negativity (Bems et a l, 1996). This correlation has recently been further 
highlighted by compelling in vivo studies by D’Assoro et al. (2008) who demonstrated 
that mice, carrying xenograft with MCF-7 cells overexpressing a dominant negative p53 
mutant, developed poorly differentiated tumours lacking not only ERa expression, but 
also PR and HER2, characteristic of the triple negative breast cancer subgroup. Very
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interestingly, the same authors proposed that ERa downregulation could be mediated by 
an Akt-induced activation o f Mdm2 (a key negative regulator of p53 function found to be 
overexpressed in the xenograft model), whose ubiquitin-ligase activity has been shown to 
promote ERa protein degradation by another study (Duong et al., 2007). Given that Akt 
activity was considerably increased in TamR-30 cells, the mechanism of ERa 
downregulation proposed by D ’Assoro et al. could be very relevant for the present study.
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4.8 Summary and conclusion
Data presented in this thesis indicate that considerable ERa loss can occur in 
response to prolonged anti-hormonal treatment of breast cancer cells as part of an 
adaptive mechanism, and that this can lead to a more aggressive phenotype. 
Encouragingly, however, even after 30 months exposure to tamoxifen, the process is 
reversible by inhibition of Src kinase activity. Should future evidence reveal that this re­
expressed ERa remains functional and interacts with growth factor signalling pathways in 
TamR-30 cells, the data from this study provides more evidence in support of combining 
a Src inhibitor with anti-hormonal therapy in order to circumvent the emergence of 
aggressive cancer cell behaviour. In view of the ubiquitous expression of Src and its 
regulatory role in many critical cellular processes in normal tissues, one would expect that 
Src inhibition may cause high toxicity in many patients. Although it is too early to 
determine the long-term effects o f Src inhibitors in breast cancer patients, previous phase 
I clinical trials revealed that Src inhibitors are well tolerated and with low side effect 
(Summy & Gallick, 2006). Furthermore, data herein may not only be clinically relevant 
for ERa-postive patients loosing the receptor during endocrine therapy but also for 
patients with intrinsic ERa-negative breast tumours for whom alternative treatments are 
still very much needed. However, as rightfully quoted by Johnston et al. (2008), 
translation of these pre-clinical studies (advocating STIs/endocrine combinations 
therapies) into successful clinical trials will depend on the systematic identification of the 
drug target, through the use of relevant biomarkers within an appropriately selected 
cohort of patients.
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APPENDIX A.
Protocol Overview for Affymetrix U133A Genechip
Microarray analysis was performed on triplicate RNA samples, which were extracted 
from MCF7 and TamR cell lines by the TRI REAGENT® procedure, as described in 
Chapter 2 {section 2.2.1). Total RNA was DNAse-digested and RNA integrity and 
quality was assessed by agarose gel electrophoresis and spectrophotometry. RNA 
samples were sent to a specialist microarray facility in Cardiff University (Central 
Biotechnology Services) for further RNA quality control and subsequent Affymetrix 
GeneChip hybridization using the Affymetrix Human Genome U133A GeneChips™, 
which has approximately 23,000-gene coverage, including in-built quality control 
genes on RNA samples. Specific hybridization data were generated using 
Affymetrix MAS-5 software. Data were then normalized, log-transformed, and the 
quality of replicate data confirmed statistically (including MVA plots). To enable full 
analysis, the hybridization data for each sample was then uploaded into the 
commercial analysis software GeneSifter®.
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A P P E N D IX  B.
Log-intensity plots and heat m ap representing gene expression levels of 
transcrip tion  factors short-listed in Table 3.2. Gene expression analysis was 
carried out using GeneSifter® software (http://www.genesifter.net/web/r). The heat 
map and probe number for each transcription factor is shown with P values (student 
/-test) and Affymetrix calls (P, present; A, absent, M, marginal).
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